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General inTroducTion and 
ouTline of The Thesis
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The lack of accurate imaging options 
for prostate cancer (PC) remains an 
unresolved issue. It hampers the clini-
cal management of disease, including 
staging of primary PC and localisation 
of PC tumour recurrence. Another ma-
jor concern in PC management is the 
absence of curative treatment options 
for metastasised disease. 
The field of nuclear medicine provides 
opportunities that may fill these limita-
tions in PC management by employing 
radiopharmaceuticals, such as radio-
labelled peptide-based biotracers, that 
can be visualised by the nuclear imag-
ing modalities single photon emission 
tomography (SPECT) and positron 
emission tomography (PET). Further-
more, such radiolabelled peptides may 
be applied to offer targeted peptide 
receptor radionuclide therapy (PRRT 
). In the case of PC, bombesin (BN) 
is a promising receptor-targeting pep-
tide due to its high affinity to Gastrin-
Releasing Peptide Receptors (GRPR) 
overexpressed on the membranes of PC 
cells. The use of radiolabelled BN ana-
logues has been proposed for improve-
ment of imaging and staging of PC as 
well as for treatment of localised or oc-
cult PC metastases.
ProsTaTe cancer; 
incidence and 
ProGnosis
PC is a major health problem in the 
Western world due to its high inci-
dence and significant overall mortality 
1, 2. While localised PC can be treated 
with curative intent, disseminated PC 
is a deadly disease, leaving only pal-
liative treatment options 3. Therefore, 
it is crucial to accurately determine the 
extent of the disease at presentation in 
order to choose the best strategy for 
treatment. In The Netherlands the inci-
dence of PC in 2009 was 10166 men 
and mortality was 2492 4. PC confined 
to the prostate can be innocent; remain-
ing indolent during life, and with less 
than 3% the lifetime risk of PC-related 
death is low 5, 6. Autopsy studies have 
shown that a significant proportion of 
prostate tumours will never become 
clinically relevant 7. This clearly shows 
that aggressive (radical) treatment is 
not always needed in case of PC. In-
deed, incidental PC was found in 33% 
of male donors aged 60-69, and 46% of 
men over age 70 8.
deTecTion of Pc 
usinG Psa 
In earlier years when public awareness 
was little and (opportunistic) screen-
ing was unusual, most PC patients pre-
sented with symptoms of disseminated 
late stage disease. Nowadays, due to 
increased alertness, higher responsive-
ness, and improved screening options, 
PC is predominantly diagnosed at an 
early stage. Detection of PC is based 
on clinical examination, in particular 
digital rectal examination (DRE) of the 
prostate9, 10, laboratory levels of pros-
tate specific antigen (PSA) in blood 
and ultimately histopathology on pros-
tate biopsies needed for PC diagnosis. 
11
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Blood levels of PSA, a glycoprotein 
originating from the prostate gland, 
are usually increased in PC patients 
compared to the healthy population. It 
is widely used as a screening marker 
for PC 5, 11, 12. However, the use of PSA 
for screening has its limitations as it 
is prostate-specific, but not a cancer-
specific protein. Elevated PSA blood 
levels may also be caused by other non-
cancerous prostate gland conditions 
such as prostatitis and benign prostatic 
hyperplasia (BPH) 13, 14. As a conse-
quence, the specificity of PSA for the 
diagnosis of PC is rather low, leading 
to many false positive results in case 
of prostatitis or BPH. At a PSA cut-off 
level of 4.0 ng/mL specificity for PC of 
up to 70% has been reported 15.
Since the introduction of PSA it is in-
creasingly being used for PC screening. 
Obviously this has led to a tremendous 
rise in prostate biopsies. Approximate-
ly 50% of men with screen-detected 
PC carry an indolent form of PC that 
would have never caused any symp-
toms 16. The European Randomised 
Study of Screening for PC (ERSPC) 
showed that PSA-based screening does 
reduce PC-death rate by up to 31%, but 
emphasised at the same time that this 
goes at the expense of overdiagnosis 
and overtreatment 17, 18. 
risk sTraTificaTion of Pc
An important challenge in PC man-
agement is to distinguish patients who 
need invasive therapy from patients 
who need no intervention at all. Cur-
rent Dutch PC guidelines 19 agreed to 
stratify PC patients into 3 risk groups 
based on the EAU/ESTRO criteria 20:
-  Low; T1c-T2a, Gleason score <7, 
initial PSA (iPSA) <10 ng/mL
-  Intermediate; T2b-c or Gleason 
score =7 or iPSA 10-20 ng/mL 
   (two of these factors is high risk)
-  High; T3 or Gleason score >7 or 
iPSA >20 ng/mL 
   (one of these factors is high risk)
The stage of cancer is a description of 
the extent of cancer spread. In case of 
PC the TNM (Tumour, Node, Metasta-
sis) staging system, shown in Table I, is 
used. There are two types of PC staging; 
the clinical stage and the pathological 
stage. An important element of PC risk 
stratification is the clinical T-stage. It is 
an estimate of local PC extent obtained 
previous to curative therapy. T-stage is 
based on the results of DRE, PSA level, 
transrectal ultrasound (TRUS) findings 
and results of PC tumour observed in tis-
sue from transurethal resection (TUR). 
Grading of PC as expressed in the Glea-
son score is another decisive determi-
nant in risk stratification. Pathologists 
assign one grade between 0-5 to the 
most common tumour growth pattern, 
and a second to the next most common 
tumour growth pattern. The two grades 
are added together resulting in the 
Gleason Score. Lower Gleason scores 
represent more differentiated tumours 
21. The last criterion required for the as-
sessment of PC risk is the PSA value 
in blood before any form of treatment, 
called iPSA.
12
Statistically derived tools, called no-
mograms, have been composed to pre-
dict the chance of disease recurrence 
in patients with clinically localised 
PC before radical treatment for clini-
cal use. The Most accurate predictions 
have been obtained by combining the 
predictive parameters iPSA, T-stage 
and Gleason score. Based on these pa-
rameters the probability of PC recur-
rence after initial therapy with curative 
intent has been reported correctly in up 
to 79% by Kattan or Partin nomograms 
22, 23.
TheraPy
localised Pc
PC confined to the borders of the pros-
tate can often be treated curatively. 
Treatment choice is mainly based on 
risk stratification. Due to the low life-
time risk to die from PC and because 
of the currently observed overtreatment 
of PC with ensuing side effects, active 
surveillance is nowadays offered to pa-
tients with low-risk PC 24, 25. Patients 
under active surveillance are closely 
monitored for disease progression by 
frequent serum PSA analyses and re-
Stage T1 Tumour present, but not detectable clinically or by imaging
T1a Tumour incidentally found in less than 5% of prostate tissue resected
T1b Tumour incidentally found in greater than 5% of prostate tissue resected
T1c Tumour detected by prostate biopsy performed for elevated PSA
Stage T2 Organ-confined disease
T2a Tumour located in half or less than half of one prostate lobe
T2b Tumour located in more than half of one prostate lobe
T2c Tumour located in both prostate lobes
Stage T3 Extra-prostatic disease
T3a Extra capsular extension including microscopic bladder neck involvement
T3b Tumour invading the seminal vesicle(s)
T4 Tumour invading surrounding organs
N Regional lymph nodes
Nx Regional lymph nodes cannot be assessed
N0 No regional lymph node metastasis
N1 Lymph node metastases
M Distant metastasis
Mx Distant metastasis cannot be assessed
M0 No distant metastasis
M1 Distant metastasis
Modified table on the 2009 Tumour, Node, Metastasis (TNM) classification of prostate cancer.
Table 1
13
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peat prostate biopsies. When, despite 
the initial classification of low risk, 
clinical signs like PSA and re-biopsy 
show changes that lead to reclassifica-
tion towards a more aggressive pheno-
type curative radical treatment is sug-
gested and often initiated.
Localised intermediate or high risk PC 
mostly requires radical treatment 20. 
Options of radical treatment are sur-
gical excision of the prostate (open, 
laparoscopic or robot-assisted laparo-
scopic prostatectomy with or without 
lymph node dissection), or radiothera-
py by brachytherapy (radioactive seeds 
or high dose rate; HDR) or external 
beam 26-34. Various treatment modali-
ties have shown excellent survival of 
patients with localised PC, while high 
risk patients showed more frequently 
PC recurrence 26-34. Since randomised 
controlled trials are lacking, no high-
quality evidence exists to support any 
given treatment modality over another 
35. It has until now been assumed that 
both surgery and radiotherapy show 
similar survival rates. Radical treat-
ment needs to be well-considered be-
cause it is associated with significant 
morbidity, such as erectile dysfunction 
(up to 90%) and urinary incontinence 
(up to 74%), leading to a decrement in 
the quality of life 36. Besides these mor-
bidities radiotherapeutic options are 
also associated with functional bowel 
problems 37.
disseminated Pc
Growth of prostate epithelial (tumour) 
cells depends on a functional androgen 
axis with physiological levels of andro-
gens38. The first and so far most effec-
tive choice of treatment of disseminat-
ed PC is endocrine deprivation therapy 
aiming at ceasing tumour growth by 
reducing circulating testosterone levels 
or blocking the androgen receptor 39, 40. 
Different forms of endocrine therapy 
exist, all aim at reducing circulating 
androgen levels by surgical bilateral 
orchidectomy, receptor blockade by 
anti-androgens, and finally chemical 
castration by luteinizing hormone-re-
leasing hormone (LHRH) receptor an-
tagonists or LHRH receptor agonists or 
estrogens. Despite extensive research 
and numerous clinical trials, no differ-
ences in terms of survival have been 
observed between the different forms 
of endocrine treatment 19, 39, 41-43. 
Eventually PC relapse occurs in the 
majority of patients due to progressive 
tumour growth despite endocrine abla-
tion therapy. The exact mechanism of 
this progression towards so-called cas-
tration resistant PC (CRPC) is unknown 
although several theories have been 
proposed 44, 45. At the point of CRPC, 
palliative treatment options are scarce 
leaving a median survival of 10 months 
46-48. Although chemotherapeutic suc-
cesses have for long been very poor, in 
2004 the use of docetaxel in CRPC be-
came standard treatment following the 
results of two large randomised phase 
3 trails. They showed a significant sur-
vival benefit (of 2 to 3 months) as well 
as a significant improvement in quality 
of life after docetaxel-based chemo-
therapy over the standard control treat-
ment group receiving mitoxantrone / 
prednisone 49, 50. 
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develoPMenTs in 
radioloGy and 
nuclear Medicine 
for iMaGinG of Pc
Accurate anatomical discrimination be-
tween local, locally invasive or metas-
tasised PC remains a non-resolved clin-
ical issue in PC patients. Conventional 
imaging techniques, such as transrectal 
ultrasound (TRUS), computerised to-
mography (CT), Magnetic Resonance 
Imaging (MRI) and bone scintigraphy, 
have limited added value since their ac-
curacy is low, especially in low-risk pa-
tients 51-54. Evidence-based guidelines 
of the American College of Radiology 
Appropriateness Criteria, updated in 
2009, indicate that no conventional im-
aging options are appropriate for treat-
ment planning in early PC patients with 
T1-2, Gleason score ≤6, PSA <10 and 
<50% biopsy cores positive 55. In order 
to improve staging of primary PC and 
localisation of PC tumour recurrence 
research on imaging modalities is on-
going in both nuclear medicine and ra-
diology. 
The field of radiology has predomi-
nantly focussed on developments in 
ultrasound and MRI 52, 56-60. So far, only 
MRI combined with an endorectal coil 
(to obtain high quality images of the 
area surrounding the rectum) was prov-
en convincingly promising correctly 
detecting up to 93% of seminal vesicle 
invasion of PC 60. For this reason Dutch 
guidelines agreed that endorectal MRI 
≥1.5 tesla can be of additive value for 
tumour staging in patients with inter-
mediate or high risk PC 19.
Nuclear medicine applies radiophar-
maceuticals for imaging and therapy of 
various diseases. For 3-dimensional im-
aging of radioactivity distribution after 
injection of the radiopharmaceutical, 
the very sensitive imaging techniques 
SPECT and PET are being employed 
61, 62. SPECT is based on detection of 
radionuclides emitting single photons 
while PET can visualise positron emit-
ting radionuclides. Radiolabelled meta-
bolic tracers to detect PC (bone) metas-
tasis are frequently applied in nowadays 
clinical practice 63, 64. Dutch guidelines 
recommend a bone scan for PC patients 
with initial PSA ≥ 20ng/ml, locally ad-
vanced disease, Gleason score ≥ 8 or 
skeletal-related symptoms 19. Besides 
their use in metastatic (bone) imaging 
metabolism-based PET tracers, such as 
18F-FDG, 11C-choline and 11C-acetate, 
are extensively being studied for their 
potential in PC staging 52, 65.
In addition, a strong focus is directed 
towards the development of radio-
pharmaceuticals that target PC specifi-
cally. These tracers may be applied for 
both staging and treatment of PC. An 
example is the monoclonal antibody 
111In-capromab pendetide (Prostascint) 
directed to the prostate-specific mem-
brane antigen. This radiopharmaceuti-
cal has been approved by the American 
Food and Drug Administration (FDA) 
for targeted diagnostic imaging and 
staging of LN metastasis of PC 66, 67. 
The present thesis focuses on the pre-
clinical evaluation of novel and prom-
ising PC-targeting ligands based on BN 
or Gastrin-Releasing Peptide (GRP). 
These ligands can target the GRPR, 
15
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membrane receptors overexpressed on 
PC cells 68, 69. Radiolabelled BN and 
GRP-based peptide analogues show 
high affinity to GRPR leading to excel-
lent tumour-specific binding 70. Preclin-
ical and clinical studies dealing with 
GRPR-based imaging are reviewed in 
chapter 2 of this thesis. 
PePTide recePTor-based 
Pc TarGeTinG usinG 
boMbesin analoGues; 
aiMs of This Thesis
Application of BN analogues radiola-
belled with positron or gamma radia-
tion emitting radionuclides for targeted 
GRPR imaging may help to improve 
both accurate staging of primary PC 
and sensitive localisation of PC tumour 
recurrence 70. Labelled with cytotoxic 
beta or alpha emitting radionuclides 
BN analogues may even be employed 
for PRRT to treat both known and oc-
cult PC metastases or for focal PC 
therapy. The preclinical studies in this 
thesis aimed at further analysing the 
GRPR as potential target for molecu-
lar imaging and radionuclide therapy 
of PC using BN analogues and had the 
following objectives:
-  To select the optimal BN analogue 
for GRPR targeting.
-  To study GRPR expression in pa-
tient materials, human PC cell lines 
and xenografts and the influence of 
different biological and hormonal 
conditions.
-  To study the impact of various ex-
perimental conditions on BN ana-
logue pharmacokinetics in mice.
-  To validate the diagnostic value of 
a selected BN analogue comparing 
peptide-receptor-based targeting 
with metabolism-based targeting in 
a mouse model.
The research described in this thesis 
has been performed as part of a col-
laboration between the Department of 
Urology and the Department of Nuclear 
Medicine at Erasmus MC Rotterdam. 
The Department of Urology has long-
standing expertise in clinical and fun-
damental research of PC. The research 
group has established 13 unique human 
PC xenograft models and has the avail-
ability over a large panel of in vitro cell 
lines. Also, an extensive biorepository 
of human tissue samples from patients 
with long-term clinical follow-up has 
been established over the years. 
The Department of Nuclear Medicine 
of Erasmus MC in Rotterdam was one 
of the pioneers in development and 
introduction of peptide receptor-medi-
ated diagnostic and therapeutic radio-
pharmaceuticals for neuroendocrine 
tumours. The research team played 
a pivotal role in development and re-
search leading to the first radiolabelled 
peptide approved by the FDA in 1994, 
called OctreoScan, an 111In-labelled so-
matostatin analogue 71. Currently one 
of the focuses of this team is directed 
towards BN research. For this thesis, 
the department radiolabeled different 
peptide analogues and performed pre-
clinical evaluation studies, including 
16
in vivo imaging using state-of-the-art 
SPECT-CT and PET animal imaging 
devices. 
ouTline of This Thesis
The introduction of this thesis (chap-
ter 1) focuses on PC and its clinical is-
sues. It enunciates the need of new bio-
markers for detection and monitoring 
of PC and introduces the promising BN 
peptide analogues in short. chapter 2 
provides a general and more detailed 
overview of preclinical and clinical lit-
erature on the GRPR as a target for im-
aging and radionuclide therapy of PC 
using radiolabelled BN analogues. The 
potential of BN analogues in early di-
agnosis, monitoring and therapy of PC 
is discussed. 
A valid comparison of performance of 
different radiolabelled BN analogues is 
hampered by many protocol variations 
between the preclinical studies per-
formed. In chapter 3, we compared 
the PC targeting efficacy of five prom-
ising radiolabelled BN analogues for 
SPECT imaging under standardised ex-
perimental conditions in a mouse study. 
From this study we could conclude that 
the GRPR-antagonist Demobesin-1 and 
the GRPR-agonists AMBA and Pesin 
were the most promising analogues.
Since the majority of patients with dis-
seminated PC will eventually need hor-
monal therapy, it is essential to identify 
the impact of hormonal ablation treat-
ment on GRPR expression. Earlier pre-
clinical studies from our group showed 
downregulation of GRPR-expression 
after androgen withdrawal 72. In the 
literature low GRPR expression was 
suggested in CRPC as well 69. In chap-
ter 4 we explored androgen regulation 
of GRPR expression in three in vivo 
human PC xenograft models (PC82, 
PC295 and PC310) in more detail. This 
study revealed expression of GRPR 
in these androgen-responsive human 
PC xenografts to be significantly re-
duced by androgen ablation and to be 
reversed after restoring the hormonal 
status of the animals. 
Further studies to unravel the effect 
of hormonal manipulation and AR 
status on GRPR expression in PC are 
described in chapter 5. We used the 
clinically relevant androgen-respon-
sive and GRPR-expressing human 
VCaP cell line and studied GRPR ex-
pression in human tissue samples at 
various clinical stages. In contrast 
to our earlier observations described 
in chapter 4 BN-specific binding in 
VCaP was not significantly androgen 
regulated suggesting overexpression of 
GRPR in more advanced PC can escape 
‘normal’ androgen regulation control 
mechanisms rendering it constitutively 
activated. From human tissue samples 
higher overall median GRPR-specific 
uptake was seen in PC compared to be-
nign tissue, though lower PC outcomes 
showed considerable overlap with 
GRPR expression levels in benign tis-
sue samples.
chapter 6 identifies the impact of 
various experimental conditions on 
pharmacokinetics using 111In-AMBA 
in nude mice bearing human PC xeno-
grafts. 
17
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Effects of experimental characteristics 
like HPLC peptide purification of the 
(radiolabelled) peptide, variations in 
administrated specific activity and sat-
uration of the GRPR by predosing with 
BN prior to administration of radio-
labelled BN were studied. This study 
showed that not only the chemical 
structure of BN analogues determines 
its GRPR binding, but also demon-
strates significant effect on BN-binding 
to GRPR of HPLC peptide purification, 
variabilities in specific activity, varia-
tions in experimental conditions and 
saturation of the GRPR by predosing 
with BN prior to administration of ra-
diolabelled BN.
Metabolism-based targeting of PC is 
being studied as a strategy for PC im-
aging. In chapter 7 we describe the 
comparison of BN peptide receptor-
mediated targeting using 68Ga-AMBA 
with metabolism-based targeting by 
18F-choline for PET imaging of PC. 
This experimental study suggests pep-
tide-receptor based imaging to be supe-
rior to metabolism-based imaging for 
PET visualisation of PC xenografts.
This thesis concludes with the sum-
mary and future directions chap-
ter, where the study results are re-
viewed and discussed. A final statement 
is given on their clinical relevance and 
the prospective of BN-related peptides 
for use in GRPR-based PC-targeted 
SPECT/PET imaging.
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absTracT
Prostate Cancer (PC) is a type of cancer that is often diagnosed at very early 
stages due to improved detection among man in the Western World. Current im-
aging techniques are not optimal to determine extent of minimal early stage PC 
even though this is of great clinical importance. Human PC and high-grade PIN 
have shown high Gastrin-Releasing Peptide Receptor (GRPR) expression, while 
normal prostate tissue and BPH revealed to be predominantly GRPR-negative. 
Radiolabelled Gastrin-Releasing Peptide (GRP) or bombesin (BN) analogues 
targeting the GRPR can be used as non-invasive tools to diagnose, monitor and 
potentially treat PC. These BN analogues have already proven to be able to im-
age PC in both tumour-bearing mice and clinical patients showing no important 
side effects. 
It is desirable that new peptides require fast-track standardised comparative test-
ing in relevant PC models to select the best performing BN analogues for further 
evaluation in patients. Although knowledge about GRPR expression and devel-
opment of new BN analogues can be extended, it is time to study performance of 
BN analogues for peptide-receptor based imaging in patients validating results of 
PC imaging using histopathology as a golden standard.
inTroducTion
The medical specialism of nuclear medi-
cine focuses on the application of radio-
labelled tracers for scintigraphic imag-
ing or radionuclide therapy of disease. 
Molecular nuclear medicine holds the 
unique potential of being able to find, 
diagnose and treat disease as well as to 
monitor treatment response.
The current evolution of knowledge in 
molecular biology has resulted in new 
targets to detect human cancer spe-
cifically. New developments in (radio)
chemistry have improved molecular de-
livery of radionuclides to disease-target 
sites. Consequently this has resulted in 
the generation of novel tracers. Techni-
cal developments in scintigraphic instru-
ments and reconstruction software have 
improved imaging modalities allowing 
small-animal scintigraphic techniques 
useful for experimental nuclear research 
of, especially rodent, disease models. 
See for review1.
In oncology radioactive iodine intro-
duced in the early 1950s and the widely 
used 18F-fluoro-2-deoxy-D-glucose (18F-
FDG) have been developed as indicators 
of cancer cells. A promising opportunity 
for nuclear applications in oncology lies 
in the development of radiolabelled pep-
tides that target receptors for imaging 
and therapy. This technique is based on 
targeting specific receptors that are over-
expressed in tumour compared to normal 
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tissue with highly selective radiolabelled 
peptides for specific imaging and moni-
toring. Linked to appropriate therapeutic 
radionuclides these peptides can also be 
used as radiotherapeutics in peptide re-
ceptor radionuclide therapy (PRRT). 
In order to bring peptide-receptor based 
modalities into the clinic, radiopharma-
ceuticals with high affinity and high spe-
cificity for preferably cancer-specific re-
ceptors are required allowing visualisa-
tion and quantification of radioactivity in 
the tumour in a reproducible and repeat-
able manner. See for review2. Somatosta-
tin is a well-known peptide, of which 
analogues have been implemented suc-
cessfully in the clinics to visualise and 
treat various neuroendocrine tumours3, 4.
This review focuses on the use of the Gas-
trin-Releasing Peptide Receptor (GRPR) 
as a target for imaging and radionuclide 
therapy of prostate cancer (PC) using ra-
diolabelled bombesin (BN) analogues. 
The potential of these peptides for their 
use in early diagnosis, monitoring and 
therapy of PC will be discussed.
ProsTaTe cancer
PC is the most frequently diagnosed 
cancer among men in the Western world 
and is the third most common cause of 
death5. Specific antigen (PSA) PSA has 
been increasingly used to detect PC6, al-
though it has limited diagnostic specifi-
city and prognostic value7. The impact 
of PSA-based screening on survival has 
recently been reported by the European 
Randomised Study of screening for PC 
(ERSPC) study showing a significant 
reduction in death from prostate cancer, 
but at the cost of overtreatment8. Due to 
PSA-based screening, the number of pa-
tients that are detected with early disease 
is rising. Although, final diagnosis of 
PC is made by histopathological confir-
mation of transrectal ultrasound-guided 
prostate biopsies, staging of the disease 
is essential for the decision for the most 
accurate treatment. It discriminates be-
tween organ-confined disease, in which 
local therapy such as surgery or radiation 
may still be beneficial, and PC beyond 
the confines of the gland for which a sys-
temic approach like hormonal therapy is 
the first choice of treatment. None of the 
currently used imaging modalities are 
sufficiently reliable to determine the ex-
tent of disease in early detected PC9. Non-
invasive sensitive imaging strategies to 
accurately diagnose, stage and monitor 
PC are therefore essential. Radiolabelled 
peptide-based imaging by scintigraphy 
may be the alternative application to fill 
this gap and improve diagnostic sensi-
tivity for early PC. Also, PRRT may be 
an alternative tumour-specific target-
ing strategy in progressive patients with 
metastatic, therapy-resistant PC.
PET metabolic radiotracers such as 18F-
FDG, 11C-choline and 11C-acetate have 
been intensively studied for imaging PC. 
18F-FDG was found to have a low accu-
racy in primary staging of PC mainly due 
to low metabolic glucose activity and 
urinary excretion of the metabolic tracer 
[10]. Choline and acetate PET was re-
ported useful for staging of LN disease10, 
11.
ProstaScint (111In-capromab pendetide), 
a monoclonal antibody against prostate-
specific membrane antigen (PSMA) as 
28
a target, is the only nuclear imaging 
application for PC-specific imaging. 
It has been approved by the American 
Food and Drug Administration and is 
put to practice for diagnostic imaging 
and staging of LN metastasis of PC12.
An alternative target for PC imaging 
may be the GRPR using radiolabelled 
BN analogues.
 
bn for PePTide-TarGeTed 
iMaGinG of Pc
Gastrin-Releasing Peptide (GRP) is a 
27-amino acid neuropeptide that is the 
mammalian homologue of the linear 
tetradecapeptide BN originally isolat-
ed from the skin of the frog; Bombina 
bombina. GRP binds selectively to the 
GRPR. It shares homology with BN at 
the amidated C terminal sequence in 
the final 7 amino acids (Figure 1).
Using tumour autoradiography it has 
been reported that in human samples 
GRPRs are expressed at high density 
on the cell membranes of prostatic in-
traepithelial neoplasias (PIN), primary 
PC and invasive prostatic carcinomas, 
whereas normal prostate tissue and, in 
most cases, benign prostate hyperpla-
sia (BPH) were predominantly GRPR-
negative13. The underlying molecular 
mechanisms of aberrant GRPR expres-
sion and/or activation in human PC are 
unknown at present. GRP interacts with 
GRPR inducing cell growth in various 
tumours including PC14. The relation 
between GRPR and PC stage is still 
uncertain. PC in xenografts derived 
from late stage androgen-independent 
disease showed lower expression of 
the GRPR than xenografts established 
from early androgen-dependent PC15. 
Besides in PC GRPR is also over ex-
pressed in several other human tumour 
types and metastases including breast-, 
colon-, lung-, ovary-, renal, CNS and 
head or neck squamous cancer14, 16.
Four subtypes of the cell surface BN 
receptor are known. Among them three 
are mammalian: the NMB receptor 
Gastrin releasing peptide 
Ala-Pro-Val-Ser-Val-Gly-Gly-Thr-Val-Leu-Ala-Lys-Met-Try-Pro-Arg- 
(Gly-Asn-His-)Trp-Ala-Val-Gly-His-Leu-Met-NH2 
 
                                  C terminus 
 
Bombesin 
pGlu-Gln-Arg-Leu- 
(Gly-Asn-Gln-)Trp-Ala-Val-Gly-His-Leu-Met-NH2 
 
                                    C terminus 
figure 1
Amino acid sequence of the 27-amino acid neuropeptide GRP and 
its mammalian homologue; the linear tetradecapeptide BN.
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(BB
1
), Gastrin-Releasing Peptide Re-
ceptor (GRPR/BB
2
) and BN receptor 
subtype 3 (BRS-3/BB
3
). A fourth recep-
tor, BB
4,
 is only found in amphibians14, 
17. The only well characterised receptor 
to which GRP and BN bind with high 
affinity is the GRPR (BB2).
research on GrPr 
and bn-analoGues
The finding of GRPR overexpression 
in PC and other cancer types stimu-
lated the search for BN/GRP peptide 
analogues that could bind with high po-
tency to the GRPR. GRP-antagonistic 
analogues have been developed to real-
ise antiproliferative effects and indeed 
this has led to promising growth-inhib-
itory effects in human GRPR-positive 
PC cell lines and human PC3-bearing 
mice18. Besides this approach it was 
also proposed that GRP analogues 
could be used as molecular tracers for 
imaging and treatment of PC tumours, 
when those analogues would be linked 
to a radioactive agent13, 19. This applica-
tion has been studied in both preclini-
cal and clinical settings.
Synthetic BN analogues can be catego-
rized into two different types based on 
their structures. Type A-analogues are 
truncated with only a portion, usually 
BN7-14 at the C terminus, of the peptide 
retained. This C terminal sequence is 
generally thought to be essential for 
receptor recognition, signal transduc-
tion, and biologic function (Figure 1). 
Type B analogues on the other hand are 
synthesized in full length. In these ana-
logues usually one or more amino acid 
residues are selectively replaced. 
A type A-analogue is generally thought 
to be favourable while it is more stable 
than the full-length type B tetradeca-
peptides for in vivo applications and 
still binds to the GRPR adequately20, 21. 
For radiolabelling of GRP-analogues 
biomolecules are generally designed 
in a way to keep the labelling site at 
distance from the receptor-binding site, 
but at the same time tag the radiometal 
into the molecule in an irreversible way 
leading to stable radiolabelled deriva-
tives.
Preclinical 
The development of new analogues is 
mostly aimed at improving the sensitiv-
ity and specificity of GRPR targeting. 
Several new BN-analogues have been 
developed and tested for their poten-
tial in early diagnosis, monitoring and 
therapy in vivo. In a preclinical setting 
general peptide characteristics such 
as stability, biodistribution and toxic-
ity were often tested using the human 
PC3 cell line and the experimental PC3 
bearing xenograft model.
A potent 99mTc-based BN analogue de-
signed for GRPR based targeting and 
tested in the PC3 xenograft model with 
the highest absolute tumour-uptake in 
animals described in literature, is De-
mobesin-122. Other promising BN-an-
alogues that were tested in preclinical 
studies using PC3 bearing mice include 
the DOTA chelated compounds AMBA 
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and Pesin, the DTPA chelated com-
pound MP2653 (Compound 3 in Visser 
et al.) and [DTPA1, Lys3(Pm-DADT), 
Tyr4]BN (for amino acid sequence of 
native BN and  BN-analogues see Table 
1)23-26.
Rogers et al. introduced the radiola-
belled BN analogue 64Cu-DOTA-Aoc-
BN7–14 as the first GRPR targeting ra-
diopharmaceutical to use for PC-imag-
ing with PET27. The BN-analogue 18F-
FB-[Lys3]BN designed for GRPR-tar-
geted PET has also been tested showing 
promising results for PC imaging28.
At the moment a valid comparison of 
available analogues for PC detection is 
difficult as standardisation between the 
preclinical studies performed is lack-
ing. Therefore we recently performed a 
standardised preclinical study compar-
ing four DOTA-chelated BN agonists 
and one N4-chelated BN antagonist 
(manuscript submitted).
GRPR will internalise into the cell 
when it is activated by an agonistic li-
gand binding the receptor. Internalisa-
tion of the receptor-radioligand com-
plex has always been thought to be a 
crucial step for optimal imaging and 
therapy. It would provide essential ac-
cumulation and retention of radioac-
tivity in the cell, thus increasing the 
radioactive signal at the target site. In-
terestingly, high-affinity somatostatin 
receptor antagonists that poorly inter-
nalise into tumour cells have recently 
shown an equal or even higher tumour 
uptake and a higher retention rate in 
preclinical studies as opposed to ago-
nists, which do internalise29. Cescato et 
al. showed that GRPR antagonists may 
be superior targeting agents compared 
to GRPR agonists as well30. These 
data suggest a change of paradigm in 
which the intensified use of antagonis-
tic in preference to agonistic analogues 
would be justified.
PC3 and Du145 cell lines are common-
ly used in GRPR binding studies. Both 
cell lines are androgen-independent 
and show no expression of the andro-
gen receptor or PSA; characteristics 
which are essential to PC patients31. 
On the other hand, both cell lines ex-
press high levels of GRPR32. Therefore 
they remain functional for use in GRPR 
based studies. In a panel of 12 estab-
lished human PC xenograft models rep-
resenting the different stages of human 
PC, Visser et al. showed that high GRP 
receptor density was only observed in 
androgen-dependent PC xenografts. If 
Table 1
Amino acid sequence of native BN (14 amino acids) and the BN-analogues described. BN = bombesin, 
Ref(s) = reference(s).
Chelators: N4 = 6-{p-[(carboxymethoxy)acetyl]aminobenzyl}-1,4,8,11-tetraazaundecane, DOTA = 
1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid, DTPA = Diethylene triamine pentaacetic 
acid, Pm-DADT = diaminedithiol, FB = 4-Fluorobenzoyl, N
3
S = dmgly-L-ser-L-cys(acm).
Linkers: BzDig = p-aminobenzyldiglycolic acid, PEG = polyethylene glycol, Aoc = 8 carbon linker, 
Gly-5aVa = 5-amino-valeroyl, Aca = 6-amino-n-hexanoic acid.
Introduced amino acids: Phe = Phenylalanine, ACMPip = 4-Amino-carboxymethylpiperidine (non-
natural amino acid), Tha = β-(2-Thienyl)-alanine (non-natural amino acid), β-Ala = β-Alanine (non-
natural amino acid), Nle = Norleucine, Lys = Lysine, Cys = Cysteine, Pro = Proline, Tyr = Tyrosine.
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this result can be translated to the clini-
cal situation, it might indicate that high 
GRPR expression is predominantly 
present in the early, androgen-depen-
dent, stages of PC and not in later stag-
es. In addition, in this preclinical study, 
androgen ablation strongly reduced 
GRPR expression in androgen-depen-
dent tumours indicating that GRPR 
expression in human PC is androgen-
regulated15. Thus GRPR based imaging 
may be especially relevant in early PC 
and less suited for hormone-treated pa-
tients with late stage disease.
clinical
Few BN-analogues have been studied 
in PC patients. Van der Wiele pub-
lished clinical data on 99mTc-RP527 in 
four androgen independent PC patients 
with metastatic bone lesions. Selective 
uptake was observed in one patient and 
50% of the bone lesions could be vi-
sualised by SPECT in this patient. No 
short-term adverse or subjective effects 
were described in any of the subjects33.
The GRP analogue [Leu13]BN which 
complexes with 99mTc was described in 
an article by Varvarigou et al.34. Herein 
[Leu13]BN showed to be a promising 
BN-analogue in GRPR expressing ma-
lignancies other than PC. A first clinical 
study using 99mTc-[Leu13]BN for imag-
ing in an androgen-dependent PC pa-
tient by De Vincentis et al. resulted in 
the visualisation of the primary PC in 
this patient without observing relevant 
side-effects35. Scopinaro et al. proceed-
ed evaluating the same analogue in 8 
PC patients and reported all 8 primary 
PCs to be visualized in the prostate 
fossa by SPECT while 2 patients with 
benign adenomas did not show uptake. 
In this study SPECT showed uptake in 
obturator nodes which was proven to 
be cancer-specific after histopathology 
in 3 patients. MRI or CT did not show 
these LN metastases36. After this study 
Vincentis et al. reported SPECT-de-
tected PC in 12/12 patients with andro-
gen-dependent PC and loco-regional 
LN visualisation in 4 patients. Eleven 
patients got operated and results were 
histologically confirmed by surgical 
specimens. No short-term adverse ef-
fects were stated37. In a phase I study in 
hormone refractory PC patients aiming 
at PC therapy, using the 177Lu-labelled 
BN analogue AMBA, SPECT imaging 
revealed lesions in 5 out of 7 patients 
with adittional high pancreatic uptake 
of radioactivity38. For an overview of 
clinical PC-imaging studies see Table 
2.
Recently, Froberg et al. reported high 
uptake of the BN-agonist MP2248 and 
antagonist Demobesin-1 in the pancre-
atic region of 4 PC patients. Retention 
in the pancreas after injection of 111In-
MP2248 was much longer than reten-
tion of 99mTc-Demobesin-139. 
Only very few PET studies have been 
reported to date for visualisation and 
quantification of GRPR expression 
in PC patients. A clinical study using 
68Ga-DOTABOM has been described 
by Hofmann et al.40.
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fuTure ProsPecTives
Although expression of the GRPR in 
various tissue types and tumours has 
been studied it requires further investi-
gation. In case of PC, knowledge about 
the androgen regulation of GRPR is 
of great clinical relevance, as it will 
strongly determine the potential use of 
BN-based imaging and therapy in the 
different stages of PC.
A valid comparison of BN-analogues 
for PC detection, based on literature, 
is difficult as standardisation between 
studies is lacking. Differences in po-
tency between existing and future 
BN-analogues need to become clear. 
Standardised studies with appropriate 
design to compare analogues are there-
fore required.
The field of radiolabelled peptides 
for receptor-based targeting of PC is 
evolving. New BN-analogues are being 
designed in order to improve charac-
teristics like specificity, sensitivity and 
stability in vivo. BN-peptides should 
have high affinity for to the GRPR, re-
main intact in vivo for a long time and 
their clearance from circulation should 
be fast. Furthermore, for peptide-re-
ceptor targeting, receptors of interest 
should ideally be highly expressed in 
the disease tissue only. High expression 
in (non-cancerous) non-targeted tissue 
will cause non-specific peptide binding 
resulting in a high background signal 
while scanning and toxicity to healthy 
tissue when therapy is concerned. 
When developing a BN-analogue, be-
sides taking its amino acid sequence 
into consideration, attention should be 
paid to the selection of an appropriate 
chelator while this determines which 
radionuclides can be complexed with 
the analogue. 
Recent findings suggest that antagonis-
tic GRPR-based peptides show higher 
tumour uptakes and radioactivity reten-
tion in PC tissue compared to agonis-
tic peptides with comparable binding 
affinities. This finding paves the way 
for intensified development of new 
BN-antagonists. Also from a pharma-
cological point of view this change in 
paradigm is favourable, as antagonists 
may not induce the endocrinological 
side effects known from agonists, such 
as stimulation of tumour growth. Espe-
cially when a therapeutic dose is taken 
into account, agonistic BN-peptides 
could cause (side-)effects for PC pa-
tients. More research needs to be done 
to reveal the underlying mechanism in 
binding difference between agonistic 
and antagonistic peptides. To improve 
peptide-receptor targeting and increase 
the dose in target cells it might be sug-
gested to test a cocktail of BN-agonists 
and antagonists for simultaneous ad-
ministration.
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absTracT
PSA-based screening of prostate cancer (PC) has dramatically increased early 
diagnosis. Current imaging techniques are not optimal to stage early PC ade-
quately. A promising alternative for PC imaging is peptide based scintigraphy 
using radiolabelled bombesin (BN)-analogues that bind to Gastrin-Releasing 
Peptide Receptors (GRPR) being overexpressed in PC. When labelled to ap-
propriate radionuclides BN targeting of GRPRs may also provide applica-
tions for peptide radionuclide receptor therapy (PRRT). Assessment studies 
under identical experimental conditions allowing a reliable comparison of the 
potential of such analogues are lacking. This study was performed to evalu-
ate and directly compare five promising radiolabelled BN analogues for their 
targeting efficacy of PC under standardised conditions.
BN agonists 111In-DOTA-Pesin, 111In-AMBA, 111In-MP2346 and 111In-MP2653 
and one antagonist 99mTc-Demobesin-1, were evaluated in GRPR-overex-
pressing human PC-3 tumour bearing mice performing peptide stability in 
vivo, biodistribution and GRPR targeting potential by animal SPECT/CT im-
aging and ex-vivo autoradiography.
HPLC analysis of blood showed intact Demobesin-1 at 5 and 15 min after in-
jection (64.1%±1.6 and 41.0%±01, respectively) being much less for the other 
compounds. AMBA, the second most stable analogue, showed 36.1%±2.7 and 
9.8%±1.1 intact peptide after 5 and 15min. PC-3 tumour uptake at 1 hour 
was comparable for Demobesin-1, AMBA, Pesin and MP2346 (3.0±0.4, 
2.7±0.5, 2.3±0.5 and 2.1±0.9%ID/g, respectively), but very low for MP2653 
(0.9±0.2%ID/g). In addition, MP2346 showed undesirable high uptake in 
the kidneys (7.9±1.9%ID/g) being significantly less for the other analogues. 
AMBA, MP2346 and Pesin revealed favourable increases in tumour to blood 
ratios over time while changes in tumour-to kidney and pancreas ratios for 
Demobesin-1 from 1 to 24h after injection were significantly better than for 
the other analogues. All analogues visualised PC-3 tumours by SPECT-CT 
and autoradiography. 
In the present study the BN antagonist Demobesin-1 was the best performing 
analogue showing superior in vivo stability, highest tumour-uptake and reten-
tion while pancreatic and renal clearance were rapid. Pesin and AMBA were 
the best GRP-agonists with sufficient in vivo stabilities as well as high uptake 
and retention tumour. Based on these results all three analogues deserve fur-
ther evaluation for clinical use in PC patients.
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inTroducTion
Prostate cancer (PC) is the most fre-
quently diagnosed cancer among men 
in the Western world. It is the third 
most common cause of death1. After its 
introduction as a biomarker, the pros-
tate specific antigen (PSA) has been 
increasingly used to detect PC2 de-
spite its limited diagnostic specificity 
and prognostic value3. The European 
Randomised Study of Screening for 
PC (ERSPC) has shown that screening 
for PC using PSA detection and digi-
tal rectal examination, has resulted in 
fourfold increase in the detection of 
PC4. To select an optimal therapeutic 
strategy for PC at time of diagnosis, 
it is essential to discriminate between 
organ-confined disease (with local 
therapy such as surgery or radiation 
therapy still likely to be beneficial) and 
PC beyond the confines of the gland 
(for which a systemic approach such 
as hormonal therapy is the first choice 
of treatment). Yet none of the standard 
imaging modalities are sufficiently 
reliable in determining the extent of 
minimal disease at time of diagnosis5, 
6. New non-invasive sensitive imaging 
strategies to accurately diagnose, stage 
and monitor PC are therefore required. 
Radiolabelled peptide-based imaging 
by scintigraphy - single positron emis-
sion tomography (SPECT) or positron 
emission tomography (PET) - may be 
an interesting alternative to fill this gap 
and improve diagnostic accuracy for 
early PC.
Gastrin-releasing peptide receptors 
(GRPRs) are overexpressed in several 
primary human tumours and metasta-
ses7. Using tumour autoradiography, 
Markwalder and Reubi8 reported that 
GRPRs are expressed in invasive pros-
tate carcinomas and in prostatic in-
traepithelial neoplasms at high density, 
whereas normal prostate tissue and hy-
perplastic prostate tissue were predom-
inantly GRPR negative. These findings 
suggest that GRPR may be used as a 
molecular basis for diagnosing and 
staging PC, similar to somatostatin re-
ceptors (SST) which are being success-
fully used in clinical practice9-12.
Bombesin (BN) and its mammalian 
counterpart, gastrin-releasing pep-
tide (GRP) bind to the GRPR and are 
involved in the regulation of a large 
number of biological processes. Four 
subtypes of the bombesin receptor are 
known of which the neuromedin B re-
ceptor (BB
1
), GRPR (BB
2
) and BN re-
ceptor subtype 3 (BRS-3 or BB
3
) are 
mammalian receptors and the fourth 
subtype (BB
4
), is found in amphibians 
only7. The carboxyl-terminal decapep-
tide of GRP is similar to that of the 
14-amino acid amphibian BN peptide. 
BN possesses the same biologic and im-
munologic activities and has also got 
a high affinity for GRPR. Since BN is 
assumed to be more stable than GRP, 
developments have mainly been fo-
cused on BN analogues. BN peptides 
have been coupled to suitable chelators 
such as diethylenetriaminepenteacetic 
acid (DTPA), 1,4,7,10-tetraazacyclodo-
decane-N,N’,N’’, N’’’-tetraacetic acid 
(DOTA) and acyclic tetraamine (N
4
, 
1,4,8,11-tetraazaundecane function-
alised at position 6 for binding to pri-
mary amine groups of peptides) to allow 
labelling with various radionuclides.
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DOTA and DTPA coupled BN ana-
logues enable high specific labelling 
with 111In because of the superior cel-
lular retention characteristics of this 
radionuclide13. The DOTA chelator can 
also be labelled with therapeutic radio-
nuclides such as 90Y, 213Bi and 177Lu, of-
fering the possibility of using these BN 
analogues for therapeutic use. Addi-
tionally, replacement of the DTPA che-
lator with DOTA allows for radiolabel-
ling with 68Ga, making these peptides 
also suitable for PET imaging14. On the 
other hand, Demobesin-1 with its N
4 
chelator enables labelling with 99mTc, 
the most widely-used radionuclide in 
nuclear medicine diagnosis.
The suitability of several radiolabelled 
BN analogues for PC targeting has been 
tested in preclinical and clinical studies 
(for review see 15). However, a valid 
comparison of the potentials of the ra-
diolabelled BN analogues described in 
the literature is considerably limited 
due to different evaluation protocols 
followed in individual preclinical stud-
ies. This situation strongly hampers 
the selection of the most suitable ana-
logues for further clinical validation. 
Using GRPR overexpressing human 
PC-3 bearing SCID mice, we evaluated 
the PC-targeting efficacy of five prom-
ising radiolabelled BN analogues for 
SPECT imaging under identical experi-
mental conditions. With BN agonists 
Pesin, AMBA, MP2346 and MP2653 
and one antagonist Demobesin-116-20 we 
performed in vivo stability studies, bio-
distribution, SPECT/CT imaging and 
ex-vivo autoradiography along with 
haematoxylin-eosin (HE) staining.
MaTerials and MeThods
analogues and radiolabelling
The tested analogues were selected on 
the basis of their good PC targeting ef-
ficacy, as previously reported. In Fig-
ure 1A I the amino acid composition of 
BN and analogues studied are shown. 
AMBA18 and Pesin20 were kindly pro-
vided by Prof. Dr. Mäcke, University 
Hospital Basel, Switzerland. MP234616 
and MP265317 were supplied by Bio-
Synthema (St Louis, MO, USA). In this 
study radiolabelling of Pesin, AMBA, 
MP2346, and MP2653 was performed 
with 111InCl
3
 (Covidien, Petten, The 
Netherlands), as described earlier16, 21-
23. Incubation for the DOTA-peptides 
was performed at 80ºC for 20 min.
Demobesin-1 was a gift from Dr. T. 
Maina and Dr. B. Nock, Demokritos, 
Athens, Greece. This peptide was ra-
diolabelled with 99mTc as previously de-
scribed by Nock et al.19, 23.
In order to prevent oxidation and radi-
olysis quenchers were added to all ra-
diolabelled analogues. Quenchers used 
were ascorbate (Bufa BV, Uitgeest, The 
Netherlands), gentisic acid (Covidien, 
Petten, The Netherlands) and methio-
nine (Fluka Biochemika, Buchs, Swit-
zerland)23.
Quality control
The radiolabelling yield and radio-
chemical purity (RCP) of the labelled 
analogues were assessed by instant thin 
layer chromatography (ITLC) in a 1:1 
methanol:ammonium acetate solution19 
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and by HPLC (see below). For 99mTc 
labelled analogue Demobesin-1, an 
extra ITLC with a 100% acetone solu-
tion was performed to quantify 99mTcO2 
content. After radiolabelling and cool-
ing down to ambient temperature, 10 
µL 4mM DTPA was added to the 111In-
DOTA peptides in order to avoid false 
positive quality control results e.g. due 
to colloid formation to complex any 
free 111In24, 25. For the yield of incorpo-
ration of radioactivity a lower limit of 
95% was set.
HPLC analysis of radiolabelled ana-
logues was performed on a Waters 
Breeze HPLC system (Waters, Etten-
Leur, The Netherlands) based on a 
1525 binary HPLC pump connected to 
a Unispec MCA g-detector (Canberra, 
Zellik, Belgium). A Symmetry C
18
 col-
umn (5 µm, 4.6 mm x 250 mm, Waters, 
Etten-Leur, The Netherlands) served as 
stationary phase eluted with a solvent 
system consisting of 0.1% trifluoroace-
tic acid (TFA) in H
2
O (solvent A) and 
0.1% TFA in methanol (solvent B) in 
a gradient protocol; 0-2 min 100% sol-
vent A (flow rate 1 mL/min), 2-3 min 
55% solvent B, 3-30 min 65% solvent 
B (flow rate 0.5 mL/min), 30-38 min 
100% solvent B (flow rate 1 mL/min), 
38-40 min 100% solvent B, 40-46 min 
100% solvent A. 
Radiochemical purity was estimated 
for each analogue by evaluating radio-
activity peaks eluted from the HPLC 
column and calculating the area under 
the curve. 
cell culture
Human PC-3 cells were cultured in 
RPMI (LONZA, Verviers, Belgium) 
supplemented with 5% fetal calf serum 
(FCS) (GIBCO Invitrogen Co, Grand 
Island, NY, USA) and 5mL/500mL 
penicillin/streptomycin antibiotics 
(10.000 Units/mL penicillin, 10.000 
Units/mL streptomycin; LONZA, Ver-
viers, Belgium). Cells were grown 
in T175 Cellstar tissue culture flasks 
(Greiner Bio-one GmBH, Frickenhau-
sen, Germany) at 37°C in a humidified 
atmosphere containing 5% CO
2
. Cells 
were passaged using a Trypsin - EDTA 
solution (LONZA, Verviers, Belgium) 
170000 U/L Trypsine-Versene and 200 
mg/L EDTA.  For the present study, 
cells were grown to near confluency 
and were than harvested and counted. 
Suspensions of cells were dissolved 
in PBS to yield approximately 6x106 
cells/0.15 mL for subcutaneous injec-
tion.
Pc-3 xenograft
6 to 7-week old male Swiss nu/nu mice 
(Charles River, Kißlegg, Germany) were 
inoculated subcutaneously with PC-3 
cells in the right shoulder. A maximum 
of 4 mice per cage were kept in 14 x 13 
x 33.2 cm3 individually ventilated cag-
es (Techniplast), on sawdust (Woody-
Clean, type BK8/15; BMI) under a 12-h 
light-dark cycle, at 50±5% relative 
humidity and controlled temperature 
(~22°C). Mice received irradiated chow 
and acidified drinking water ad libitum. 
Experiments were initiated when the tu-
mour size reached a volume of 200-500 
mm3 (3-5 weeks after inoculation). 
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The experiment was approved by 
the Animal Experimental Committee 
(DEC) of the Erasmus MC and per-
formed in agreement with The Neth-
erlands Experiments on Animals Act 
(1977) and the European Convention 
for Protection of Vertebrate Animals 
Used for Experimental Purposes (Stras-
bourg, 18 March 1986).
Peptide stability in vivo
Non tumour-bearing 6 to 7-week old 
male Swiss nu/nu mice (Charles River, 
Kißlegg, Germany) were injected intra-
venously into a lateral tail vein with 1 
nmol radiolabelled analogue labelled 
with 30 MBq 111In or 60 MBq 99mTc in 
a volume of 100 μL. Animals were sac-
rificed at 5 and 15 min after adminis-
tration. For each time point 2 animals 
were used.
Blood was collected by orbita punc-
tion in an ethylenediaminetetraacetic 
acid (EDTA) tube to prevent clotting, 
and put on ice. Subsequently, samples 
were centrifuged for 5 min, 9500 g at 
+4 °C, after which the supernatant was 
collected and precipitated with ethanol 
(serum:ethanol 1:1). At HPLC run the 
final ethanol concentration was below 
50%. Precipitated serum was then cen-
trifuged for 5 min at 9500 g to dispose 
of large proteins. The supernatant con-
taining the radiolabelled peptide was 
used for HPLC analysis. Results were 
indicated as percentage of intact radio-
labelled peptide as determined from the 
HPLC analysis (% intact peptide of two 
mice per timepoint).
biodistribution studies
PC tumour bearing mice were injected 
intravenously into a lateral tail vein 
with 10 pmol of analogue labelled with 
an activity of 0.5 MBq 111In or 2.5 MBq 
99mTc, in a volume of 0.1 mL. Animals 
were sacrificed at 1, 4, or 24 h after ad-
ministration of test analogue. For each 
time point 4 animals were used. To 
discriminate between receptor-specific 
and non-specific binding, for each ana-
logue three additional mice were co-
injected with an excess of unlabelled 
[Tyr4]BN (0.1 mg in 0.1 mL) and sac-
rificed 4 h post injection (pi). The tu-
mours and selected tissues (blood, pan-
creas, kidney and colon) were excised, 
weighed, and counted for radioactivity 
in a γ-counter (LKB-1282-compugam-
ma system, Perkin Elmer, Groningen, 
The Netherlands). Data were calculated 
as percentage of the injected dose per 
gram of tissue (% ID/g) using counts 
from 0.01 mL of the original injectate 
as reference.
sPecT-cT
SPECT-CT scans were performed with 
a four-headed multiplexing multi-
pinhole NanoSPECT/CTTM (Bioscan 
Inc.,Washington D.C., USA). Each 
head was equipped with an application-
specific tungsten-based collimator with 
nine pinholes of 1.4 mm diameter im-
aging a cylindrical field of view, pro-
viding a reconstructed resolution in the 
submillimeter range. For SPECT-CT 
a peptide amount of 0.25 nmol in 0.1 
mL was injected intravenously. This is 
needed to enlarge peptide amount for 
tumour binding to achieve sufficient ra-
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dioactivity for imaging. Total injected 
activities ranged from 23-31 MBq for 
the 111In-analogues to 142 MBq for De-
mobesin-1. For each analogue, whole-
body scans were performed at 1 and 4 h 
after injection of the radiolabelled ana-
logue. An acquisition time of approxi-
mately 200 seconds per view was used, 
resulting in a total scanning time of 
about 1 h 30 min per animal. CT scans 
were performed with the integrated CT 
using a tube voltage of 45 kV and an 
exposure time of 1500 ms per view. Af-
ter acquisition, the SPECT data were 
reconstructed with HiSPECT software 
(Scivis GmBH, Göttingen, Germany). 
For CT reconstruction a cone beam fil-
tered back projection was employed. 
SPECT and CT data were automatical-
ly co-registered since both modalities 
shared the same axis of rotation. The 
fused data sets were analysed in the 
InVivoScope post-processing software 
(Bioscan Inc., Washington D.C., USA). 
Mice were sacrificed and their tumours 
were dissected and quickly frozen in 
liquid nitrogen for subsequent ex-vivo 
autoradiography.
ex vivo autoradiography
Frozen PC-3 tumours derived from 
SPECT animals were cut into sections 
of 10 µm (Microm Cryo-Star HM 560 
M, Walldorf, Germany) and mounted 
on glass slides (Superfrost plus slides, 
Menzelgläser, Braunschweig, Ger-
many). Tumour sections were exposed 
to Super Resolution phosphor imaging 
screens (Packard Instruments Co., CT, 
USA) in X-ray cassettes. After 24-72 
h screens were imaged by a Cyclone 
phosphor imager and analysed using 
the OptiQuant 03.00 image processing 
system (Perkin Elmer, Groningen, The 
Netherlands). After exposure, PC-3 
sections were haematoxylin-eosin (HE) 
stained and the staining pattern was 
compared to the corresponding autora-
diogram.
statistics
Statistical analyses were performed us-
ing SPSS 11.01 (SPSS Inc., IL, USA). 
For this study we applied the Mann-
Whitney U test. Statistical significance 
was assumed if p values were lower 
than 0.05.
resulTs
Quality control
HPLC radiochromatograms for all 
analogues are presented in Figure 1B. 
Analyses of ITLC (data not shown) and 
HPLC indicated a labelling yield for all 
analogues of more than 97%. For De-
mobesin-1, formation of 99mTcO
2 
col-
loid was <1% as concluded from ITLC 
analysis. RCP ranged from 74 to 93% 
for the various peptides. 
Peptide stability in vivo 
Peptide stability in vivo was highest for 
Demobesin-1 for both timepoints. At 5 
min pi 64.1%±1.6 was still intact fol-
lowed by AMBA (36.1%±2.7), Pesin 
(23.3%±1.4), MP2346 (21.2%±0.8), 
and MP2653 (9.8%±0.5). At 15 min pi 
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still 41.03%±0.11 of intact Demobe-
sin-1 could be recovered with lower 
recoveries for AMBA (9.8%±1.1), 
MP2346 (3.4%±1.3), MP2653 
(2.8%±0.4), and Pesin (1.8%±0.6) (Ta-
ble 1). As derived from dose-calibrator 
measurements of activities in superna-
tant and serum it could be concluded 
that over 90% of total activity had been 
extracted from the serum after the pre-
cipitation procedure (data not shown).
HPLC of all 5 radiolabelled analogues 1 h after labelling.
figure 1b
mean (5 min) mean (15 min)
Analogue Mouse 1 Mouse 2 Mouse 1 Mouse 2
99mTc-Demobesin-1 62.9 65.2 41,0 41.1
111In-AMBA 34.2 38.0 9,0 10.6
111In-Pesin 24.4 22.4 1.4 2.3
111In-MP2346 21,8 20.6 4.3 2.4
111In-MP2653 10.2 9.5 2.6 3.1
Table 1
In vivo stability of all analogues at 5 and 15 min pi injecting 1 nmol of radiolabelled ana-
logue (30 MBq 111In or 60 MBq 99mTc) i.v. in a volume of 0.1 mL in non-tumour-bearing nude 
mice. Results are indicated as % intact analogue from total injected analogue per mouse.
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biodistribution studies
Uptake results in various tissues for 
all radiolabelled analogues at all time 
points are summarised in Table 2. 
Figure 2 shows a graph of the tumour 
uptake results for all analogues at all 
timepoints. The highest PC-3 tumour 
uptake was obtained with Demobe-
sin-1 (3.0±0.4 %ID/g) at 1h pi. The 
analogues AMBA, Pesin, MP2346, and 
MP2653 showed lower tumour uptakes 
at this time point: 2.7±0.5, 2.3±0.5, 
2.1±0.9 and 0.9±0.2 % ID/g, respec-
tively. The differences in tumour up-
take at 4 h pi were consistent with those 
at 1 h. At 24 h, tumour retention of the 
111In-DOTA analogues AMBA and Pe-
sin was highest: 1.6±0.4 and 1.2±0.2 
Table 1
A. 1 hour pi (%ID/g ± SD)
 Organ 111In-MP2653 111In-MP2346 111In-Pesin 111In-AMBA 99mTc-Demobesin-1
Blood 0.2±0.1 0.4±0.5 0.3±0.1 0.2±0.0 0.6±0.1
Pancreas 14.7±3.8 9.0±2.5 20.8±3.9 40.9±3.3 23.8±3.2
Kidneys 2.0±0.3 7.9±1.9 2.7±1.0 3.6±0.7 3.2±1.2
Colon 2.5±0.4 2.1±0.4 2.9±1.5 6.8±0.9 2.5±1.2
Tumour 0.9±0.2 2.1±0.9 2.3±0.5 2.7±0.5 3.0±0.4
B. 4 hour pi (%ID/g ± SD)
 Organ 111In-MP2653 111In-MP2346 111In-Pesin 111In-AMBA 99mTc-Demobesin-1
Blood 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 0.2±0.0
Pancreas 11.4±2.5 8.9±2.1 17.5±2.8 40.5±7.6 4.1±1.6
Kidneys 1.2±0.4 10.6±1.6 1.5±0.4 3.4±1.4 1.1±0.2
Colon 1.6±0.6 1.8±0.7 3.6±0.4 5.6±1.2 1.2±0.3
Tumour 0.7±0.2 1.4±0.4 1.6±0.2 1.9±0.3 2.2±0.4
C. 24 hour pi (%ID/g ± SD)
 Organ 111In-MP2653 111In-MP2346 111In-Pesin 111In-AMBA 99mTc-Demobesin-1
Blood 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0
Pancreas 2.4±0.7 5.8±1.4 14.5±2.8 32.9±5.2 0.1±0.0
Kidneys 0.6±0.3 2.8±0.9 0.7±0.4 1.3±0.5 0.1±0.0
Colon 0.8±0.2 0.6±0.3 1.0±0.4 3.2±0.8 0.1±0.1
Tumour 0.4±0.1 0.7±0.4 1.2±0.2 1.6±0.4 0.4±0.1
Biodistribution data of all five radiolabeled analogues at time points A, B and C in PC3 
tumour-bearing athymic nude mice injected with 10 pmol peptide, labelled with an activ-
ity of 0.5 MBq 111In or 2.5 MBq 99mTc, in a volume of 0.1 mL into a lateral tail vein. Re-
sults are the mean and standard deviation of 4 mice per analogue per time point.
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%ID/g, respectively, with lower out-
comes for MP2346, Demobesin-1 and 
MP2653 (0.7±0.4, 0.4±0.1 and 0.4±0.1 
%ID/g, respectively). 99mTc labelled 
Demobesin-1 showed the most sub-
stantial decline in tumour uptake of 7.1 
fold from 1 to 24 h, unlikely to what 
was observed for the other peptides. 
Tumour uptake of MP2653 was signifi-
cantly lower than that of the other ana-
logues at all time points.
AMBA showed the highest uptake in 
the GRPR expressing pancreas at 1 h 
pi (40.9±3.3 %ID/g). Lower uptake 
was found for Demobesin-1, Pesin, 
MP2653, MP2346 (23.8±3.2, 20.8±3.9, 
14.7±3.8 and 9.0±2.5 %ID/g, respec-
tively). Demobesin-1 showed a con-
siderable wash-out from pancreas re-
sulting in a 25-fold increase in tumour 
to pancreas ratio from 1 to 24 h pi. 
Increase in the tumour to pancreas ra-
tio over time was significantly less for 
MP2653, Pesin, AMBA, and MP2346: 
2.7, 1.0, 0.7 and 0.5 fold, respectively 
(Figure 3a). 
In addition to the pancreas, also GRPR-
specific specific uptake of radiolabel in 
colon was observed. Receptor specific-
ity of peptide uptake was confirmed by 
co-injecting an excess of unlabelled 
[Tyr4]BN resulting in strongly re-
duced uptake (>80%) of radiolabel in 
the colon. PC-3 tumours and GRPR-
expressing pancreas showed a compa-
rable blocking pattern for all analogues 
indicating GRPR-specific uptake. 
Colon uptake was highest for AMBA 
as compared to other analogues at all 
time points: 6.8±0.9 versus 2.9±1.5, 
2.5±1.2, 2.5±0.4 and 2.1±0.4 %ID/g at 
1h pi for Pesin, Demobesin-1, MP2653 
and MP2346, respectively (Table 1). 
The uptake of radiolabel by the kidneys 
was significantly higher for MP2346 
(7.9±1.9 %ID/g at 1h) as compared to 
the other analogues at all time points: 
3.6±0.7, 3.2±1.2, 2.7±1.0 and 2.0±0.3 
%ID/g at 1h for AMBA, Demobesin-1, 
Pesin and MP2653, respectively (Table 
1). The change in tumour to kidney ra-
tio from 1 to 24 h pi was significantly 
higher for Demobesin-1 as compared 
to the other analogues: 3.6 fold versus 
figure 2
Tumour uptake for all analogues 
in PC-3 tumour-bearing athymic 
nude mice injected with 0.5 MBq 
111In or 2.5 MBq 99mTc bound to 
10 pmol of peptide-conjugate, 
in a volume of 0.1 mL into a 
lateral tail vein sacrificed at 
1, 4 and 24 h pi. Results are 
indicated as mean±standard 
deviation of 4 mice per 
analogue per time point.
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2.1, 1.8, 1.8 and 1.0 fold for 
Pesin, AMBA, MP2653, and 
MP2346, respectively (Fig-
ure 3b).
All peptides, except for 
MP2653 and Demobesin-1, 
showed high tumour to blood 
ratios indicating fast clear-
ance from circulation. Pesin 
showed the largest increase 
in tumour to blood ratio of 
14.4 fold from 1 to 4 h fol-
lowed by MP2346, and 
AMBA (5.7 and 5.5, respec-
tively) with the lowest ratios 
for MP2653 and Demobe-
sin-1 (3.5 and 2.6, respec-
tively) (Figure 3c).
sPecT-cT and ex vivo 
autoradiography
All analogues were able to 
image subcutaneous PC-3 
tumours by SPECT-CT at 1 
and 4 h pi (Figure 4 I). Ad-
ditionally, ex vivo autora-
diography of PC-3 tumours 
was performed at 1 and 4 h 
pi. Autoradiography revealed 
considerable heterogeneity 
of peptide binding within 
the tumour for all analogues 
with reduced binding in some 
(central) areas of the tumour 
as was also observed by in 
vivo SPECT-CT imaging as 
well. HE staining of consecu-
tive slides revealed that this 
heterogeneous expression 
pattern coincided with re-
A
C
B
figure 3
Ratios calculated from biodistribution in PC-3 
tumour-bearing athymic nude mice injected with 
0.5 MBq 111In or 2.5 MBq 99mTc bound to 10 pmol of 
peptide-conjugate, in a volume of 0.1 mL into a lat-
eral tail vein sacrificed at 1, 4 and 24 h pi.
Data show the tumour-blood ratio (a), tumour-
pancreas ratio (b) and tumour-kidney ratio (c) at 
all time points for all radiolabelled analogues.
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duced cell density in these tumour ar-
eas (Figure 4 II).
discussion
In order to initiate BN-based scinti-
graphic (SPECT) patient studies for 
the imaging of early PC, we reviewed 
preclinical studies from the literature 
as well as our own studies in search of 
a promising BN-analogue. Due to the 
lack of standardisation of experiments 
performed by various research groups, 
finding consistent comparisons - and 
thus a reliable choice of candidates - 
for further clinical validation, was very 
difficult. For this reason, we decided 
to set up a comparative study using a 
I SPECT-CT image of the PC-3 
tumour in athymic xenografts 
at 1 h after i.v. tail injection of 
0.25 nmol of radiolabelled ana-
logue (23-31 MBq for 111In and 
142 MBq for 99mTc) in a volume 
of 0.1 mL into a lateral tail vein. 
a. AMBA, b. Demobesin-1, c. 
MP2653, d. Pesin, e. MP2346
II Autoradiograms (right) and 
corresponding haematoxylin-
eosin stained sections (left) of a PC-3 
tumour derived from a mouse 4 h after 
injection of MP2346 (a) and AMBA (b). 
Ex-vivo tumour sections were derived from 
PC-3 tumour-bearing athymic nude mice 
injected with 0.25 pmol peptide, labelled 
with 23-31 MBq for 111In analogues in a 
volume of 0.1 mL into a lateral tail vein.
figure 4 i
a b c
d e
a
b
ii
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number of BN analogues under identi-
cal experimental conditions. Five ra-
diolabelled analogues that had already 
been shown to have good GRPR affini-
ties and targeting characteristics were 
selected for this study. Four of the ra-
diolabelled BN analogues were GRPR 
agonists (AMBA, Pesin, MP2653, and 
MP2346) and one was an antagonist 
(Demobesin-1)16-20.The choice for the 
BN agonist Pesin was based on stud-
ies that reported PC-3 tumour uptake of 
Pesin labelled with 67Ga of 14.8 %ID/g 
1 h after injection20. In another study, 
PC-3 tumour uptake of AMBA labelled 
with 177Lu at 1 h pi was 6.4 %ID/g18. 
This analogue has already been ap-
plied in a therapeutic clinical study26. 
MP234616 and MP265317 labelled with 
111In have also shown high affinity for 
GRPR. All agonists were labelled with 
111In via a DTPA or DOTA.
The antagonist Demobesin-1 was in-
cluded because of its very good profile 
(tumour uptake 1 h pi of 16.2 %ID/g 
in PC-3 bearing mice) shown in a pre-
clinical study by Nock et al.19. Further-
more, recent preclinical studies using 
SST analogues suggest that radiola-
belled antagonists are superior to ago-
nists with regard to tumour uptake and 
retention of radioactivity27. Although 
it was shown that the antagonists did 
not trigger receptor internalisation in 
SST receptor expressing cells - a fea-
ture that was previously thought to be a 
crucial characteristic for good retention 
of tumour radioactivity - tumour values 
were reported to be higher for the an-
tagonist than for the agonist. Also, the 
antagonists were shown washed out 
from normal organs much faster than 
agonists, which would potentially re-
sult in a reduction in radiotoxicity of 
normal organs. Recently, GRPR-based 
PC-3 tumour targeting using Demobe-
sin-1 was also shown to be superior to 
an agonistic BN analogue with compa-
rable receptor affinity28.
The differences in half-life between the 
radionuclides we used required the in-
clusion of both early and late evalua-
tion time points (1, 4 and 24 h pi). This 
enabled us to evaluate tissue and blood 
retention rates of the analogues over 
time. In the biodistribution studies we 
used 10 pmol of peptide per animal for 
all analogues. The peptide mass select-
ed was based on the amounts reported 
in the literature19, 20. Also it was chosen 
while the peptide mass enables an ap-
propriate labelling yield for biodistri-
bution for all analogues19, 20.
In the present study Demobesin-1 
showed the highest tumour uptake at 1 
and 4 h pi, although these values were 
not statistically significantly differ-
ent from those of AMBA, Pesin, and 
MP2346. Tumour uptake of MP2653 
was significantly lower when compared 
with that of all other analogues at all 
time points. Since sufficient tumour up-
take is a prerequisite for diagnostic and 
therapeutic use, MP2653 was exclud-
ed from further evaluation. Although 
MP2346 showed good tumour-uptake, 
it had an unfavourable and signifi-
cant higher uptake in the kidney when 
compared with the other analogues at 
all time points. This high renal uptake 
strongly limits its clinical use because 
of potential nephrotoxicity during 
PRRT. For this reason, MP2346 was 
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not further considered as best clinical 
analogue.
In contrast to the reduction in tumour 
uptake of Demobesin-1 from 3.0±0.4 
%ID/g at 1 h to 0.4±0.1 %ID/g at 24 
h pi, tumour retention of radioactivity 
after AMBA and Pesin injection re-
mained fairly stable over this time peri-
od, indicating that these two analogues 
have potential for imaging at later time 
points. Also, this characteristic may be 
well suited for PRRT when BN ana-
logues are coupled to therapeutic radio-
nuclides for PRRT. Since a DOTA che-
lator allows AMBA and Pesin to bind 
a wide variety of radionuclides, both 
conjugates are suitable for imaging and 
PRRT purposes. Research on labelling 
N
4
-chelated analogues with the beta-
emitting 188Re is ongoing.
The pancreas is the organ with the high-
est GRPR expression in mice. Its (non-
intended) peptide uptake in relation to 
the targeted tumour uptake is of concern 
when evaluating GRPR targeted pep-
tides. The tumour to pancreas ratio of 
Demobesin-1 showed an impressive and 
significant 4.6-fold increase from 1 to 4 
h, which was much less marked in the 
other analogues (0.7-fold in AMBA and 
1.2-fold in Pesin). In accordance with the 
study of Cescato et al.28, the BN antago-
nist Demobesin-1 was rapidly washed 
out from the GRPR-expressing pancreas, 
while tumour uptake remained relatively 
high resulting in 25-fold higher tumour 
to pancreas ratios. We also observed this 
phenomenon in a patient study where 
we administered Demobesin-1 and com-
pared it with an agonist 111In-[DTPA-
Pro1,Tyr4]bombesin (unpublished data).
Besides uptake of radioactivity in pan-
creas, GRPR-specific uptake - as could 
be concluded from in blocking data - by 
the colon was also observed. Colon up-
take is also highly relevant to PC imag-
ing as it may interfere with detection 
of PC metastatic lesions at abdominal 
sites. Furthermore it may induce colon-
radiotoxicity when employed for PRRT. 
Unfavourable GRPR-specific colon up-
take was 2-fold higher for AMBA than 
for the other peptides.
Ideally, the tumour to blood ratios of 
analogues should increase over time 
with high retention in the tumour and 
declining activity in the circulation. 
Both AMBA and Pesin analogues 
showed large increases in tumour to 
blood ratios from 1 to 4 h (5.5-fold and 
14.1-fold respectively). In contrast, De-
mobesin-1 showed the smallest change 
in this ratio (a 2.7-fold change between 
1 and 4 h). The slower clearance of De-
mobesin-1 from the blood resulting in 
a lower tumour to blood ratio in com-
parison with the DOTA chelated pep-
tides, may be related to the fact that the 
agonists are more hydrophilic and are 
therefore rapidly cleared by the kidney, 
whereas the lipophilic Demobesin-1 is 
excreted by the hepatobiliary tract as 
well. This could influence clearance ki-
netics. Rapid conversion to hydrophilic 
metabolites may also accelerate blood 
clearance of the agonists. Despite its 
favourable high tumour to blood ratio, 
the very high renal uptake of MP2346 
remains a major disadvantage of this 
peptide.
Generally, peptides for use in pep-
tide receptor-targeted scintigraphy 
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or therapy are chosen for their good 
BN receptor-targeting characteristics 
and in vitro stability. The in vitro se-
rum half-life data of the BN peptides 
used in this study ranged from 3 hrs to 
several days17-19, 21. Peptide stability of 
analogues in vivo is, however, of much 
more relevance. For this reason, in the 
present study we determined the in vivo 
peptide stability of all analogues using 
HPLC. Peptide stability in vivo of all 
4 agonists was very similar. Demobe-
sin-1 was the most stable analogue. We 
can however not completely exclude 
the presence of unknown radiolabelled 
metabolites beside the intact peptide in 
the main peaks from HPLC. Despite 
the significantly longer in vivo peptide 
stability of Demobesin-1, tumour up-
takes for this analogue were not signifi-
cantly different from those of AMBA 
and Pesin. This implies that interac-
tions between GRPR and BN occur 
rapidly. There was no direct correlation 
between in vivo peptide stability and 
analogue performance in mice.
The administration of pharmacological-
ly-active agonistic peptides is known 
to cause endocrine and haemodynamic 
effects by the process of endocytosis29. 
Antagonists on the other hand do not 
have the potential to enter and activate 
cells and, as a consequence, pharmaco-
logical side effects may be less. This 
is especially relevant for PRRT where 
higher amounts of peptide are used than 
for imaging studies. Furthermore, sev-
eral experimental studies have shown 
that BN antagonists induce anti-tumour 
effects30-34, while BN agonists gener-
ally stimulate PC tumour growth7, 35, 
36. Another advantage of Demobesin-1 
is that it is highly selective for GRPR 
and has no affinity for other BN recep-
tor subtypes, NMB-R and BB3-R19. 
The agonists AMBA and Pesin are not 
selective and bind to both GRPR and 
NMB-R18, 20.
With regard to absolute tumour up-
take of radioactivity, the present study 
showed lower tissue uptakes than is de-
scribed for these analogues in the lit-
erature. The variation in radionuclides, 
amounts of peptide, mouse strain (spe-
cies, sex, weight), PC-3 tumour cells 
(passage number, culture conditions) 
used, tumour size and vascularisation 
of the tumour may all be factors that 
determine uptake of radioactivity re-
sulting in variable outcomes. This fur-
ther underlines the necessity to evalu-
ate and compare such analogues under 
standardised conditions. 
The present study showed that all ana-
logues were able to target subcutaneous 
PC-3 tumours as visualized by SPECT-
CT. Ex vivo autoradiography of PC-3 
tumours further revealed that in all ana-
logues there was considerable hetero-
geneity in the distribution of radioac-
tivity between individual tumours. The 
heterogenic pattern could be histologi-
cally related to areas with reduced cell 
density, predominantly in the centre of 
the tumours. This was further support-
ed by the SPECT-CT images showing a 
rim-like tumour image. When consider-
ing using radiolabelled BN for PRRT, 
it should be taken into account that the 
area that will be irradiated contains all 
vital PC cells. Mouse models are not 
ideal while central necrosis results in 
underestimation of uptake (%ID/g). 
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This underlines the necessity to per-
form biodistribution on mice with small 
tumours only. Furthermore it should be 
investigated whether central necrosis 
occurs in patient tumours as well.
In conclusion, the comparison of five 
analogues performed in the present 
study provides a realistic reflection of 
the potential of a number of peptides, in 
spite of the differences between tumour 
uptake and normal organ values found 
in our experiments and those of pre-
vious studies. The BN antagonist De-
mobesin-1 showed the highest tumour 
uptake 1 and 4 hours pi, with a particu-
larly good tumour to pancreas ratios 
and a significantly higher in vivo ana-
logue stability compared with the other 
analogues. This good performance, in 
combination with the advantages of the 
use of antagonists over agonists and its 
99mTc label, make Demobesin-1 a very 
attractive analogue for PC imaging. 
Based on high tumour uptake, retention 
profiles and good tumour to blood ra-
tios combined with sufficient stability 
in vivo, Pesin and AMBA outperformed 
the other two agonists. As they have a 
DOTA chelator, both analogues are cur-
rently more easily applicable for PRRT 
than the N
4
–functionalized Demobe-
sin-1 analogue. Our results indicate 
that all three BN analogues deserve 
further evaluation for clinical nuclear 
imaging, and possibly PRRT, of human 
PC. Demobesin-1 has been selected for 
a first proof of concept clinical study.
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absTracT
Human prostate cancer (PC) overexpresses the Gastrin-Releasing Peptide 
Receptor (GRPR). Radiolabelled GRPR-targeting analogues of bombesin 
(BN) have successfully been introduced as potential tracers for visualization 
and treatment of GRPR-overexpressing tumours. A previous study showed 
GRPR-mediated binding of radiolabelled BN analogues in androgen-depen-
dent but not in androgen-independent xenografts representing the more ad-
vanced stages of PC. 
We have further investigated the effect of androgen modulation on GRPR-ex-
pression in three androgen-dependent human PC-bearing xenografts: PC295, 
PC310 and PC82 using the androgen-independent PC3-model as a reference.
Effects of androgen regulation on GRPR expression were initially studied on 
tumours obtained from our biorepository of xenograft tissues performing RT-
PCR and autoradiography (125I-universal-BN). A prospective biodistribution 
study (111In-MP2653) and subsequent autoradiography (125I-GRP and 111In-
MP2248) was than performed in castrated and testosterone resupplemented 
tumour-bearing mice. 
For all androgen-dependent xenografts tumour uptake and binding decreased 
drastically after 7 days of castration. Resupplementation of testosterone to 
castrated animals restored GRPR expression extensively. Similar findings 
were concluded from the initial autoradiography and RT-PCR studies. Re-
sults from RT-PCR, for which human specific primers are used, indicate that 
variations in GRPR expression can be ascribed to mRNA downregulation and 
not to castration-induced reduction in the epithelial fraction of the xenograft 
tumour tissue. 
In conclusion, expression of human GRPR in androgen-dependent PC xeno-
grafts is reduced by androgen ablation and is reversed by restoring the hor-
monal status of the animals. This knowledge suggests that hormonal therapy 
may affect GRPR expression in PC tissue making GRPR-based imaging and 
therapy especially suitable for non-hormonally treated PC patients.
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inTroducTion
Prostate cancer (PC) is the third leading 
cause of cancer-related deaths and the 
most frequently diagnosed cancer in 
men in Western countries 1. PC will in-
crease to be a major health problem due 
to the aging of people in the Western 
world and currently developed screen-
ing strategies that result in diagnosis 
at more early stage of disease.  In case 
of metastasised late stage PC standard 
therapy exists of hormone deprivation 
which is initially effective in the ma-
jority of patients 2. Eventually however 
PC patients will relapse due to progres-
sion of PC towards hormone-indepen-
dent growth of the tumour.  Unfortu-
nately, advanced PC responds poorly 
to chemotherapeutic agents of which 
taxane-based treatments are nowadays 
considered the standard second-line 
treatment of hormone-resistant PC 3, 
4. Finally, most patients with metasta-
sised PC will die of progressive, hor-
mone-independent disease. Treatment 
and imaging of PC demands for new 
concepts, a potential strategy lies in 
targeting tumour-specific receptors. It 
could improve staging of PC determin-
ing locality of disease at time of diag-
nosis which is required to define treat-
ment decisions.
It has been shown that prostate tumours 
overexpress the Gastrin-Releasing Pep-
tide Receptor (GRPR) 5-9. Overexpres-
sion of these receptors in PC is restrict-
ed to the malignant cells, as normal and 
hyperplastic prostate tissue were shown 
to be GRPR-negative 5. The GRPR is a 
member of the bombesin (BN) recep-
tor family consisting of four known 
receptor subtypes. Three of them the 
neuromedin B (NMB) receptor (BB
1
), 
GRPR (BB
2
) and BN receptor subtype 
3 (BRS-3 or BB
3
), are mammalian re-
ceptors, whereas the fourth subtype 
(BB
4
) is found only in amphibians 9-13. 
BN-like receptors, such as NMB, BB
2
 
and BB
3
 are involved in the regulation 
of a large number of biological pro-
cesses in the gut and central nervous 
system 14 and mediate their action by 
binding to their BN receptor subtypes. 
BN analogues are attractive peptides to 
be used to target the GRPR. Its use has 
been proposed for chemotherapy using 
cytotoxic BN analogues and for nuclear 
interventions employing radiolabelled 
BN analogues to perform peptide-re-
ceptor scintigraphy and radionuclide 
therapy (PRRT) 5.
In a previous study we evaluated the 
expression of GRPRs in different stag-
es of tumour development using a panel 
of 12 xenograft models from 9 different 
patients representing the various stages 
of human PC ranging from androgen-
dependent to androgen-independent 
disease 15, 16. We found GRPR-mediated 
binding of radiolabelled BN analogues 
only in androgen-dependent, but not in 
androgen-independent xenografts rep-
resenting the more advanced stages of 
prostate tumour development 17. Also, 
in a pilot study, GRPR-expression of an 
androgen-dependent xenograft showed 
reduced uptake after androgen ablation 
treatment, suggesting that GRPR-ex-
pression may be influenced by andro-
gens and may be related to the progres-
sive state of PC. 
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Since the majority of patients are 
treated with hormonal therapy dur-
ing the course of their disease, it is 
highly relevant to study the impact of 
hormonal ablation treatment on GRPR 
expression in order to reveal whether 
such patients could still be eligible to 
GRPR targeted modalities. Therefore, 
the purpose of the present study was 
to further investigate androgen regula-
tion of the GRPR in three androgen-
dependent human PC xenograft models 
PC82, PC295 and PC310 that represent 
the early androgen-responsive state of 
human PC 18. We hypothesized that if 
GRPR is androgen regulated, the ex-
pression is reduced by androgen abla-
tion in androgen-dependent xenograft-
bearing mice, and should be reversed 
by restoring the hormonal status of the 
animals. This experimental design al-
lows to elucidate the direct effects of 
hormonal changes on GRPR expres-
sion in relevant models for human PC. 
Since re-supplementation of patients 
with testosterone is not likely to be 
applicable in PC patients, the present 
study set-up is merely experimental in 
nature and less intended to mimic the 
clinical setting. Knowledge about the 
background of hormonal regulation of 
the GRPR will provide crucial infor-
mation for the clinical use of GRPR-
based technologies. It enables to define 
patient groups that may benefit from 
GRPR targeted modalities. As a refer-
ence the androgen-independent xeno-
graft model PC3 was used. Although 
PC3 is androgen-independent, GRPR 
is constitutively overexpressed and, 
therefore, this model is frequently used 
in studies on GRPR expression in PC. 
MaTerials and MeThods
Pc xenografts
For this study we made use of intact 
male nude NMRI (Naval Medical Re-
search Institute) mice (Taconic M&B, 
Ry, Denmark) 15-17. The experiment 
was approved by the Dutch National 
Animal Experimental Committee and 
performed in agreement with The Neth-
erlands Experiments on Animals Act 
(1977) and the European Convention 
for protection of Vertebrate Animals 
used for Experimental Purposes (Stras-
bourg, 18 March 1986).
Mice were implanted subcutaneously 
with small fragments of the androgen-
dependent PC82, PC295 and PC310 
human prostate tumour 15. Mice were 
supplemented with testosterone to ob-
tain optimal tumour take (80-85%) and 
tumour growth by implanting silastic 
tubings filled with crystalline steroid 
(6mg/tubing; AppliChem, Darmstadt, 
Germany). These implants result in 
constant delivery of testosterone ex-
ceeding the low physiological levels 
in intact male nude mice for at least 75 
days 19. For the androgen-independent 
PC3 xenografts, cell suspensions (5 
million cells per mouse) were injected 
subcutaneously without additional tes-
tosterone supplementation. 
androgen ablation and 
testosterone resupplementation
Androgen withdrawal was performed 
by surgical castration under Ketamin 
(Alfasan, Woerden, The Netherlands) 
and Rompun (Bayer AG, Leverkussen, 
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Germany) anaesthesia (mix of 1:1), and 
subsequent removal of testosterone im-
plants. At 2, 4 and 7 days after castra-
tion mice were used for biodistribution 
studies. Control mice were used when 
tumour volumes were between 600 and 
800mm3, which was reached approxi-
mately 90 days after tumour implanta-
tion. Castration of tumour-bearing mice 
was planned in such a way that tumour 
volumes at time of inclusion were in the 
same range as those of the control mice.
Resupplementation of testosterone to 
mice was accomplished under Keta-
min: Rompun anaesthesia by subcuta-
neous re-implantation of testosterone 
implants at 7 days after castration. 
Biodistribution was then performed at 
a predefined number of days after re-
supplementation (2, 4 or 14 days).
radiolabelled Peptides 
Bombesin analogue [D-Tyr6, b-Ala11, 
Phe13, Nle14]BN(6-14), referred to as 
universal-BN, was provided by Bio-
synthema Inc. (St. Louis, USA) and ra-
diolabelled with 125I as described previ-
ously (radiolabelled compound as from 
now referred to as 125I-universal-BN) 
20. 125I labelled GRP was obtained com-
mercially from Amersham Biosciences 
(Buckinghamshire, United Kingdom).
Bombesin analogues (MP2248) and 
(MP2653) were provided by Mallinck-
rodt Inc. (St. Louis, USA), and radiola-
belled with 111In (111InCl
3
, Tyco Health-
care, Petten, the Netherlands, DRN 
4901, 370 MBq/ml in HCl, pH 1.5-1.9) 
as described earlier 21-24.
rna isolation and quantitative 
reverse transcriptase polymerase 
chain reaction (rT-Pcr)
For RT-PCR an independent set of 
PC82, PC295 and PC310 tumour tissue 
was obtained from our biorepository of 
xenograft tissues (snapfrozen material 
stored at minus 80°C) and not from tis-
sues from the biodistribution studies as 
snapfrozen tissues are essential to ob-
tain high quality RNA. Tumours from 
the biodistribution studies could only 
be frozen after counting in the gam-
macounter, which time delay strongly 
affects RNA quality. 
Total RNA was isolated using RNAzol 
B kit (Bio-connect, Huissen, The Neth-
erlands) according to the manufactur-
er’s protocol. The reverse transcriptase 
reaction was performed with 1 μg RNA 
and 100 ng/µl oligo(dT)
12-18
 primer (In-
vitrogen, Carlsbad, CA) for 10 min at 
70°C in 11 µl volume and chilled on 
ice. cDNA was reverse transcripted in 
first-strand buffer (4 µl, 5x; Invitro-
gen) plus 2 µl 100 mM DTT, 1 µl 10 
mM dNTP mix, 1µL RNasin ribonucle-
ase inhibitor (Invitrogen) and 200 U 
MMLV-RT (Invitrogen) followed by 1 
hr incubation at 37°C. The process was 
inactivated by heating to 95°C for 10 
min samples were than stored at minus 
20°C.
Gene expression of GRPR and the 
housekeeping gene glyceraldehydes-
3-phosphate dehydrogenase (GAPDH) 
was performed with human-specific 
primers and probes purchased as a FAM 
dye-labelled TaqMan MGB primer 
probe kit (Applied Biosystems, Foster 
City, USA). GAPDH was used as the 
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endogenous reference gene in order to 
relate GRPR mRNA levels to the total 
epithelial (human) cell content of each 
sample. The real time PCR reaction was 
performed in a volume of 25 ul contain-
ing cDNA. PCR mixture contained a 
final concentration of 360 nM primer, 
100 nM probe, commercially available 
PCR mastermix (TaqMan Universal 
PCR Mastermix; Applied Biosystems). 
The PCR mastermix contained 10 mM 
Tris-HCl (pH 8.3), 50 mM KCl, 5 mM 
MgCl
2
, 2.5 mM deoxynucleotide tri-
phosphates, 0.625 U of AmpliTaq Gold 
DNA polymerase and 0.25 U AmpEr-
ase UNG per reaction. Samples were 
amplified in an automated fluorometer 
(ABI Prism 7700 Sequence Detection 
System; Applied Biosystems). Amplifi-
cation conditions were 2 min at 50°C, 
10 min at 95°C, 40 cycles of 15 s at 
95°C and 60 s at 60°C. The amount of 
target gene expressed was related to a 
calibrator composed of a mixture of 
cDNAs from different PC xenografts. 
Results were calculated for each cell 
line as the average relative quantity of 
the 2 tissue samples analysed in dupli-
cate.
Statistical analysis was performed us-
ing the unpaired 2-tailed t-test using 
SPSS 15.0 (SPSS Inc., Chicago, United 
States). A probability of less than 0.05 
was considered significant.
biodistribution studies
For biodistribution studies, mice were 
injected intravenously with 4 MBq / 60 
pmol (0.1 µg) / 200 µl of the radiola-
belled BN analogue 111In- MP2653 at 
predefined time points, and sacrificed 
4 hours after peptide injection. Tumour 
tissue and the GRPR-positive pancreas 
as well as kidneys and intestines (rele-
vant organs for clearing) were collected 
for counting of radioactivity in a LKB-
1282-compugamma system (Perkin 
Elmer, Oosterhout, the Netherlands). 
Radioactive uptake was calculated 
as % injected dose per gram of tissue 
(%ID/g) as a percentage of the con-
trol group (100%). Immediately after 
counting, the tumours were snapfrozen 
in liquid nitrogen for autoradiography. 
Statistical analysis was performed us-
ing the Mann Whitney and unpaired t-
test. A probability of less than 0.05 was 
considered significant.
autoradiographic analyses 
PC xenograft tumour tissues derived 
from hormonally manipulated mice 
were evaluated for GRPR expression 
by in vitro autoradiography as de-
scribed previously 17. In short, frozen 
xenograft sections (10 µm) were incu-
bated for 1 hour at room temperature 
with 0.1 nM radiolabeled compound. 
To discriminate between GRPR-
mediated binding and non-receptor-
mediated binding, sections were in-
cubated in the presence of an excess 
(1 µM) of unlabelled GRP or [Tyr4]
BN (Sigma Aldrich, Zwijndrecht, The 
Netherlands) as a blocking agent. Sec-
tions were exposed to phosphor im-
aging screens (Perkin Elmer, Boston 
U.S.A.) for 16-72 hours. Screens were 
read using a Cyclone Storage Phosphor 
System (Packard, Meriden, USA) and 
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autoradiograms were quantified using 
Optiquant Software (Packard, Meriden, 
USA). Results are indicated as average 
GRPR-mediated radiolabelled peptide 
binding (net Density Light Units/ mm2 
of total binding minus non-specific 
binding) as a percentage of the control 
group (100%).  
Statistical analysis was performed us-
ing the Mann Whitney and unpaired t-
test. A probability of less than 0.05 was 
considered significant.
resulTs
effect of androgens on GrPr 
mrna levels: Quantitative rT-
Pcr
To evaluate changes in mRNA expres-
sion of GRPR during androgen manipu-
lation, RT-PCR was performed on RNA 
from an independent set of PC82, PC295 
and PC310 tumour tissue obtained from 
our biorepository of xenograft tissues. 
In order to correct for variability of stro-
mal (murine) content of the otherwise 
human (epithelial) tumours, human-
specific probes were used and GRPR 
mRNA levels were related to GAPDH. 
Relative GRPR mRNA levels under con-
trol conditions were high for PC295 and 
PC310 with a mean GRPR/GAPDH ra-
tio of 27.2 and 21.5, respectively. PC82 
showed much lower GRPR mRNA lev-
els with a mean GRPR/GAPDH ratio of 
4.1. After androgen ablation, the relative 
GRPR expression dropped considerably 
for PC295, PC310 and PC82 (Figure 1). 
Re-supplementation with testosterone 
resulted in recovery of GRPR mRNA 
levels for all xenografts although recov-
ery levels were quite variable (Figure 1).
Effect of Androgens on GRPR-Medi-
ated Tumour Uptake: Biodistribution 
Studies 
Subsequent to the RT-PCR and initial 
autoradiography a prospective bio-
distribution study was performed to 
evaluate potential androgen regulation 
of GRPR and thus the effect of andro-
gen status on GRPR-mediated tumour 
uptake in vivo using the radiolabelled 
BN analogue 111In-MP2653 in PC tu-
mour-bearing mice under hormonal 
manipulation. Table 1 summarizes the 
results of 3 independent biodistribu-
tion studies. The first experiment was 
performed with the androgen depen-
dent PC295 xenograft. The outcome of 
this study was further substantiated in 
a subsequent biodistribution study us-
ing the androgen sensitive xenograft 
PC82 with a more extended time point 
of testosterone re-supplementation. Fi-
nally, to validate the outcome of these 
2 experiments, a third  biodistribution 
study was performed with the andro-
gen sensitive xenograft models PC295, 
PC82 and PC310, comparing GRPR 
expression in intact mice (control), cas-
trated mice (cas 7), and castrated and 
re-supplemented mice (cas 7 T 14) with 
the androgen-independent PC3 as ref-
erence model.
The uptake of the 111In-labeled pep-
tide at 4 hours after injection in the 
GRPR-positive tumour and GRPR-
expressing pancreas as well as in the 
clearance organs (kidneys and intes-
tines) were found to be in agreement 
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with our previous results obtained with 
111In-MP2653 in mice bearing PC3 tu-
mours 25. Tumour and pancreas uptake 
in all PC xenografts are summarized in 
Table 1A. The androgen-dependent PC 
tumours demonstrated a significant inhi-
bition of growth after androgen ablation 
(data not shown). The androgen-depen-
dent xenografts also show a reduction in 
tumour uptake of 111In-MP2653 after 4 
and 7 days of castration. This decline was 
strongest in PC295 showing a decrease in 
tumour uptake of 73% (p = 0.0002) af-
ter 7 days of castration. The reduction 
of peptide uptake in androgen depleted 
PC82 and PC310 tumours was less pro-
nounced than in PC295, although still 
significant (54 % and 41% respectively 
after 7 days of castration, p < 0.017). 
Re-supplementation of testosterone 
to castrated mice for 14 days resulted 
in near complete recovery of tumour 
uptake in PC82 and PC310 mice to 
control levels (86% and 99%, respec-
tively). For PC295, a partial restoration 
(40%) of peptide uptake by the tumours 
was observed after 4 days of testoster-
one resupplementation.
Tumour growth of the androgen-inde-
pendent PC3 model was not affected by 
ablation treatment nor by testosterone 
suppelmentation (data not shown). In 
contrast to the androgen sensitive xeno-
grafts, tumour uptake of 111In-MP2653 
was significantly increased up to 141% 
at 7 days post-castration, which was 
normalized after testosterone resupple-
mentation. 
A B 
C figure 1
Results of RT-PCR performed in androgen- 
dependent PC bearing mice; PC295 (A), PC82 (B) 
and PC310 (C). Tumour tissue was obtained from 
control mice, castrated mice (castration 9-22 
days before tumour collection) or castrated mice 
that were testosterone resupplemented (castration 
12-22 days before testosterone resupplementation 
of 7-45 days). Each tissue sample was performed 
in duplicate. Results are shown as an average of 
the two GRPR/GAPDH measurements (mean ± 
SD). * = statistically significant difference com-
pared to the mean of the control group (p < 0.05).
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111In-MP2653 uptake in the GRPR ex-
pressing pancreas was similar for all 
mice under the various hormonal con-
ditions (Table 1).
effect of androgens on 
GrPr-mediated binding: 
autoradiographic analyses
The effect of androgen status on GRPR-
mediated binding in human PC was 
evaluated in vitro by autoradiography. 
Initially, autoradiographic analysis was 
performed on tumour sections derived 
from our biorepository of xenograft tis-
sues (snapfrozen material stored at mi-
nus 80°C) using 125I-universal-BN (74 
TBq/mmol). This tumour collection 
contained tissues from control mice, 
castrated mice (castrated 8-10 days pri-
or to sacrifice) and castrated mice that 
were resupplemented with testosterone 
for indicated days (see Figure 2). Bind-
ing of 125I-universal-BN was drastically 
reduced after androgen ablation in all 3 
androgen-dependent PC xenografts re-
sulting in 95%, 77% and 90% reduced 
binding in PC295, PC310, and PC82, 
respectively. Testosterone re-supple-
mentation partially restored binding to 
70% and 54% of control level as ob-
served for PC295 and PC82, respec-
tively, while such restoration of peptide 
binding was not observed for PC310 
after 13 days of testosterone adminis-
tration (Figure 2).
Additional autoradiographic evalua-
tions were performed on tumour sec-
tions derived from the prospective 
biodistribution studies using 125I-GRP 
(74 TBq/mmol) or 111In- MP2248 (200 
MBq/nmol) as ligands. In compliance 
figure 2
GRPR-specific binding of 125I-universal-BN (= total binding 125I-universal-BN 10-10M) minus 
non-specific binding (125I-universal-BN 10-10M + GRP 10-6M) to androgen-dependent PC xeno-
graft sections. Tumour tissue was obtained from control mice, castrated mice (castration 7-10 
days before tumour collection) or castrated mice that were testosterone resupplemented (cas-
tration + testosterone=  57 + 38 days, 29 + 13 days and 20 + 22 days respectively for PC295, 
PC310 and PC82). Results are shown as average net Density Light Units per mm2 (net DLU/
mm2). Results are average from 3 independent samples (except for the castration + testoster-
one group of which we had 1 sample) ± SD. We used 2-4 sections per independent sample.  
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with the biodistribution results, PC295 
and PC82 showed strong and signifi-
cant responses to androgen ablation. 
After 7 days of castration GRPR-bind-
ing was reduced by more than 96% (p 
<0.0001) 88% (p = 0.0003) for PC295 
and PC82, respectively (Figure 3A and 
B). A partial, though significant recov-
ery of GRPR-binding was observed 
for PC295 and PC82 (17% p = 0.004 
and 56% p = 0.0002, respectively) at 
4 days of testosterone re-supplemen-
tation with near-complete restoration 
of receptor-binding at 14 days of tes-
tosterone resupplementation for PC82 
(to 91%). For PC310, the reduction in 
A 
B 
C 
D 
figure 3
Receptor-mediated binding of 111In-MP2248 to androgen-dependent PC295 (A), PC82 (B), PC310 (C), 
and androgen-independent PC3 (D) xenograft sections. Tumour tissue was derived from the tumour-
bearing mice from the biodistribution study. Autoradiography results are average receptor-mediated 
binding (net Density Light Units/ mm2 of total binding minus non-specific binding) as percentage of the 
control group (100%) ± SEM. N = 4-14 xenografts / group, 2 sections per xenograft tumour were used. 
cas = castration for 2, 4 or 7 days; T = testosterone resupplementation for 2, 4, or 14 days; * =  signifi-
cantly different from control group (p < 0.05); ** =  significantly different from cas 7 group (p < 0.05). 
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peptide binding after castration as was 
less pronounced (45%) and recovery 
after testosterone resupplementation 
was only moderate (Figure 3C). Con-
sistent with the biodistribution data, 
the androgen-independent PC3 model 
demonstrated a rise in GRPR-binding 
after testosterone ablation, which was 
restored to control levels after testos-
terone resupplementation (Figure 3D).
Autoradiograms of PC82 tumour sec-
tions incubated with 10-10M 111In-
MP2248 with or without blocking 
agent Tyr4-BN (10-6M) revealed a het-
erogeneous distribution pattern of the 
BN-tracer within these samples (Figure 
4).
discussion
Opportunistic screening for PC has led 
to diagnosis of more PC tumours still 
confined to the prostate in which cura-
tive surgical intervention is still an op-
tion. However, due to lack of accurate 
imaging modalities for PC, the (micro)
metastatic stage of the tumour is often 
difficult to determine. The metastatic 
stage of PC greatly influences progno-
sis and determines therapeutic options 
of the disease. Therefore, reliable and 
sensitive diagnostic tools are highly 
wanted to improve staging at time of 
diagnosis. Radiolabelled BN analogues 
may be promising new radiopharma-
ceuticals for imaging and therapy for 
patients with GRPR-expressing tu-
mours, such as PC 26-31.
Evaluation of GRPR expression 
throughout the different stages of hu-
man prostate tumour development us-
ing a panel of 12 well established hu-
man PC xenograft models has shown 
that GRPRs were predominantly ex-
pressed in androgen-dependent xeno-
grafts and were very low in androgen-
independent xenografts 17. This ob-
servation stimulated further research 
into the potential effects of androgen 
status on the expression of the GRPR 
in PC patients and, consequently, the 
relevance of their clinical history (ther-
apy sequence). To further study andro-
control cas 2 cas 4 cas 7 cas 7 T 2 cas 7 T 4 cas 7 T 14 
111In-MP2653 
block 
figure 4
In vitro autoradiograms of PC82 tumour sections incubated with 10-10M 111In-MP2248 
with or without an additional blocking agent Tyr4-BN (10-6M).  Xenografts were derived 
from castrated and testosterone resupplemented mice used in the biodistribution.
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gen regulation of the GRPR we used 
three androgen-responsive prostate 
cancer models. We hypothesized that 
if GRPR-expression was indeed regu-
lated by androgens, androgen ablation 
of androgen-dependent xenograft bear-
ing mice would reduce GRPR expres-
sion and recovery of androgen status 
would induce re-appearance of GRPR 
expression. An initial in vitro autora-
diographic binding study using 125I-uni-
versal-BN as ligand supported our hy-
pothesis. Complete inhibition of GRPR 
binding was observed after androgen 
withdrawal for all xenografts, which 
could be recovered after supplementa-
tion with testosterone for PC295 and 
PC82. The reason for the lack of re-
covery of GRPR binding in the PC310 
tumour is not completely clear. It might 
be related to the shorter resupplemen-
tation period indicating that restoration 
of GRPR mRNA expression is a rela-
tively slow process. (Figure 2). 
RT-PCR study than showed that after 
ablation of androgens GRPR mRNA 
expression was significantly reduced in 
all androgen-dependent tumour types 
while restoration of relative GRPR 
mRNA levels was achieved after an-
drogen re-supplementation. Variability 
in recovery of GRPR may be related to 
differences in the kinetics of the pro-
cess of GRPR translation from mRNA 
to protein and reappearance. These re-
sults supported our hypothesis that in 
androgen-dependent xenografts repre-
senting early stage of PC, transcription 
of GRPR mRNA is androgen regulated.
Subsequent in vivo biodistribution 
studies were performed with the previ-
ously evaluated 111In-MP2653 analogue 
25. Consistent with the autoradiographic 
results, 111In-MP2653 tumour uptake 
was significantly reduced in all three 
androgen-dependent xenografts upon 
castration of tumour-bearing mice, 
which could be largely restored by 
resupplementation with testosterone. 
GRPR-expression of the androgen in-
dependent PC3 model was not down-
regulated by androgen withdrawal. 
Likewise, uptake of peptide by the 
GRPR expressing pancreas was not af-
fected indicating that GRPR expression 
in the pancreas was not androgen regu-
lated. These observations were further 
substantiated by additional in vitro au-
toradiographies showing a similar trend 
in which castration induced reduction 
of GRPR binding and testosterone re-
supplementation induced restoration of 
GRPR expression in all 3 models of an-
drogen-regulated human PC. Although 
results between biodistribution and au-
toradiography did show the same trend, 
the changes in GRPR expression were 
larger in autoradiography studies. This 
may be explained by the more complex 
physiology of the in vivo biodistribu-
tion process that involves interfering 
aspects such as in vivo stability of the 
peptide (affecting retention of the pep-
tide/label), tumour vascularisation (in-
fluencing uptake), and clearance of the 
peptide from the blood  32-34.
We wanted to define to which bombe-
sin receptor(s) variations in binding 
of 125I-universal-BN were related and 
especially if they were exclusively 
GRPR-related. Therefore we examined 
if binding of 125I-universal-BN to the 
androgen-dependent PC295, PC310 
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and PC82 tumour tissues could be 
blocked by 10-6 M of unlabelled GRP 
which was indeed the case (data not 
shown). Results are consistent with our 
previous findings 17. Since 125I-univer-
sal-BN binding showed to be exclu-
sively GRPR related the natural GRPR 
ligand, 125I-GRP, was employed for a 
subsequent autoradiography study. 
GRP is however a larger peptide than 
bombesin and therefore it is more vul-
nerable to enzymatic degradation, mak-
ing it not a very suitable peptide for 
in vivo experiments. For this reason 
the shorter and more stable bombesin 
analogue 111In- MP2248 was also used. 
Similarities between the autoradiogra-
phies of both peptides confirmed that 
the bombesin analogue In-111-MP2248 
indeed targets the GRPR like the natu-
ral GRP peptide. The relatively small 
variations in absolute values can be 
explained by the small differences in 
GRPR affinities of GRP and MP2248. 
The present study showed that peptide 
uptakes by the tumours are compara-
ble. These data indicate that for future 
studies only one peptide, preferably a 
BN-analogue, may be chosen as the 
preferred ligand since this ligand can 
be employed for both in vitro and in 
vivo studies.
PC3 is a GRPR expressing androgen-
independent model of human PC that is 
extensively used in literature. It has no 
androgen receptor and lacks the abil-
ity to produce PSA. Although GRPR 
is constitutively active in PC3 and the 
model is not suitable for studying an-
drogen regulation of GRPR, its use in 
the field of bombesin-targeted imaging 
of PC obliged its use as reference mod-
el in this study. Our results confirm that 
GRPR expression in PC3 xenografts is 
not downregulated by castration and 
upregulated by resupplementation of 
androgens.
Xenograft tumour tissue consists of 
human epithelial tumour cells and sup-
portive stromal cells originating from 
the mouse. Androgen-dependent PC 
xenografts will have regression of epi-
thelial tumour fraction upon androgen 
ablation. Consequently tumours in such 
xenografts will contain less (human) 
epithelial cells as compared to the (non 
androgen responsive) stromal compart-
ment. It was essential to verify whether 
the observed effects were caused by 
regulation of GRPR expression itself or 
by changes in the total epithelial (hu-
man) content of the xenograft. RT-PCR 
enables to correct for these changes 
while expression of GRPR mRNA was 
related to GAPDH mRNA expression 
levels using human-specific primer 
probe sets for both GRPR and GAPDH 
hereby excluding the non human stro-
mal compartment. 
Although none of our xenograft mod-
els representing late stage disease ex-
pressed GRPR 35, it cannot be excluded 
that GRPR may be re-expressed in pro-
gressive, late stage disease as has been 
suggested from patient samples 5 and 
few patients in clinical studies 31.
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conclusion
GRPR-binding of androgen-dependent 
human PC xenograft models is andro-
gen-regulated. Androgen ablation re-
sults in down-regulation of GRPR ex-
pression. This expression can be (par-
tially) restored by subsequent resupple-
mentation with testosterone. Data fur-
ther showed that the decline in GRPR-
binding is the result of GRPR mRNA 
down-regulation rather than the con-
sequence of the castration-induced re-
duction in the epithelial fraction of the 
xenograft. This suggests that hormonal 
therapy may affect GRPR expression 
in early stage, hormonally-treated pa-
tients with PC. Our observations do not 
exclude, however, that GRPR expres-
sion may reappear in progressive late 
stage patients.
Our data indicate that GRPR is a prom-
ising target for imaging of early PC in 
patients that have not been treated by 
hormonal therapy. GRPR-based im-
aging modalities may thus be used to 
improve staging of hormone naïve pa-
tients with PC. Its potential as a thera-
peutic modality for PC may be limited 
to non-hormonally treated patients, al-
though reports suggest that GRPR may 
be reexpressed at later stages of PC. 
Studies are underway to further vali-
date and compare GRPR expression in 
tumour tissue derived from both hor-
monally treated and untreated patients 
at different stages of PC.
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absTracT
Prostate cancer (PC) is a major health problem in the Western world due 
to its high incidence and significant overall mortality. A crucial step in the 
management of PC is to discriminate between localised and metastasised dis-
ease. Current imaging techniques are not accurate enough to make this dif-
ferentiation. Radiolabelled bombesin (BN) analogues with high affinity for 
the Gastrin-Releasing Peptide Receptor (GRPR), overexpressed in PC, form 
promising radiopharmaceuticals for targeted imaging and therapy of PC. Me-
tastasised PC is initially treated by hormonal ablation therapy resulting in tu-
mour regression, but eventually develops into castration resistant PC (CRPC). 
Previously, we have demonstrated androgen regulation of GRPR in androgen-
responsive xenografts of human PC. In this study we further investigated the 
dynamics of GRPR expression and BN analogue binding under various hor-
monal conditions using the androgen-responsive VCaP cell line and evaluated 
GRPR expression in human PC samples of various disease stage.
GRPR mRNA expression levels as determined by quantitative reverse tran-
scriptase polymerase chain reaction (RT-PCR) and GRPR-specific uptake of 
the BN analogues 111In-DOTA-AMBA and 99mTc-N
4
-Demobesin-1 were per-
formed with VCaP cells under various hormonal conditions in vitro and in 
vivo. In addition, GRPR mRNA expression (by RT-PCR) and binding of the 
BN analogue 111In-DOTA-Pesin and 111In-MP2346 (by autoradiography) to PC 
cell lines and xenografts and to clinical PC samples. 
 In contrast to our earlier findings in early androgen-responsive PC xeno-
grafts, GRPR mRNA expression in VCaP cells was not significantly affected 
by androgen manipulation both in vivo and in vitro. GRPR-specific uptake of 
the BN antagonist 99mTc-Demobesin-1 was similar between VCaP cells cul-
tured in the presence of androgens (27.3±9.7%D/mg protein) or depleted from 
androgens for 6 days (30.3±7.0%D/mg protein). Human PC samples were 
predominantly GRPR positive, although mRNA expression levels were highly 
variable. In contrast to PC samples from patients not previously treated by 
hormonal therapy, only samples of (hormonally treated) CRPC showed con-
sistent reduced GRPR mRNA expression, suggesting therapy-induced down-
regulation of GRPR. Median GRPR-specific uptake of the BN-analogue 111In-
DOTA-Pesin was higher in PC samples as compared to benign prostate tissue. 
The overlap of GRPR-specific binding between PC and benign prostate tissue 
negatively affects BN-specificity.
In conclusion, the present study could not proof androgen regulation of GRPR 
in androgen-responsive VCaP cells. We hypothesize that GRPR expression 
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is androgen-regulated in early PC, and that the overexpression of GRPR ob-
served in more advanced PC3 and VCaP is caused by an escape from ‘nor-
mal’ androgen control resulting in constitutively activated GRPR in these cell 
lines. While the majority of (hormonally untreated) PC was GRPR positive, 
the relatively low GRPR mRNA expression levels observed in CRPC suggest 
that hormonal therapy generally results in down-regulation of GRPR expres-
sion. The above described escape phenomenon may thus be a rather uncom-
mon clinical event. Overall, these data suggest that BN-based GRPR targeted 
imaging and therapy of PC seems feasible in the early diagnosis of PC in men 
that have not previously been treated by hormonal therapy. Furthermore, out-
comes reveal that pre-selection of GRPR expressing patients is required when 
opting for GRPR-targeted BN-based response monitoring and therapy of PC.
inTroducTion
Prostate cancer (PC) is the most fre-
quently diagnosed cancer among men 
in the Western world and the third 
cause of cancer related death 1, 2. Ag-
ing of the general population, increased 
public awareness as well as the strong 
rise in the use of prostate specific an-
tigen (PSA) to screen for PC have all 
contributed to the dramatic increase in 
its early diagnosis 3. 
PC presents as a heterogeneous and 
multi-stage disease 4. As long as the tu-
mour remains confined to the prostate 
capsule, treatment may be curative ei-
ther by surgical or radiotherapeutic op-
tions. However, when the tumour has 
invaded surrounding tissue or when 
tumour cells have escaped the primary 
tumour, only systemic palliative treat-
ment strategies are available. Like the 
normal prostate, early PC generally 
depends on androgens for growth and 
survival 5. Initially, advanced (dissemi-
nated) PC is treated with androgen ab-
lation therapy leading to PC regression 
6, 7. However, eventually all patients 
will develop castration resistant PC 
(CRPC), rendering androgen ablation 
therapy ineffective 8, 9. As opposed to 
androgen-responsive PC, CRPC does 
not require androgens to proliferate. 
When facing metastatic CRPC, treat-
ment options are scarce leaving a me-
dian survival of 10 months 10-12. Clearly, 
discrimination between organ-confined 
disease and PC beyond the borders of 
the gland is a crucial step in the opti-
mal management of PC. Unfortunately, 
current imaging techniques are not suf-
ficiently accurate to determine extent 
of PC at diagnosis and to visualise mi-
crometastases 3-5. More sensitive imag-
ing techniques are therefore strongly 
needed.
Nuclear imaging using single pho-
ton emission computed tomography 
(SPECT) and positron emission tomog-
raphy (PET), may offer applications 
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to improve accuracy of PC imaging 13. 
The Gastrin-Releasing Peptide Recep-
tor (GRPR) constitutes an interesting 
target for peptide-receptor radionu-
clide imaging and therapy as this re-
ceptor is reported to be overexpressed 
on the cell membrane of PC while it is 
not detectable in normal prostate tissue 
14, 15. Bombesin (BN) and its mamma-
lian counterpart, the Gastrin-Releasing 
Peptide (GRP), are natural ligands for 
the GRPR to which they bind with high 
affinity 14. BN analogues are applicable 
for SPECT when labelled with gamma 
emitting radionuclides while labelling 
of the BN analogue with positron emit-
ting radionuclides enables utilisation 
for PET imaging. Moreover, labelling 
of BN analogues with cytotoxic radio-
nuclides, emitting beta or alpha rays, 
may provide a therapeutic agent for 
PC.
Markwalder et al. reported a gener-
ally high density of GRPR in pri-
mary PC and high-grade PIN against 
a generally low density of GRPR in 
benign hyperplasia of prostate (BPH) 
and non-neoplastic prostatic stroma 
15. Previously, we have shown high 
GRPR expression predominantly in 
androgen-responsive, early PC xeno-
grafts with low expression in xeno-
grafts representing late stage disease 
16. Moreover, we described reduced 
GRPR-mediated tumour uptake of 
BN after androgen ablation and res-
toration of uptake after resupplemen-
tation of testosterone in androgen-
responsive xenografts. These studies 
suggested that expression of GRPR is 
androgen regulated 16, 17. These obser-
vations (see Figure 1) and the domi-
nant role of androgen ablation therapy 
in the management of PC called for a 
more detailed characterisation of the 
androgen regulation of the GRPR in 
order to define the potential role of 
BN-based imaging and therapy of PC. 
Androgens and the androgen recep-
tor (AR) are strongly involved in PC 
growth and play a key role in the trans-
formation from androgen-responsive 
PC towards progressive CRPC 8, 18, 19. 
To better define the role of androgens 
and the AR in GRPR regulation, we 
studied the dynamics of GRPR expres-
figure 1
GRPR-mediated average tumour uptake of 
111In-MP2653 in androgen-responsive PC82, 
PC295 and PC310 human prostate cancer 
xenografts. Tumours were obtained from 
male mice supplemented with testosterone (T) 
(control), tumour-bearing mice castrated for 
7 days (Castration) and from 7 days cas-
trated mice resupplemented with T for 14 days 
(Castration+T) in case of PC82 and PC310, 
and for 4 days in case of PC295. Results are 
presented as percentage of the injected dose per 
gram of tissue (%ID/g) per xenograft sample. Per 
treatment group 4 to m14 animals were used.
* significantly different (p<0.05) from control, ** 
significantly different from Castration (p<0.05).
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sion and BN analogue binding under 
various hormonal conditions in an ex-
perimental human PC model system. 
To allow direct comparison of both in 
vitro and in vivo data, we selected a 
human GRPR expressing, androgen-
responsive VCaP cell line that can be 
applied in vitro and has tumourigenic 
capacity to grow as a xenograft. The 
PC-3 cell line is the most often selected 
PC cell line in BN-related studies be-
cause of its high GRPR expression and 
easy use 13. PC-3 cells, however, do not 
express AR and lack PSA, important 
characteristics of clinical CRPC, and 
therefore this cell line may not accu-
rately represent late stage disease. We 
selected the androgen-responsive and 
GRPR expressing VCaP cell line based 
on its high GRPR expression and gen-
eral PC characteristics such as expres-
sion of wild type, non-mutated AR, 
PSA and prostatic acid phosphatase 
(PAP) 16. The cell line belongs to the 
acinar adenocarcinomas accounting for 
more than 95% of the prostate tumours 
20. VCaP tumours in athymic nude mice 
show androgen-responsive growth 21, 
22. Clearly, these characteristics make 
VCaP a very relevant cell line to study 
the mechanisms of androgen regulated 
GRPR expression. 
In this study we investigated the dy-
namics of GRPR gene expression and 
of BN analogue binding under various 
hormonal conditions in vivo and in vi-
tro using VCaP. PC-3 was used as ref-
erence cell line. To further define the 
potential role for GRPR-targeted BN-
based imaging and therapy of PC, tissue 
samples from PC patients from various 
clinical stages were assessed for GRPR 
expression and BN binding. We show 
that, in contrast to our earlier observa-
tions in 3 different androgen-responsive 
PC xenograft models 17, GRPR expres-
sion in the VCaP cell line was not an-
drogen regulated and that BN analogue 
binding was not different under differ-
ent hormonal conditions. These results 
may suggest that constitutively active 
GRPR, like in VCaP and PC-3 cells, is 
provoked by an escape of ‘normal’ an-
drogen regulation mechanisms that is 
present in early, androgen-responsive, 
non-hormonally treated PC. Patient 
samples from early PC were predomi-
nantly GRPR positive, although with 
variable expression. GRPR expression 
in samples from CRPC patients was ab-
sent or low. Despite low numbers, this 
observation suggest that GRPR expres-
sion, and consequently BN binding, is 
(at least initially) androgen regulated. 
GRPR expression may become abro-
gated during tumour progression in a 
subset of patients resulting in constitu-
tively high expression levels. 
MaTerials and MeThods
cell culture
VCaP and PC-3 cells were cultured in 
RPMI (LONZA, Verviers, Belgium) 
supplemented with 10% or 5% fetal 
calf serum (FCS) (GIBCO Invitrogen 
Co, Grand Island, NY, USA), respec-
tively. 5mL/500mL penicillin/strep-
tomycin antibiotic solution (LONZA, 
Verviers, Belgium; 10.000Units/mL 
penicillin, 10.000Units/mL strepto-
mycin) was added to medium of both 
cell lines. Cells were grown in Cellstar 
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tissue culture flasks (Greiner Bio-one 
GmBH, Frickenhausen, Germany) at 
37°C in a humidified atmosphere con-
taining 5%CO2 at 37°C. 
Cells were grown to near confluency, 
harvested using Trypsin/EDTA (LON-
ZA, Verviers, Belgium), 170000U/L 
Trypsine-Versene and 200mg/L EDTA 
and counted for further experimental 
use. 
Hormonal manipulation of VCaP
For RT-PCR analysis of GRPR and AR 
mRNA levels, VCaP cells were cul-
tured in T25 flasks in RPMI with 10% 
FCS (containing an undefined amount 
of androgen) or 10% of DCC (steroid-
deprived serum) with or without sup-
plementation of 10-10M of the synthetic 
androgen R1881 (T). Control VCaP 
cells were cultured with DCC and 
R1881 for 72h (DCC72+T). Separate 
cultures of VCaP cells were incubated 
with DCC and R1881 for 24h and were 
then depleted of R1881for 8, 16 or 24h 
respectively (DCC24+T>8,16,24-T). 
Finally, VCaP cells were cultured with 
DCC and R1881 for 24h, depleted of 
R1881 for 24h and subsequently resub-
stituted with R1881 for 8, 16 or 24h 
(DCC24+T>24-T>8,16,24+T). Refer-
ence groups received RPMI 10%FCS 
(FCS72) or DCC without addition of 
R1881 for 72h (DCC72-T). All culture 
conditions were performed in dupli-
cate.
To study uptake of radiolabelled BN 
analogues, VCaP and PC-3 cells were 
cultured in RPMI with FCS and seeded 
into 6-well plates at a density of 1x106 
cells per well and cultured in the pres-
ence or absence of R1881 for several 
days. Control VCaP cells were cultured 
with 10% of DCC in the presence of 
R1881 for 3 days (DCC3d+T). In ad-
dition, VCaP cells were cultured with 
10% of DCC without R1881 for 3 and 
6 days (DCC6d-T and DCC6d-T). The 
reference group using PC-3 cells was 
seeded at a density of 2x106 cells per 
well with RPMI 5% FCS for 3 days 
(FCS3d).
Pc xenografts
VCaP and PC-3 bearing mice were es-
tablished as described earlier 23. NMRI 
nu/nu mice were inoculated subcuta-
neously with PC-3 or VCaP cells (ap-
proximately 5x106/100µl PBS) on the 
right shoulder of athymic male NMRI 
nu/nu mice (Taconic, Ry, Danmark). 
The experiment was approved by the 
Dutch Animal Experimentation Com-
mittee (DEC Consult) and performed in 
agreement with the Dutch Animal Ex-
perimentation Act (1977) and the Euro-
pean Convention for Protection of Ver-
tebrate Animals Used for Experimental 
Purposes (Strasbourg, 18 March 1986).
Hormonal manipulation of tumour-
bearing mice 
Hormonal manipulation of VCaP xe-
nografts was performed as described 
earlier 17. Tumour-bearing mice were 
surgically castrated at 2, 4 or 7 days 
(7d-T) prior to biodistribution studies. 
Other mice were castrated and after 7 
days resupplemented with testoster-
one by subcutaneous implantation of 
testosterone-containing silastic tubings 
for 2, 4 or 14 days (7d-T/2,4,14d+T). 
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radiolabeling and Quality control
Analogues and Radiolabelling
BN-agonists DOTA-AMBA and DO-
TA-Pesin were kindly provided by Prof. 
Dr. Mäcke, University Hospital Basel, 
Switzerland 24, 25. MP2346 is an ago-
nistic BN-peptide supplied by BioSyn-
thema (St Louis, MO, USA) 26. Radio-
labelling of MP2346, Pesin and AMBA 
with Indium-111 was performed using 
111InCl3 (Covidien, Petten, the Neth-
erlands), as described earlier 26-29.
Demobesin-1 an antagonistic BN-an-
alogue was a gift from Dr. T. Maina 
and Dr. B. Nock, Demokritos, Athens, 
Greece. This peptide was radiolabelled 
with Technetium-99m (99mTc) as previ-
ously described by Nock et al. 30.
In order to prevent oxidation and radi-
olysis quenchers were added to all ra-
diolabelled analogues. Quenchers used 
were ascorbic acid (Bufa BV, Uitgeest, 
the Netherlands), gentisic acid (Covi-
dien, Petten, the Netherlands) and me-
thionine (Fluka Biochemika, Buchs, 
Switzerland) 29.
Quality Control and HPLC 
purification 
Incorporation of radiolabelling was as-
sessed by instant thin layer chromatog-
raphy (ITLC) and radiochemical purity 
(RCP) of the labelled analogues was 
performed by high performance liquid 
chromatography (HPLC). ITLC and 
HPLC analysis of 99mTc-Demobesin-1 
and 111In labelled peptides was per-
formed as described earlier 31.
For HPLC-purified 111In-AMBA solu-
tion the HPLC derivative of 111In-AMBA 
was quantified and diluted for injection 
(0.1mL saline and 0.1MBq per animal). 
The peptide amount of 111In-AMBA 
from the main peak was considered neg-
ligible, since 37MBq 111In ≈ 2.15x10-
11gram atoms. For this reason, to obtain 
an HPLC-purified 111In-AMBA solution 
containing a total AMBA amount of 
10pmol per injective, 10pmol of non-
labelled AMBA was added.
biodistribution studies
Biodistribution studies were performed 
as described earlier 31. VCaP or PC3 tu-
mour bearing mice were injected with 
HPLC-purified 111In-AMBA (0.1MBq 
in 10 pmol) into the lateral tail vein. 
Animals were sacrificed by cervical 
dislocation at 1h post injection (pi). 
Each study group consisted of 4 mice. 
Selected tissues were excised, weighed, 
and radioactivity was determined in 
a 1480 Wizard 3’’ γ-counter (Perkin 
Elmer, Groningen, the Netherlands). 
Radioactivity data were shown as per-
centage of the injected dose per gram 
of tissue (%ID/g).
In vitro BN uptake studies
GRPR-mediated uptake of VCaP was 
compared with PC-3 under standard 
culture conditions (RPMI with 5 or 
10% FCS) using the BN analogue 111In-
MP2346, diluted from 50MBq/nmol 
stock. BN analogue uptake by VCaP 
cells that were cultured under different 
hormonal conditions (see subheading 
cell culture) was studied using the BN 
analogue 99mTc-Demobesin-1.
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BN analogue uptake by the cells (to-
tal peptide uptake into the membrane 
fraction plus cellular internalisation 
of the peptide) was studied essential-
ly as described earlier32. Cell cultures 
were seeded into 6-well plates and all 
conditions were performed in tripli-
cate. Wells were washed twice with 
2mL warm (37oC) PBS (pH7.4). One 
ml of internalisation media (sterilised 
RPMI1640 plus GlutaMAX, 20mM 
HEPES, 1%BSA fraction V purity≥96% 
pH7.4) containing 10-10M labelled BN 
analogue was added. To determine spe-
cific versus non-specific uptake control 
wells were incubated with an excess of 
blocking agent, 10-6M Tyr4-BN (Sigma 
Chemical Co., St. Louis, MO) in addi-
tion to the 10-10M of labelled BN ana-
logue. Each plate (one per time point) 
was incubated on a rotating wheel at 
37oC for 1h. VCaP cells were cultured 
in the presence or absence of R1881 for 
1h. To verify whether incubation with-
out R1881 had effect on BN analogue 
uptake, an additional 6-well plate was 
incubated with 10-10M R1881. After 
1h, cellular uptake of BN was stopped 
by removal of the incubation medium. 
Cells were rinsed twice with 2ml ice-
cold PBS (4oC). 1ml of 0.1M sodium 
hydroxide was added for lysis of cells 
to determine radioactivity in a gamma 
counter; 1480 Wizard 3’’ (Perkin El-
mer, Groningen, the Netherlands). Pro-
tein content was determined by Protein 
Assay Kit (Bio-Rad, Veenendaal, the 
Netherlands). Receptor-specific uptake 
in the membrane fraction and internali-
sation of BN analogue in the cells was 
combined to obtain (total) peptide up-
take. BN analogue uptake is expressed 
as percentage of dose per mg of cellular 
protein (%D/mg protein). Results are 
indicated as mean±standard deviation 
(SD) of 2-3 wells with experiments be-
ing performed in triplicate.
rna isolation and quantitative 
reverse transcriptase polymerase 
chain reaction (rT-Pcr)
RT-PCR was performed to evaluate 
GRPR gene expression in PC cell lines 
and xenografts and in a set of human 
patient samples. Patient samples were 
obtained from the Erasmus MC biore-
pository and consisted of 12 specimens 
of radical prostatectomy, 13 lymph 
node metastases, 19 samples of trans-
urethral resection of prostate, 8 CRPC 
samples and 11 benign prostate hyper-
plasia tissues. Procedures for RNA iso-
lation and RT-PCR were performed as 
described earlier17. Total RNA was iso-
lated using RNAzol B kit according to 
the manufacturer’s protocol and stored 
at -20°C.
Gene expression of GRPR, AR, PSA 
and the reference housekeeping gene 
glyceraldehydes-3-phosphate dehydro-
genase (GAPDH) was performed with 
human-specific FAM dye-labelled Taq-
Man probes. Gene expression of the 
second reference gene porphobilinogen 
deaminase (PBGD) was determined in 
Power SYBR Green PCR Master Mix 
(25µl), containing 0.33μmol/L forward 
and reverse primer in an ABI Prism 
7700 sequence Detection System (Ap-
plied Biosystems, Foster City, USA) 
by the quantification of fluorescence 
signals of site-specific hybridization 
probes. Relative mRNA expression 
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of GRPR is indicated for each sample 
relative to the average of GAPDH plus 
PGBD expression.
In vitro autoradiography
From the Erasmus MC bio-repository 
of human tissue samples, 27 indepen-
dent patient specimens were collected: 
10 radical prostatectomy specimens, 
7 samples of transurethral resection 
of prostate, 3 samples of benign pros-
tate hyperplasia (BPH) and 7 samples 
of stromal tissue of ‘normal’ prostate. 
Frozen tumours were cut into sections 
of 10 µm using the HM 560 Cryo-
Star (Microm, Walldorf, Germany) 
and mounted on Superfrost plus slides 
(Menzelgläser, Braunschweig, Germa-
ny). In vitro autoradiography was per-
formed as described earlier16, 17. Frozen 
xenograft sections (10 µm) were incu-
bated with 111In-Pesin, exposed to Super 
Resolution phosphor imaging screens 
and read using a Cyclone (Perkin El-
mer, etc.). Radioactivity was quantified 
using Optiquant software. Results are 
depicted in digital light units per mil-
limeter square (DLU/mm2).
Statistics
Statistical analyses were performed us-
ing SPSS 11.01 (SPSS Inc., IL, USA). 
For this study the unpaired t-test was 
applied. Statistical significance was as-
sumed if p-values were <0.05.
resulTs
rT-Pcr of Pc cell lines and 
xenografts 
Relative mRNA levels of GRPR were 
detectable (higher than 0.05) in the 
majority of androgen-responsive xeno-
grafts (PC82, PC295, PC310, PC374) 
and cell lines (VCaP, DuCaP, LNCaP, 
PC346mAR) (Figure 2A). This was 
not the case for androgen-unresponsive 
PC cell lines and xenografts in which 
mRNA levels of GRPR were only de-
tectable in PC-3 and PC374F. GRPR 
mRNA expression was 8.4 times higher 
in VCaP cells than in PC-3 cells. Du-
CaP cells showed the highest mRNA 
GRPR expression. In line with this 
observation, GRPR-mediated uptake 
of the BN agonist 111In-MP2346, was 
significantly higher in VCaP compared 
to PC-3 cells (p<0.01). 111In-MP2346 
uptake was 91.1±2.3%D/mg protein 
for VCaP and 63.0±2.7%D/mg protein 
for PC-3 (Figure 2B). In vivo studies 
showed that both PC-3 and VCaP xeno-
grafts showed substantial uptake of the 
BN agonist 111In-AMBA; 4.9±1.7%ID/g 
and 4.6±1.3%ID/g, respectively, which 
was not significantly different (Figure 
2C). As was expected, BN analogue 
uptake in normal pancreas was not dif-
ferent between mice bearing different 
tumour types. Co-injection of an ex-
cess of unlabelled [Tyr4]BN resulted 
in >90% blockade, confirming BN-
specificity of 111In-AMBA tumour and 
pancreatic uptake (data not shown).
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hormonal manipulation of vcaP 
cells and xenografts
Relative mRNA expression of GRPR 
and AR as determined by RT-PCR in 
VCaP cultures under various hormon-
al conditions are shown in Figure 3A. 
Withdrawal of androgen from the cul-
ture medium for 72h led to a signifi-
cant increase (p<0.01) of relative AR 
mRNA levels over control (DCC72+T 
or FCS72), but not of GRPR mRNA 
levels. When cells were cultured for 
A
B C
figure 2a
Quantitative RT-PCR analysis of GRPR in PC cell lines and xenografts. Re-
sults are presented as relative mRNA expression to the housekeeping gene 
GAPDH and are shown as mean±SD of two independent samples.
figure 2b
In vitro uptake of 10-10M BN-analogue 111In-MP2346 in PC-3 and VCaP cells af-
ter incubation for 1h. Results are shown as percentage of dose per mg pro-
tein (%D/mg protein) and represent mean±SD of 3 independent cultures.
* significantly different between VCaP and PC-3 (p<0.01)
figure 2c
Receptor-mediated binding of the BN analogue 111In-AMBA in VCaP and PC-3 bearing mice. An 
injection-volume of 0.1 mL containing 0.1 MBq and 10 pmol was administered into a lateral tail 
vein. Mice were sacrificed at 1h pi. Data are presented as percentage of the injected dose per 
gram of tissue (%ID/g) and are shown as mean±SD of 4 mice per analogue per time point.
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24h in DCC + R1881 (DCC24+T) and 
subsequently incubated in media with-
out R1881 for various time periods, 
relative GRPR and AR mRNA were 
not affected until 24h of depletion 
(DCC24+T>24-T) at which time point 
relative mRNA expression of both genes 
was significantly increased as com-
pared to control. Subsequent resupple-
mentation with R1881 (DCC24+T>24-
T>X+T) resulted in a rapid and sig-
nificant decrease of expression of AR 
mRNA, but not of GRPR, at 8h, which 
was restored to control levels at 24h 
of resupplementation (DCC24+T>24-
T>24+T). RT-PCR of GRPR in hor-
monally manipulated VCaP bearing 
mice revealed a similar trend (Figure 
3B). Castration of VCaP bearing mice 
for 4 days (4d-T) induced a small, but 
significant (P<0.03) increase in relative 
mRNA levels of GRPR as compared 
to the levels detected in intact control 
mice, which was not observed at 7 days 
post-castration (7d-T). In contrast to 
the in vitro data, subsequent re-supple-
mentation of animals for up to 14 days 
(7d-T/14d+T) did not result in substan-
tial downregulation of GRPR and PSA 
mRNA to control values. 
Also, GRPR-mediated uptake of the 
BN analogue 99mTc-Demobesin-1 in 
VCaP cultures under various hor-
monal conditions was not affected by 
androgens (Figure 3C). VCaP cells 
grown in the absence of R1881 for 3 
or 6 days (DCC3d-T or DCC6d-T) 
showed no significant difference in 
BN uptake as compared to control (an-
drogen containing) cultures (FCS3d 
or DCC3d+T). Mean uptake of 99mTc-
Demobesin-1 at 6 days of R1881 de-
pletion was 30.3±7.0%D/mg protein 
and 27.3±9.7%D/mg protein in con-
trol cells. 99mTc-Demobesin-1 uptake 
in VCaP cells was comparable to that 
of the reference androgen independent 
PC-3 cell line (30.7±8.3%D/mg pro-
tein). Furthermore, uptake of 99mTc-
Demobesin-1 in VCaP cells grown 
without R1881 for 1h was not differ-
ent from that of cells to which 10-10M 
R1881 was added (data not shown).
GrPr expression in human Pc 
samples
Relative mRNA levels of GRPR deter-
mined in a set of human PC samples 
are summarised in Figure 4A. Radical 
prostatectomy specimens, lymph node 
metastases, transurethral resection of 
prostate (TURP), benign prostate hy-
perplasia (BPH) material all showed 
a comparable mean of relative mRNA 
expression of the GRPR. Interestingly, 
a lower median, although not statisti-
cally significant, was observed only 
in the CRPC group as compared to 
the other tumour groups. No correla-
tion of GRPR mRNA levels could be 
found when stratifying for percentage of 
glandular tissue per sample or Gleason 
score (data not shown). 45 out of 52 PC 
samples were GRPR positive (relative 
mRNA GRPR levels higher than 0.05). 
From the 7 GRPR negative PC samples, 
3 were obtained from patients that were 
treated with hormone deprivation ther-
apy. From all PC samples (including 
CRPC) known to be treated by androgen 
deprivation therapy 19 out of 21 tumour 
samples were GRPR positive (relative 
mRNA GRPR higher than 0.05).
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In vitro autoradiography performed 
on a small set of frozen samples from 
a different patient group, showed that 
GRPR-specific uptake of 111In-Pesin 
was higher in cancer (radical prostatec-
tomy and TURP) than in the benign tis-
sue groups (BPH and stroma), although 
again with substantial overlap (Figure 
4B). BN uptake in radical prostatectomy 
samples and stromal tissues were signif-
icantly different (p<0.05). Also now, no 
relation was found between BN-uptake 
and Gleason score in tissue from radical 
prostatectomies (data not shown).
discussion
In this study we aimed at elucidating 
the putative regulation of GRPR by 
androgens and its relationship to the 
GRPR expression in PC tumours of 
patients in different stages of PC pro-
gression. We analysed GRPR expres-
sion in clinical samples from our bio-
repository of human PC tissue samples 
and attempted to relate clinical PC 
characteristics with GRPR expression 
levels. For studying androgen regula-
tion of GRPR we selected the VCaP 
cell line as model system. We did not 
select the highly GRPR-expressing 
DuCap cell line while GRPR expres-
sion in this cell line may be affected 
by stromal contamination (of murine 
origin), which can be as high as 50% 4. 
To focus on androgen regulation rather 
than the characteristics of a specific BN 
analogue, we deliberately varied in BN 
analogues between independent stud-
ies. Amongst a large panel of cell lines 
and xenografts VCaP (and DuCaP) 
figure 3a
Quantitative RT-PCR analysis of GRPR and 
AR in VCaP cell lines cultured under vari-
ous hormonal incubations. In vitro androgen 
manipulation was performed by culturing in DCC 
containing medium (steroid-deprived serum) in 
the presence or absence of the synthetic androgen 
R1881 (referred to as +T). FCS72= incubation for 
72h in full 10% serum-containing medium serving 
as control. GRPR and AR mRNA expression is 
indicated relative to housekeeping gene (HKG = 
the average of the housekeeping genes GAPDH 
and PBGD). RT-PCR analysis was performed 
in duplicate. Data are expressed as mean±SD 
of two independent cultures per condition.
* significantly different to control 
(DCC72+T) (p<0.01), ** significantly dif-
ferent to DCC24+T>24-T (P<0.01)
figure 3b
Quantitative RT-PCR analysis of GRPR and 
PSA in VCaP xenografts that were grown under 
various hormonal conditions. In vivo hormonal 
manipulation was performed by surgical castra-
tion of tumour-bearing mice and subsequent 
androgen (re-)substitution with testosterone 
containing pellets (indicated as +T). Tumours 
were sampled at various days of treatment (d). 
GRPR and PSA mRNA expression is indi-
cated relative to housekeeping gene (HKG 
= the average of the housekeeping genes 
GAPDH and PBGD). RT-PCR analysis was 
performed in duplicate. Data are expressed 
as mean±SD of 3 mice per condition. 
* significantly different to control 
(P<0.03); ** significantly different to 
mice castrated for 7 (P<0.00).
figure 3c 
In vitro uptake (membrane plus internalisa-
tion) of 10-10M BN-analogue 99mTc-Demobesin-1 
in PC-3 and VCaP cells. VCaP was incubated 
in DCC containing medium (steroid-deprived 
serum) in the presence or absence of the synthetic 
androgen R1881 (referred to as T) for 3 or 6 
days. PC-3 incubated in FCS for 3 days served 
as reference. Results are shown as percentage 
of dose per mg protein (%D/mg protein). VCaP 
cells were cultured under variable testosterone 
conditions. PC-3 cells were used as refer-
ence. Results are indicated as mean±SD of 2 
independent cell cultures per condition. 
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A
B
figure 4a
Quantitative RT-PCR analysis of GRPR of human PC samples at different stages of disease from 
the Erasmus MC tissue bank. The sample set consisted of 12 specimens of radical prostatectomy 
(Rad PC), 13 lymph node-metastases (LN+), 19 transurethral resection of prostate (TURP), 8 
castration-resistant prostate cancer = TURP samples shown to be hormone refractory (CRPC) 
and 11 benign prostate hyperplasia (BPH). RT-PCR analysis was performed in duplicate. GRPR 
mRNA expression is indicated relative to housekeeping gene (HKG = the average of the house-
keeping genes GAPDH and PBGD). Median expression per tissue group is indicated.
figure 4b
GRPR-specific binding of the BN-analogue 111In-Pesin to frozen sections of clinical pros-
tate cancer tissue from PC patients at different stages of disease. Tissues were obtained from 
the Erasmus MC biorepository of human tissue samples. Autoradiography was performed 
on frozen sections of 10 radical prostatectomy specimens (Rad PC), 7 transurethral resec-
tion of prostate (TURP), 3 benign prostate hyperplasia (BPH) and 7 samples of stroma from 
prostate origin. GRPR specific binding is depicted in digital light units per millimeter square 
(DLU/mm2). Median expression per tissue group is indicated. GRPR-specific binding was sig-
nificantly higher in the radical prostatectomy group than in the stroma group (p<0.05).
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showed strong mRNA expression of 
GRPR. Also, GRPR-specific uptake of 
99mTc-Demobesin-1 was high in VCaP 
and both mRNA GRPR levels and BN-
analogue uptake were similar from 
those of PC-3, a cell line often used for 
GRPR-related research. This finding 
was in line with our earlier PET study 
in which we used the BN-tracer AMBA 
labelled with Galium-68 23. 
In previous studies we have shown 
GRPR expression of early stage andro-
gen-responsive xenograft models to be 
strongly dependent on androgen lev-
els 16, 17. GRPR-specific binding of BN 
analogues was reduced after castration 
of tumour-bearing mice while resubsti-
tution with androgen restored BN-up-
take. These data suggested that GRPR 
expression is androgen regulated. Our 
present study does not confirm this as 
both in vitro and in vivo androgen ma-
nipulation did not result in significant 
changes in GRPR mRNA expression 
and BN analogue uptake in the andro-
figure 5
GRPR-specific binding of the BN-analogue 125I-Tyr4-bombesin in human non-neoplastic prostate 
and prostate cancer tissue sections as obtained by autoradiography. Groups were subordinated in 5 
independent prostate tissue groups consisting of the following samples: 29 primary PC, 8 CRPR, 26 
High-grade prostatic intraepithelial neoplasia (PIN), 50 hyperplasia (known as BPH), and 50 stroma 
from prostate origin. Results are depicted in disintegrations per minute per mg tissue (dpm/mg tissue). 
The median of each tissue group is indicated. 125I-Tyr4-bombesin binding was significantly higher 
in combined cancer groups as compared to benign tissues (hyperplasia and stroma) (P<0.001). 
This scatter plot was modified from original data from; ‘Gastrin-releasing pep-
tide receptors in the human prostate: relation to neoplastic transformation’ by R. 
Markwalder and J.C. Reubi in Cancer Research 1999 (PMID: 10070977). 
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gen-responsive VCaP cells. In vitro and 
in vivo androgen withdrawal resulted 
in slightly higher GRPR mRNA levels, 
only statistically significant at one time 
point. GRPR expression was reduced to 
its control levels upon androgen re-sup-
plementation. The AR expression on 
the other hand did show androgen reg-
ulation. The androgen-responsive be-
haviour of VCaP cells was endorsed by 
reduced cell proliferation after andro-
gen depletion (data not shown). It ap-
pears that androgen depletion of VCaP 
drives compensatory mechanisms that 
stimulate GRPR mRNA transcription. 
However, at the protein level, GRPR-
specific binding of 99mTc-Demobesin-1 
was not affected after 3 and 6 days of 
androgen ablation. Overall, our data do 
not support a strong androgen regula-
tion of GRPR expression. It may be 
hypothesised that VCaP and PC3 cell 
lines, representing a more advanced 
stage of PC, have a constitutively ac-
tivated GRPR expression that has es-
caped ‘normal’ androgen regulation 
control mechanisms, while, in the case 
of VCaP, growth control is still (partial-
ly) retained by androgens. It remains to 
be determined if this is a physiological 
relevant phenomenon that may occur in 
a subset of tumours as represented by 
these two cell line models.
GRPR protein expression in late stage 
metastatic PC has been reported in the 
literature with varying results. Mark-
walder et al.15 described either absent 
(43%) or low (57%) GRPR binding in 7 
human samples of androgen-unrespon-
sive PC bone metastasis as determined 
by autoradiography. In an autoradiog-
raphy study by Thomas et al. 33 AMBA 
labelled with 177-Lutetium showed spe-
cific GRPR-binding in 14 out of 17 PC 
patients with no difference in uptake 
between 3 primary androgen-unrespon-
sive PC tissues and their secondary 
lymph nodes metastates. In an immu-
nohistochemical study by Ananias et al. 
34 GRPR density was studied in 15 early 
stage PC lymph node samples derived 
from radical surgical treatment (of a to-
tal of 21 samples since some samples 
were ipsilateral lymph nodes from the 
same patient) and 17 samples of human 
PC bone metastasis obtained either by 
biopsy or by resection as part of ortho-
paedic surgery. Bone metastases were 
GRPR positive in 53% of cases while 
PC lymph nodes were GRPR posi-
tive in 86%. Interestingly, only 2 of 7 
CRPC samples showed positive GRPR 
staining as opposed to 5 of 8 positive 
samples in the group that received no 
hormone therapy. The drawback of this 
study was, however, that the GRPR an-
tibody used resulted in poor contrast 
of staining between tumour and back-
ground. As a consequence, the GRPR 
expression scores were very weak and 
not very convincing. From 27 positive 
samples weak staining was reported 
in 24 samples and moderate staining 
in only 3 samples. None of the posi-
tive samples showed strong staining. 
We also attempted to use immunohis-
tochemistry for evaluation of GRPR 
expression in clinical PC samples. 
Several antibodies that claimed GRPR 
specificity as well as different immu-
nohistochemical protocols were tested, 
but we were unable to reach acceptable 
contrast between tumour and back-
ground required for reliable scoring. 
Acceptable staining contrast was only 
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observed in pancreatic Islets of Langer-
hans that were used as positive control. 
In our hands the antibody and protocol 
used by Ananias et al. 34 was neither 
successful.
As an alternative for the evaluation 
of GRPR in human samples of PC, 
we used RT-PCR to determine GRPR 
mRNA expression. Also, we performed 
autoradiography for GRPR density in 
a subset of patient samples. Tumour 
samples of early PC were predominant-
ly GRPR positive, although with con-
siderable variability in mRNA levels. 
PC and non-cancerous tissues showed 
considerable overlap in expression 
levels resulting in comparable mean 
expression levels of relative mRNA 
GRPR. A lower average uptake was 
only observed in the CRPC group, al-
though difference was not statistically 
significant. Autoradiography on frozen 
sections of human prostate tissue re-
vealed higher average GRPR-specific 
uptake of 111In-Pesin in cancer (radi-
cal prostatectomy and TURP) than in 
the benign tissue groups (BPH and 
stroma), but also with considerable 
overlap. Only between radical prosta-
tectomy and stromal tissues BN pep-
tide uptake was significantly different 
(p<0.05), confirming PC specificity. 
The data reveal that GRPR expression 
is present in nearly all PC tissues. Al-
though the sample numbers are too low 
for a definite conclusion, the data also 
indicate that expression of GRPR, and 
GRP-specific binding, is variable and 
overlaps with non-cancerous tissue. 
In order to be able to compare our 
present findings with those obtained 
by Markwalder et al.15 we composed a 
scatter plot of their data (Figure 5) sim-
ilar to the one composed for our data 
(Figure 4B). We interpreted primary 
PC similar to our specimens of radi-
cal PC, bone metastases of androgen-
unresponsive prostatic cancers similar 
to our CRPC group and hyperplasia 
similar to our BPH samples. In addi-
tion, Markwalder et al. also included 
high-grade PIN samples. The compari-
son of studies reveals that differences 
in GRPR expression between primary 
PC and benign tissue is more pro-
nounced in the study of Markwalder et 
al., which may be caused by the larger 
sample set analysed in their study. Also 
in this study GRPR specific binding 
showed substantial overlap between 
PC and benign tissue. The observed 
overlap in relative GRPR mRNA lev-
els as well as in GRPR-specific binding 
in benign and malignant prostate tissue 
negatively affects specificity of BN-
based GRPR targeting for diagnosis 
of PC, leading to false-positive cases. 
This finding may limit the use of BN as 
a reliable diagnostic tool for PC. The 
reduced mean levels of GRPR-specific 
binding in CRPC samples described by 
Markwalder et al. corresponds with our 
data suggesting that hormonal therapy 
generally results in down-regulation of 
GRPR expression. The above described 
escape phenomenon of VCaP and PC-3 
may thus be a rather uncommon clinical 
event. Despite this reduced expression, 
we were able to detect (at least some) 
expression of GRPR mRNA in 19 out of 
21 PC samples (including CRPC) that 
underwent hormone treatment. This is 
supported by a few studies that report 
accurate visualisation of androgen-un-
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responsive PC in 6 out of 10 patients 
35, 36. It appears that pre-selection of 
GRPR expressing patients is required 
when opting for GRPR-targeted BN-
based response monitoring and therapy 
of PC in previously hormonally treated 
patients. The use of GRPR-based imag-
ing and therapy in the hormone-naïve 
PC population, however, continues to 
be a promising strategy. 
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absTracT
Prostate cancer (PC) is a major health problem. The Gastrin-Releasing Pep-
tide Receptor (GRPR) offers a promising target for staging and monitoring 
of PC since it is overexpressed in PC and not in normal prostatic tissue. To 
improve receptor-mediated imaging we investigated the impact of various 
experimental conditions on pharmacokinetics using the Indium-111 labelled 
bombesin (BN) analogue AMBA. Besides frequently used androgen-resistant 
PC-3 also the clinically more relevant androgen sensitive VCaP celline was 
used as human PC xenograft in nude mice.
Non-purified 111In-AMBA was compared with HPLC-purified 111In-AMBA. 
Effect of specific activity was studied administrating 0.1MBq 111In-AMBA 
supplemented with different amounts of AMBA (1-3000pmol). GRPR was 
saturated with Tyr4-BN 1 and 4h prior to injection of 111In-AMBA. 
GRPR-positive tissue showed a significant 2 to 3-fold increase in absolute 
uptake after HPLC-purification while keeping a stable tumour-to-pancreas 
ratio. Lowering specific activity resulted in decline in uptake to 43% in tu-
mour, 49% in kidney and 92% in pancreas between 10 and 3000pmol. Tumour 
to pancreas ratio improved six-fold from 0.1±0.0 after 10pmol up to 0.6±0.2 
after 3000pmol (p<0.01). When saturating GRPR 4h prior to 111In-AMBA in-
jection tumour to pancreas ratio improved from 0.10±0.3 to 0.22±0.2 (p<0.01) 
and tumour to kidney ratio increased from 0.92±0.16 to 3.45±0.5 (p<0.01).
Besides specific peptide characteristics also the experimental conditions, 
such as HPLC-purification, variations in specific activity and saturation of 
the GRPR prior to 111In-AMBA administration essentially affect radiopeptide 
pharmacokinetics. Experimental conditions therefore need to be carefully se-
lected in order to compose ideal standardised protocols for optimal targeting.
inTroducTion
Prostate cancer (PC) is the most fre-
quently diagnosed cancer among men 
in the Western world and the second 
cause of cancer related death 1. PSA-
based screening of PC has dramatically 
increased early diagnosis 2, but for opti-
mal management of disease it is essential 
to discriminate between organ-confined 
disease and PC beyond the borders of 
the gland. Current imaging techniques 
are not sufficiently accurate to determine 
extent of PC at diagnosis and to visualise 
micrometastases 3-5. Therefore more sen-
sitive imaging techniques are required.
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Nuclear imaging - using single pho-
ton emission computed tomography 
(SPECT) and positron emission tomog-
raphy (PET) - might offer applications 
for desired accurate PC imaging. The 
Gastrin-Releasing Peptide Receptor 
(GRPR) constitutes an interesting tar-
get for peptide-receptor radionuclide 
imaging and therapy. GRPR is a G-
protein coupled receptor overexpressed 
on cell-membranes of PC while not on 
normal prostate 6. Bombesin (BN) and 
its mammalian counterpart, the Gas-
trin-Releasing Peptide (GRP), are natu-
ral ligands for the GRPR and can bind 
to it with high affinity. The 14 amino 
acid COOH-terminus of the 27 amino 
acid GRP is the biologically active end 
and corresponds to that of BN 6. 
Several radiolabelled BN-analogues 
have been developed and tested in 
preclinical and clinical settings as di-
agnostic and therapeutic tools for 
management of PC in patients. Our 
group has performed a standardised 
study on PC targeting efficacy of five 
radiolabelled BN analogues 7. In this 
study the agonist DOTA-CH2CO-Gly-
[4-aminobenzoyl]-Gln-Trp-Ala-Val-
Gly-His-Leu-Met-NH2 (AMBA) was 
demonstrated to be one of the best BN-
analogues with relatively high in vivo 
stability, tumour uptake and retention 
8. Also, AMBA is one of the few BN-
based analogues that have been used 
for PET imaging in patients 9-10.
The focus for improvement of BN-
based imaging (by increasing tumour 
to background ratio) has predomi-
nantly relied on development of new 
BN peptides with enhanced affinity for 
the GRPR 8, 10-12. Instead, in the pres-
ent study we investigated the impact of 
various experimental factors in order 
to improve peptide receptor-mediated 
imaging. 
To ensure purity of tracer peptide, 
many study groups perform purifica-
tion of BN-analogues by high-perfor-
mance liquid chromatography (HPLC) 
between labelling and administration. 
In order to determine the impact of this 
purification step, we studied the effect 
of HPLC-purification methods on BN 
biodistribution. 
An essential parameter to evaluate the 
performance of targeted imaging probes 
is the ratio between radioactivity in tu-
mour and that in background organs. 
Contrast between the two is dependent 
on the amount of peptide administered. 
BN analogues have pharmacological 
effects in the nanomolar range. Capac-
ity of the GRPR in tumour and other 
tissues is relatively low and varies be-
tween tissues 8, 13-14. Therefore, in the 
present study we investigated receptor-
saturation of target versus non-target 
organs using different peptide amounts 
15. We studied the impact of specific 
activity on tumour to background ratio 
by varying injected peptide amounts 
while remaining a constant radioactiv-
ity level.
GRPR-binding of BN-agonists like 
AMBA causes internalisation of the 
receptor 12, 16 and over time gradually 
re-expression of receptors on the cell 
membrane occurs indicating receptor 
turn-over. Tumour cells are assumed to 
have a higher metabolic rate than nor-
106
mal tissue 17-18. We therefore assumed 
that GRPR turnover is faster in PC than 
in normal tissue resulting in a higher 
tumour to background ratio. We per-
formed a biodistribution study to evalu-
ate the impact of GRPR saturation with 
unlabelled compound (GRP or BN) 4h 
prior to labelled tracer injection.
In this study we investigated the ef-
fects of HPLC-purification, specific 
activity and GRPR saturation prior to 
labelled tracer on BN tumour uptake. 
Biodistribution studies were performed 
administrating Indium-111 labelled 
BN-agonist AMBA (111In-AMBA) as 
a reference peptide intravenously to 
athymic nude mice bearing GRPR-ex-
pressing PC-3 or VCaP xenografts. The 
data show that all factors affect peptide 
receptor-mediated biodistribution and 
thereby influence PC imaging.
MaTerials and MeThods
cell culture
Human PC cells were cultured in RPMI 
(LONZA, Verviers, Belgium) supple-
mented with fetal calf serum (GIBCO 
Invitrogen Co, Grand Island, NY, USA), 
5% for PC-3 and 10% for VCaP cells. 
An additional 5mL/500mL penicillin/
streptomycin antibiotic solution (LON-
ZA, Verviers, Belgium; 10.000Units/
mL penicillin, 10.000Units/mL strepto-
mycin) was added to medium of both 
cell lines. Cells were grown in T175 
Cellstar tissue culture flasks (Greiner 
Bio-one GmBH, Frickenhausen, Ger-
many) at 37°C in a humidified atmo-
sphere containing 5%CO
2
. Cells were 
passaged using a Trypsin/EDTA so-
lution (LONZA, Verviers, Belgium), 
170000U/L Trypsine-Versene and 
200mg/L EDTA. Cells were grown to 
near confluency after which they were 
harvested and counted. Suspensions of 
approximately 5x106cells were yield 
and dissolved in 100µL PBS for subcu-
taneous injection in xenografts.
Prostate cancer xenografts
Six to seven-week old male Swiss 
nu/nu mice (Charles River, Kißlegg, 
Germany) were inoculated subcuta-
neously with PC-3 or VCaP cells (5 
x 106cells/100µL PBS) on the right 
shoulder. A maximum of 4 mice per 
cage were kept in 14x13x33cm3 indi-
vidually ventilated cages (Techniplast 
BV, Wognum, The Netherlands), on 
Woody-Clean sawdust type BK8/15 
(Technilab-BMI, Someren, The Neth-
erlands) under a 12-h light-dark cycle, 
at 50±5% relative humidity and con-
trolled temperature (~22°C). Mice had 
access to irradiated chow and acidified 
drinking water ad libitum. Experiments 
were initiated when tumours were es-
tablished and clearly visible ranging 
from 200-500mm3 (3-5 weeks after in-
oculation). 
The experiment was approved by the 
Animal Experimental Committee of the 
Erasmus MC and performed in agree-
ment with the Dutch Animal Experi-
mentation Act (1977) and the European 
Convention for Protection of Verte-
brate Animals Used for Experimental 
Purposes (Strasbourg, 18 March 1986).
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radiolabeling of aMba and 
Quality control
AMBA (MW: 1503g/mol) was kind-
ly provided by Prof. Dr. H.R. Mäcke 
(University Hospital Basel, Switzer-
land) and was dissolved in Milli-Q wa-
ter, final peptide concentration 10−3M. 
111In-Cl
3
 (DRN 4901, 370MBq/mL in 
HCl, pH1.5–1.9) was obtained from 
Covidien (Petten, The Netherlands). 
All chemicals were purchased from 
Sigma-Aldrich (Zwijndrecht, The 
Netherlands) at the highest available 
grade. Radioactivity was measured in a 
VDC-405 dose calibrator (Veenstra In-
struments BV, Joure, The Netherlands). 
AMBA, 111In-Cl
3
 and quenchers (me-
thionin, ascorbic acid and gentisic 
acid) were heated for 20min 80oC. 
Sodium acetate was used to control 
pH (3.5-4) 19. Small volume reac-
tions were performed in typical vials 
as described 20. Vials were placed in a 
temperature-controlled heating block. 
After cooling down DTPA was added 
to bind free 111In-. Instant thin-layer 
chromatography Silica Gel (ITLC-SG) 
was performed with mobile phase: both 
sodium citrate 0.1M and ammonium 
acetate 1M / methanol (1:1 v/v) 21-22. 
Activity was subsequently detected us-
ing a Phosphor Imaging system, Pack-
ard Cyclone, with OptiQuant software 
(PerkinElmer, Groningen, The Nether-
lands). HPLC quality control and puri-
fication were performed using a Breeze 
system with a 1525 binary HPLC-pump 
(Waters, Etten-Leur, The Netherlands). 
Radioactivity was detected with a Uni-
spec MCA γ-detector (Canberra, Zelik, 
Belgium). For separation a Symmetry 
5µm, 4.6mmx250mm C
18
 column (Wa-
ters, Etten-Leur, The Netherlands) was 
used. HPLC-gradient was applied as 
described 20. Injections of 200μL were 
performed with a 717plus autosampler 
(Waters, Etten-Leur, The Netherlands). 
HPLC-Purification
To study the effects of specific activ-
ity on imaging we needed to obtain a 
fixed and well-characterized amount 
of 111In-AMBA. Hereto we performed 
HPLC-purification of a labelled AMBA 
solution. 
HPLC-purified 111In-AMBA was quan-
tified and diluted with saline for injec-
tion (0.1MBq per animal). The peptide 
amount of HPLC-purified 111In-AMBA 
from the main peak was considered neg-
ligible, since 37MBq 111In- ≈ 2.15x10-
11gram atoms. Eventually non-labelled 
AMBA (AMBA) was added to obtain 
a HPLC-purified 111In-AMBA solu-
tion containing a determined amount 
of AMBA (range 1 to 3000pmol). For 
stabilisation and reduction of radiolysis 
methionin, ascorbic acid and gentisic 
acid were added as quenchers directly 
after HPLC-purification.
biodistribution studies
Mice (either non-tumour bearing, PC-3 
or VCaP tumour-bearing) were injected 
with 111In-AMBA solution into the later-
al tail vein. Animals were sacrificed by 
cervical dislocation at fixed time points 
post injection (pi). Study groups con-
sisted of 3-5 mice. Tumour and other 
selected tissues were excised, weighed, 
and radioactivity was determined in a 
LKB-1282-compugamma γ-counter 
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(Perkin Elmer, Groningen, The Nether-
lands). Data were expressed as percent-
age of the injected dose per gram of tis-
sue (%ID/g) using 10μL of the original 
injectate as reference (100%).
effect of hPlc-purification 
A biodistribution study comparing tis-
sue distribution of non-purified 111In-
AMBA and HPLC-purified 111In-AM-
BA was performed. An equal peptide 
amount (10pmol) and radioactivity 
(0.1MBq) of purified or non-purified 
111In-AMBA was injected in PC-3 and 
VCaP bearing mice (n=4/group). Mice 
were sacrificed 1h pi. 
Effect of specific activity 
In PC-3 bearing mice a biodistribu-
tion study was performed comparing 
tissue distribution of injections with 
different specific activity: a fixed ra-
dioactivity level of HPLC-purified 
111In-AMBA (0.1MBq per mouse) 
supplemented with different amounts 
of AMBA (1-3000pmol). Mice (n=4 
per condition) were sacrificed 1h pi.
effect of receptor saturation
The effect of pre-saturation of GRPR 
prior to the administration of 111In-
AMBA was studied in PC-3 bearing 
mice. At different time points after 
GRPR saturation with Tyr4-BN (60 
nmol), HPLC-purified 111In-AMBA 
(0.1MBq≈10pmol) was administered 
(n=4/time point). Mice received 111In-
AMBA without pre-saturation (t=0) or 
111In-AMBA at 1 (t=1) or 4 (t=4) hours 
after Tyr4-BN injection. Mice were 
sacrificed 1h after injection of labelled 
peptide.
statistics
Statistical analyses were performed us-
ing the unpaired 2-tailed t-test in SPSS 
11.01 (SPSS Inc., Chicago, United 
States). Statistical significance was as-
sumed if p-values were <0.05.
figure 1
HPLC-chromatogram with UV at 278 nm and 
base to base separation. The graph shows HPLC 
of an 111In-AMBA solution. Difference in retention 
time between AMBA and 111In-AMBA is 1.5 min.
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resulTs
biodistribution studies
Effect of HPLC-purification 
HPLC-purification of 111In-AMBA 
solution resulted in carrier free end 
product, as shown in Figure 1. The 
main peak containing carrier free 111In-
AMBA had a retention time (RT) of 
16.1min while for unlabelled AMBA 
this was 14.6min. Radiochemical pu-
rity, measured directly after labelling, 
was always >90%. 
When administrating non-purified 111In-
AMBA in PC-3 bearing mice tumour 
uptake was 3.3±0.7%ID/g and pan-
creas uptake was 28.6±2.2%ID/g 1h pi. 
Significantly higher uptakes (p<0.01) 
for both tissues were seen after injec-
tion of HPLC-purified 111In-AMBA: 
tumour uptake was 6.8±1.1%ID/g and 
pancreas uptake was 60.5±14.0%ID/g 
at 1h pi. However, uptake was signifi-
cantly higher in all gastro-intestinal or-
gans after HPLC-purified 111In-AMBA 
as compared to 111In-AMBA as well 
(Figure 2).
In VCaP-tumour-bearing mice the 
same tendency was seen. Uptake in 
tumour increased significantly from 
1.6±0.2%ID/g for non-purified 111In-
AMBA to 4.3±1.3%ID/g after injec-
tion of HPLC-purified 111In-AMBA 
at 1h pi. Pancreatic uptake values 
were also higher: 23.4±2.9%ID/g and 
70.0±20.3%ID/g, respectively. 
Tumour to pancreas ratio remained the 
same in both experiments.
Effect of specific activity 
Injecting 111In-AMBA at a fixed amount 
of radioactivity while varying in pep-
tide amount resulted in significant dif-
ferences in PC-3 tumour uptake when 
injecting over 1000pmol of peptide. 
Lower specific activity resulted in a 
43% decline (p=0.09) in tumour uptake 
between 10pmol (5.7±2.5%ID/g) and 
3000pmol (2.9±1.0%ID/g), as shown 
in Figure 3.
Significant differences in pancreas up-
take were observed already at peptide 
amounts beyond 100pmol. Compared 
to tumour uptake, a stronger decline 
in uptake (92%) was observed for pan-
creas uptake when lowering specific 
activity. Injection of 10pmol 111In-AM-
BA resulted in a pancreas uptake of 
63.2±14.9%ID/g. For 3000pmol uptake 
was 5.1±0.4%ID/g (Figure 3). Due to 
a rather stable tumour uptake and de-
creasing pancreas uptake, tumour to 
pancreas ratios improved six-fold from 
0.1±0.0 at 10pmol up to 0.6±0.2 at 
3000pmol. 
Uptake in kidneys showed a gradual de-
crease at lower specific activities. Up-
take decreased 49% from 4.3±1.0%ID/g 
(10pmol) to 2.0±0.3%ID/g (3000pmol). 
Tumour to kidney ratio remained stable 
with an average ratio of 2.1±0.6.
Effect of receptor saturation 
Tumour uptake of 111In-AMBA when 
no receptor saturation was applied was 
3.9±0.6%ID/g at 1h pi. When 111In-
AMBA was injected 1h after receptor 
saturation with Tyr4-BN pre-dosing, tu-
mour uptake decreased significantly to 
1.3±0.5%ID/g (p<0.01). When tracer 
110
was injected 4h after receptor satura-
tion with Tyr4-BN, 111In-AMBA tumour 
uptake was 2.4±0.7%ID/g at 1h pi.
Pancreas uptake of 111In-AMBA without 
receptor saturation was 29.8±1.7%ID/g 
1h pi. Uptake was significantly lower 
(p<0.001) when receptor saturation 
was applied 1h and 4h prior to trac-
er application (12.2±0.6%ID/g and 
10.8±3.0%ID/g, respectively). As a re-
sult tumour to pancreas ratio improved 
figure 2
Biodistribution results of non purified versus purified 111In-AM-
BA in PC-3 bearing mice, 1h post injection.
figure 3
Uptake in pancreas and PC-3 tumour after administration of 111In-AM-
BA with variable specific activity. X-axis depicts amount in pmol.
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significantly (p<0.01) from 0.10±0.3 to 
0.22±0.2 (Figure 4A).
Tumour to kidney ratios significantly 
increased after GRPR saturation by ad-
ministration of Tyr4-BN prior to 111In-
AMBA. Without pre-dosing kidney 
uptake was 4.4±1.5%ID/g 1h pi, while 
111In-AMBA uptake after pre-dosing 
for 1h and 4h was 0.8±0.1%ID/g and 
0.7±0.1%ID/g. As a result also tumour 
to kidney ratio increased significantly 
(p <0.01) from 0.92±0.16 to 3.45±0.5 
(Figure 4B). 
discussion
Nuclear imaging offers new applica-
tions for desired accurate imaging of 
PC. Targeting of GRPR with radiola-
belled BN has shown promising results 
in preclinical studies 7-8, 11-12. A variety 
of BN analogues have been developed 
and tested for (in vivo) stability, re-
ceptor affinity and specificity. Since 
not only specific tracer characteristics 
but also experimental conditions like 
HPLC-purification of labelled peptide, 
specific activity (peptide amount) and 
saturation of GRPR (pre-dosing) may 
affect GRPR-targeting performance 
of BN analogues, we have focused on 
A
B
figure 4
Tumour-pancreas (A) and tumour-kidney (B) ratio when administering purified 
111In-AMBA at different time points after injection of Tyr4-BN in PC-3 bearing mice.
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these aspects is this study. Hereto we 
compared biodistribution results of pu-
rified versus unpurified tracer, various 
peptide amounts, and saturation versus 
no saturation of GRPR before injection 
of labelled peptide injection, aiming at 
optimising GRPR targeting. Many fac-
tors showed to have an effect receptor-
mediated uptake. 
To determine the impact of the differ-
ent experimental conditions on peptide 
biodistribution and resulting target to 
background ratio, we chose the BN ag-
onist 111In-AMBA as reference agonist 
peptide. AMBA was selected as a result 
of good performance in preclinical and 
clinical studies 7-8. We used the GRPR-
expressing PC-3 and VCaP xenografts 
as model systems. The androgen-resis-
tant PC-3 cell line was chosen because 
of its use in the vast majority of experi-
mental PC studies. In addition, in some 
experiments also the less applied VCaP 
celline was used. It has GRPR expres-
sion comparable with PC-3 while it is 
more clinically relevant because of its 
expression of the androgen receptor 
and ability to secrete PSA 23-24. There-
fore, it is a more realistic model for fu-
ture peptide-based imaging as well as 
therapeutic PET/SPECT studies. In this 
study VCaP indeed showed reasonable 
tumour uptake indicating expression 
of the GRPR, nevertheless absolute tu-
mour-uptake of PC-3 was significantly 
higher. 
HPLC enables separation of radiola-
belled analogue from non-incorpo-
rated (free) radionuclides and from 
unlabelled intact or oxidised peptide 
to achieve radiolabelled carrier-free 
Uptake 111In-AMBA mean SD P-value mean SD P-value
 Tumour   Pancreas   
Sep-Pak C
18       
Non-purified - - - 22.5 1.5  
Purified - - - 27.1 7.5 0.30
Eluents       
None 5.4 0.9  42.9 5.1  
Methanol 14% 5.5 1.4 0.73 48.0 6.9 0.49
Ethanol 14% 7.5 2.5 0.25 55.0 1.8 *0.02
Acetonitril 14% 7.4 0.6 *0.03 62.0 5.9 *0.01
HPLC purification       
Non-purified - - - 19.4 4.1  
Purified before labelling - - - 29.3 17.4 0.39
Purified after labelling - - - 41.8 6.0 *0.01
* indicates significance compared to normal (non-purified / eluents: none) 
Table 1
Uptake in %ID/g in pancreas (and tumour) after administration of variable 
111In-AMBA solutions in VCaP tumour-bearing mice.
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peptide (Figure 1). We showed that 
compared to non-purified 111In-AMBA 
HPLC-purified 111In-AMBA showed a 
significant two-to threefold higher up-
take in GRPR positive tissues. We in-
vestigated a few possible explanations 
for these differences in biodistribution, 
results are summarized in Table 1.
HPLC-purification requires aqueous 
solutions containing various organic 
eluents such as methanol, ethanol or 
acetonitril to separate labelled and non-
labelled peptides. When supplementing 
these commonly used organic solvents 
to non HPLC-purified 111In-AMBA be-
fore administration a tendency towards 
higher uptake in GRPR-expressing or-
gans was seen. These differences, how-
ever, could not fully explain the signifi-
cant differences seen with HPLC-puri-
fied 111In-AMBA. We also performed 
a biodistribution study in order to in-
vestigate whether the HPLC-procedure 
itself caused differences in uptake. In 
this study we used an 111In-AMBA so-
lution in which the unlabelled AMBA 
peptide was purified by HPLC prior to 
labelling and compared that to HPLC-
purified labelled AMBA. No increase 
in uptake of GRPR-positive tissues 
was seen though. Only HPLC-purifi-
cation after peptide labelling showed 
a significant increase in uptake. In 
contrast to HPLC-purification, separa-
tion procedures using Sep-Pak C
18
 do 
not separate 111In-AMBA from non-
labelled AMBA. Consequently, after 
purification of labelled peptide, in the 
injection solution no additional non-
purified AMBA amount was needed. 
As a result the potential contamina-
tion of 111In-AMBA solution is higher. 
In non-tumour-bearing mice no differ-
ence in pancreas uptake was observed 
when comparing Sep-Pak C
18
 purified 
111In-AMBA with 111In-AMBA. Also, 
a biodistribution study was performed 
in which we added 10pmol of HPLC-
purified 115In-AMBA to HPLC-purified 
111In-AMBA (neglectable amount) in 
order to study the differences in affinity 
and uptake between labelled and unla-
belled AMBA. As compared to HPLC-
purified 111In-AMBA the solution of 
111/115In-AMBA showed no significant 
differences in GRPR uptake (data not 
shown). Clearly, substitution of 111In-
AMBA by 115In-AMBA did not affect 
GRPR affinity.
There is no consensus in literature about 
the optimal BN peptide amount for op-
timal targeting in mice. We previously 
reported an optimal peptide amount 
for GRPR targeting between 10pmol 
and 50pmol for analogue [111In-DTPA-
Pro1,Tyr4]BN in non-tumour-bearing 
Lewis rats 15. Basso et al. reported that 
in man a BN infusion of 15ng/kg per 
minute resulted in the maximal gastrin 
response 25. In experimental studies 
using mice often 10pmol of radiola-
belled BN is injected 11-12. Our current 
study clearly showed that differences 
in peptide amount have a significant 
influence on BN biodistribution. The 
best tumour to background ratios were 
reached when injecting 3000pmol of 
purified 111In-AMBA (Figure 3). This 
was caused by rapid decrease in trac-
er uptake in most background organs, 
especially pancreas, while tumour up-
take remained fairly stable. This im-
plies that the GRPR saturation is faster 
in background than in tumour tissue. 
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Similar results - although saturation of 
the tumour seemed not reached - were 
seen in a study by Lantry et al. in which 
177Lu-AMBA with various specific ac-
tivities (between 1.7 and 426pmol) was 
administered to PC-3 bearing mice 8.
In this study we assumed that the main 
peak from HPLC of an 111In-labelled 
AMBA solution contains carrier-free 
111In-AMBA only. It needs to be men-
tioned that the 111In-AMBA peak might 
also contain AMBA labelled with other 
metals like Fe and Zn. Total peptide 
amount collected from HPLC might 
therefore be higher than foreseen. 
Since we neglected the amount of 111In-
AMBA from HPLC we have added 
10pmol AMBA to achieve a final injec-
tion solution of 0.1MBq (10pmol). In 
theory, if the total amount of peptide 
injected to HPLC would be completely 
incorporated with 111In- and trace met-
als, this would result in a maximum 
peptide amount of 10pmol. Therefore, 
after addition of 10pmol AMBA, the 
maximum peptide amount of 111In-AM-
BA solution is 20pmol. As concluded 
earlier this would not affect tumour 
uptake since receptor-mediated uptake 
remained stable up to 300pmol. 
Biodistribution of BN was also affected 
when GRPR was saturated using unla-
belled Tyr4-BN prior to injection of ra-
diolabelled 111In-AMBA. It resulted in 
significantly lower uptakes in tumour, 
pancreas and kidney. At four hours af-
ter injection of the pre-dose, a recovery 
in HPLC-purified 111In-AMBA uptake 
in tumour was seen while restoration 
of uptake in pancreas and kidney was 
not observed. Our data support the hy-
pothesis that malignant PC cells regener-
ate the GRPR faster than normal tissues, 
probably caused by a higher metabolic 
rate 17-18. In agreement with Lantry et al. 
pre-dosing with unlabelled AMBA re-
sulted in just a small reduction of 111In-
AMBA uptake in tumour whereas a 
stronger reduction of 111In-AMBA uptake 
in pancreatis was seen. This resulted in 
an optimised tumour-to-pancreas ratio 8. 
Noticeably, receptor saturation goes 
with a reduction in absolute tumour 
uptake and therefore higher amounts 
of peptide will be required to equal up-
take when pre-dosing with unlabelled 
peptide. The need for higher peptide 
amount may result in more side-effects 
especially when receptor agonists are 
being used. The use of BN antagonists 
instead will however likely circumvent 
this problem.
conclusions
In the present study we investigated 
on experimental factors that interfere 
with GRPR-targeted biodistribution us-
ing the BN analogue AMBA as a test 
tracer. We demonstrated that HPLC-
purification of 111In-AMBA, variations 
in specific activity and saturation of 
the GRPR prior to the administration 
of 111In-AMBA essentially affect ra-
diopeptide pharmacokinetics. All influ-
ence absolute tumour uptake and often 
tumour to background ratio is affected 
as well. Experimental conditions there-
fore need to be carefully selected in or-
der to compose ideal standardised pro-
tocols for optimal targeting.
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absTracT
Prostate cancer (PC) is a major health problem. For staging and monitoring of 
PC the Gastrin-Releasing Peptide Receptor (GRPR) offers a promising target 
since this receptor is overexpressed in PC, but not in hyperplastic prostate. As 
cancer cells show increased metabolic activity also metabolism-based tracers 
are being used for PC imaging. We compared GRPR-targeted imaging us-
ing the 68Ga-labelled bombesin (BN) analogue AMBA with metabolism-based 
imaging using 18F-methylcholine (18F-CH) in nude mice bearing human PC 
xenografts (VCaP and as reference PC-3).
PET and biodistribution studies were performed with both tracers in all mice. 
Scanning started immediately post-injection (pi). Dynamic PET was recon-
structed and analyzed quantitatively. Biodistribution uptake was expressed as 
% of injected dose per gram tissue (%ID/g).
All tumours were clearly visualised using 68Ga-AMBA. 18F-CH showed 
significantly less tumour/background contrast. Quantitative PET analyses 
showed fast tumour uptake and high retention for both tracers. VCaP tumour 
uptake determined from PET at steady state was 6.7±1.4 %ID/g (20-30 min 
pi, N = 8) for 68Ga-AMBA and 1.6±0.5 %ID/g (10-20 min pi, N = 8) for 18F-
CH which was significantly different (p < 0.001). PC-3 outcome was compa-
rable. Biodistribution results were in accordance with PET showing a VCaP 
tumour uptake of 9.5±4.8 %ID/g for 68Ga-AMBA and 2.1±0.4 %ID/g for 18F-
CH. Apart from the GRPR-expressing organs, uptake in all organs was sig-
nificantly lower after 68Ga-AMBA than 18F-CH.
Tumour uptake of 68Ga-AMBA was higher while overall background activ-
ity was lower than observed for 18F-CH in the same PC-bearing mice. These 
results suggest that peptide-receptor mediated PET using BN analogue is su-
perior to metabolism-based PET using choline for scintigraphy of PC.
inTroducTion
Prostate cancer (PC) is the third lead-
ing cause of cancer-related deaths and 
the most frequently diagnosed cancer 
in men in Western countries1-2. Meas-
urement of serum prostate-specific 
antigen (PSA) is widely used for the 
detection of early PC3-4 and PSA-based 
screening has resulted in a sharp in-
crease of PC detection. As long as PC 
is organ-confined, prostate surgery or 
radiation therapy with curative intent is 
the first choice of treatment. However, 
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when facing metastasised PC curative 
treatment is no longer available and 
palliative hormone ablation therapy is 
indicated. Therefore, accurate staging 
of early PC at time of diagnosis as well 
as monitoring of patients following lo-
cal or systemic treatment are crucial 
steps in management of the disease.
Accuracy of conventional imaging tech-
niques – such as transrectal ultrasound 
(TRUS), CT, MRI, and bone scintigra-
phy - is not sufficiently adequate to de-
termine extent of PC at diagnosis and 
to visualise micrometastases5-7. New 
and more sensitive, preferably non-in-
vasive, imaging strategies are required. 
Molecular imaging by nuclear scintig-
raphy using positron emission tomog-
raphy (PET) or single photon emission 
computer tomography (SPECT) may 
provide alternative technologies for de-
tection. It enables biochemical cellular 
targets, such as cell-specific receptors, 
and more general metabolic processes 
to be targeted with tracers coupled to 
radionuclides for sensitive imaging.
In peptide-receptor based scintigraphy 
radiolabelled peptides are being used 
to target specific cell membrane recep-
tors. For PC imaging the Gastrin-Re-
leasing Peptide Receptor (GRPR) of-
fers a promising target since this recep-
tor is overexpressed in malignant cells 
originating from the prostate while 
normal and hyperplastic prostate cells 
show low or no expression of GRPR8. 
Gastrin releasing peptide (GRP), con-
sisting of 27-amino acids, is the mam-
malian homologue of the linear tetra-
decapeptide bombesin (BN) found in 
amphibians. Both peptides are natural 
ligands with a very high affinity for the 
GRPR. Several analogues - predomi-
nantly BN based - with the ability to be 
labelled with radionuclides have been 
developed and tested for their potential 
to treat and image PC using SPECT and 
PET modalities; for review see Schroed-
er et al.9. AMBA is a BN analogue which 
has shown good targeting performance 
in (pre-)clinical studies10-11. It is coupled 
to the DOTA chelator which enables la-
belling with Galium-68 (68Ga) - a posi-
tron emitting radionuclide suitable for 
PET - resulting in 68Ga-DOTA-AMBA 
(68Ga-AMBA). 
Apart from peptide-receptor-based tar-
geting, also metabolism-based tracers 
are being used to image cancer cells. 
Metabolic targeting is based on the 
assumption that cancer cells show in-
creased activities of several metabolic 
processes; for review see Jager et al.12. 
Malignant transformation of cells has 
been found to be associated with in-
creased metabolic activity13. High cell 
activity and cell turnover in cancer is 
assumed to be directly related to high 
activity of a variety of biological pro-
cesses such as glycolysis, prolifera-
tion and membrane synthesis. Although 
metabolic activity of PC is considered 
to be rather low because of its relative-
ly low proliferative activity14-15, results 
obtained with metabolism-based trac-
ers have been promising. For imaging 
of PC radiolabelled choline and acetate 
have shown to be the most promising 
tracers6, 16, 17-20. We selected choline as 
metabolic reference tracer in this study 
to compare its imaging ability with that 
of the peptide-receptor-based BN ana-
logue AMBA.
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Choline is an essential nutrient that 
serves as a precursor for the synthesis 
of phosphatidylcholine, a major con-
stituent of the cell membrane21. Nuclear 
magnetic resonance (NMR) spectrosco-
py has demonstrated higher concentra-
tions of phosphocholine in human tu-
mour tissues and in normal cells when 
stimulated by (mitogenic) growth fac-
tors22-23. In prostate cancer the cellular 
uptake and phosphorylation of choline 
is often increased compared to normal 
prostate epithelial and stromal cells24-25. 
Most PC imaging studies perform PET 
using choline labelled with Carbon-11 
(11C)26, 16, 6, 27. Since 11C has a relatively 
short half-life of 20 minutes (min), use 
of this radionuclide is limited to centres 
with on-site cyclotrons. This drawback 
has led to the development of choline 
derivatives like N-[18]fluoromethyl-
N-(2-hydroxyethyl)-N,N-dimethylam-
monium (18F-CH) with a radionuclide 
half life of 110 min. Biodistribution of 
18F-CH is comparable to 11C-choline al-
though 18F-CH shows higher renal ac-
tivity28. Structures of bombesin, 68Ga-
AMBA and 18F-CH are shown in Figure 
1.
To compare the potential of both radio-
active tracers we made use of PC-tu-
mour-bearing male NMRI nu/nu mice. 
The GRPR-expressing PC-3 cell line, 
originating from a PC bone metastasis, 
is the most widely used model for the 
study of radioactive BN-analogues29, 9, 
27. PC-3 is an androgen independent 
cell line34 that does not express the an-
drogen receptor or secretes PSA while 
most prostate tumours in patients, ex-
cept for late stage disease, do. The 
VCaP cell line on the other hand is an-
drogen responsive. It not only express-
es the androgen receptor and secretes 
PSA, it also expresses the GRP recep-
tor30-31. While it is a more representa-
tive PC model than PC-3 in this study 
we used the VCaP cell line. GRPR ex-
pression of both is comparable (data 
not shown). For comparison with lit-
erature we included the PC-3 xenograft 
as reference model.
To our knowledge, this is the first study 
comparing BN-analogue-based GRPR 
targeting to metabolic targeting for PC 
imaging. From PET and biodistribution 
in VCaP-bearing nude mice it became 
clear that peptide-receptor based imag-
ing using 68Ga-AMBA for targeting of 
the GRPR is superior to metabolic im-
aging using 18F-CH for detection of PC 
in nude mice.
MaTerials and MeThods
cell culture
Human PC-3 and VCaP cells were cul-
tured in RPMI-1640 (LONZA, Verv-
iers, Belgium) supplemented with pen-
icillin/streptomycin antibiotics (10.000 
Units/mL penicillin, 10.000 Units/mL 
streptomycin; LONZA, Verviers, Bel-
gium) with addition of 5% fetal calf 
serum (GIBCO Invitrogen Co, Grand 
Island, NY, USA) for PC-3 or 10% for 
VCaP. Cells were grown in T175 Cell-
star tissue culture flasks (Greiner Bio-
one GmBH, Frickenhausen, Germany) 
at 37°C in a humidified atmosphere 
containing 5% CO
2
. Cells were pas-
saged using a Trypsin - EDTA solution 
(LONZA, Verviers, Belgium) 170000 
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U/L Trypsine-Versene and 200 mg/L 
EDTA. For the present study, cells were 
grown to near confluency, harvested 
and counted. Cells were resuspended 
in PBS to yield approximately 5 x 106 
cells / 100 µL for subcutaneous injec-
tion into nude mice.
Pc xenografts
Eight male NMRI nu/nu mice (Taconic, 
Ry, Denmark) aged six to seven weeks 
were inoculated subcutaneously with 
VCaP cells on the right shoulder. For 
reference, 3 mice were injected with 
PC-3 cells in the same way. A maxi-
mum of 4 mice were kept in 14 x 13 x 
33.2 cm3 individually ventilated cages 
(Techniplast) on sawdust (Woody-
Clean, type BK8/15; BMI) under a 12-h 
light-dark cycle, at 50 ± 5% relative hu-
midity and controlled temperature (~22 
°C). Mice received irradiated chow and 
acidified drinking water ad libitum. Ex-
periments were initiated when tumours 
bombesin
68Ga-aMba
18f-ch
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figure 1
Structure formulas of bombesin, 68Ga-AMBA and 18F-CH.
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reached a volume of 200-600 mm3 (2-5 
weeks after inoculation). 
This study was approved by the Animal 
Experimental Committee (DEC) of the 
Erasmus MC and performed in agree-
ment with The Netherlands Experi-
ments on Animals Act (1977) and the 
European Convention for Protection of 
Vertebrate Animals Used for Experi-
mental Purposes (Strasbourg, 18 March 
1986).
radiolabelling & quality control
68Ga-DOTA-AMBA
Physical characteristics and radio-
chemistry of the 68Ge/68Ga generator:
68Ge/68Ga 370MBq generator (obtained 
from IDB Holland BV, Baarle Nassau, 
the Netherlands and originating from 
iThemba Labs, Somerset West, South 
Africa), t
1/2
 68Ge: 280 days, t
1/2
 68Ga: 68 
min was used. The carrier of this gen-
erator is SnO
2
. The generator was elut-
ed with 1 M Ultrapure HCl 30% (J.T. 
Baker, Deventer, the Netherlands). All 
chemicals were of the highest available 
grade. Fractionated elution of the gen-
erator was performed in the following 
fractions: 1.5 mL (void volume), 2.0 
mL (80% of total activity) and 2.5 mL 
(waste), the fractions were collected 
and measured in a VDC-405 dose cali-
brator (Veenstra Instruments BV, Joure, 
the Netherlands). 68Ga was quantified 
as described previously32. Anion puri-
fication was performed with an Oasis® 
WAX 1 cc column (Waters, Etten-Leur, 
the Netherlands). Before use the anion 
column was pretreated with 2 mL etha-
nol followed by 2 mL HCl 5 M. Total 
peak fraction (2 mL ≈ 300 MBq) was 
added to a 4 mL HCl solution (final 
concentration HCl 5 M). This solution 
was eluted over the anion column and 
subsequently washed with 2 mL of HCl 
5 M containing 68Ge, which was quanti-
fied as described32. Approximately 0.4 
mL of Milli-Q was used to desorp 68Ga 
(recovery ±80%). 
Radiolabeling:
DOTA-AMBA (MW: 1503 g/mol) 
was kindly provided by Prof. Dr. H.R. 
Maecke (University Hospital Basel, 
Switzerland). Before application of the 
peptide, it was dissolved in Milli-Q wa-
ter (final concentration 10−3 M). Pep-
tide, desorped 68Ga (200µL in Milli-Q) 
and HEPES 1 M (200µL) were heated 
for 10 min at 80oC. Radiolabelling 
was performed in reaction volumes of 
1.5 mL in polypropylene or glass vials 
(Waters, Etten-Leur, the Netherlands). 
Final pH of radiolabelled product was 
between 3-3.5. The vials were placed in 
a temperature-controlled heating block. 
Instant thin-layer chromatography 
Silica Gel (ITLC-SG) was performed 
with mobile phase sodium-citrate 0.1 
M and ammoniumacetate 1 M / meth-
anol (1:1 v/v)32-33. Activity was sub-
sequently detected using a Phosphor 
Imaging system, Packard Cyclone, 
with OptiQuant software (PerkinElmer, 
Groningen, the Netherlands). HPLC 
quality control and purification were 
performed using a Waters breeze sys-
tem with a 1525 binary HPLC pump 
(Waters, Etten-Leur, the Netherlands). 
Radioactivity was detected with a Uni-
spec MCA γ-detector (Canberra, Zelik, 
Belgium). For separation a Symmetry 5 
µm, 4.6mm x 250mm C
18
 column (Wa-
125
chaPTer 7
b
n
-G
r
P
r
 i
M
a
G
in
G
 s
u
P
er
io
r
 T
o
 M
eT
a
b
o
li
sM
-b
a
se
d
 i
M
a
G
in
G
 i
n
 P
c
 x
en
o
G
r
a
fT
s
ters, Etten-Leur, the Netherlands) was 
used.
HPLC mobile phase: 0.1% TFA (A) and 
methanol (B). HPLC gradient: 0-2 min 
100% A (Flow 1 mL / min), 2-3 min 
55% B (Flow 0.5 mL / min), 3-20 min 
60% B (Flow 0.5 mL/min), 20-20:01 
min 100% B (Flow 1 mL/min), 20:01- 
25 min 100% A (Flow 1mL / min), 
25:01- 30 min 100% A (Flow 1mL / 
min). Injections of 200 μL were per-
formed with a 717 autosampler (Wa-
ters, Etten-Leur, the Netherlands).
After labeling, the main peak contain-
ing 68Ga-AMBA was collected carrier 
free. Retention times were 12.4 min for 
DOTA-AMBA and 13.5 min for 68Ga-
DOTA-AMBA. After activity quantifi-
cation of the purified main peak the so-
lution was diluted for injection (0.5-1.5 
MBq per animal). Non-labeled DOTA-
AMBA was added to obtain a solution 
containing a fixed mass (300 pmol). 
The 68Ga-DOTA-AMBA mass, col-
lected with HPLC, was considered to 
be negligible (68Ga ≈ 3,6x10-13 moles/ 
37 MBq). After HPLC purification me-
thionin, ascorbic acid and gentisic acid 
were added as quenchers to stabilize. 
Radiochemical purity was ±90%.
18F-fluoromethyl-dimethyl-2-
hydroxyethylammonium (18F-CH)
Radiosynthesis and control of radio-
chemical purity was adapted from the 
methods described by Iwata et al.34. The 
synthesis of 18F-CH was performed at 
the VU University Medical Centre (Am-
sterdam, the Netherlands). An in-house 
developed remotely operated radiosyn-
thesis system was used. The 18F was iso-
lated from 18O-enriched water through 
a PS-HCO
3
 ion-exchange column and 
was subsequently eluted into the reac-
tion vial with 1 mL of a Kryptofix 2.2.2 
/ K
2
CO
3
 solution (12.5 mg K2.2.2, 2 mg 
K
2
CO
3 
in aconitril/water 9:1 v/v). Under 
reduced pressure and a flow of helium 
(50 mL/min) the solvents were evapo-
rated at 100°C. The residue was azeo-
tropically dried by addition of 500 µL 
dry acetonitril followed by its evapora-
tion as before. After cooling the reaction 
vial to room temperature followed by 
removal of the vacuum and helium, a 
dry solution of 50% dibromomethane in 
acetonitril was added. The temperature 
was raised to 100°C, and the dibromo-
methane was allowed to react with the 
18F for 5 min after which the vial was 
again cooled to 35°C. 18F-bromofluoro-
methane was than distilled from the vial 
using a stream of helium (50 mL/min) 
and passed through 4 connected Sep-Pak 
Plus Silica cartridges and consecutively 
through a ‘on column reaction’ setup, 
consisting of 1) a Sep-Pak Plus C
18
 car-
tridges loaded with 700 µL of dimethyl-
ethanolamine, 2) a second Sep-Pak Plus 
C
18
 cartridge and 3) an activated Sep-
Pak Light Accell Plus CM ion-exchange 
cartridge connected in series. Activity 
on these cartridges was monitored and 
after it reached a maximum (8-12 min) 
distillation was terminated. The ‘on col-
umn reaction’ setup was rinsed with 10 
mL ethanol followed by 10 mL of water 
and subsequently the 18F-CH was eluted 
with 5 mL of 0.9% NaCl (aq) into a flask 
containing 10 mL of a 0.9% NaCl/7.09 
mM NaH
2
PO
4
 (aq) solution yielding the 
final product.
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PeT scanning 
Mice were anaesthetized by a mix-
ture of isoflurane / oxygen and were 
placed in prone position and kept un-
der anaesthesia in a MicroPET scanner 
(Inveon©, Siemens / CTI, Knoxville, 
TN). Tumour-bearing mice were in-
jected intravenously using a tail vein 
cannula with 300 pmol / 100 µl 68Ga-
AMBA (68Ga-AMBA: 1.5-0.5 MBq) or 
100 µl 18F-CH (8.1-1.2 MBq). Based 
on their unique pharmacokinetics an 
ideal scanning schedule for each tracer 
was constructed. So, dynamic full body 
acquisition started at time of injection 
for a continuous period of 30 min using 
68Ga-AMBA or 20 min using 18F-CH. 
During scanning mice were kept warm 
by an external heating mat.
Each mouse was scanned after injec-
tion of the tracers 68Ga-AMBA and 18F-
CH on two consecutive days. In order 
to be able to correct for potential in-
terference between the tracers, the first 
group of mice was scanned first with 
68Ga-AMBA and one day later with 18F-
CH and the remaining animals were 
scanned first with 18F-CH and one day 
later with 68Ga-AMBA (see Table 1).
List mode data were stored on IAW 
1.2.2.2 (Inveon© Acquisition Work-
place; Siemens). From there they were 
histogrammed and framed: 25 x 60 sec 
frames for 68Ga-AMBA and 15 x 60 sec 
frames for 18F-CH. Attenuation correc-
tion on sinograms was subsequently 
performed. Images were reconstructed 
using filtered back projection (2DFBP) 
with a 50% rampfilter for analyses and 
quantification. For visualisation the 
ordered-subsets expectation maximi-
zation / maximum a priori (OSEM3D/
MAP) algorithm was used. To achieve 
steady state for both quantification 
and visualisation a sum of the last 10 
frames was displayed.
Quantification was performed by 
manually drawing volumes of inter-
est (VOIs) over preselected organs 
(kidneys and bladder) and tumours in 
all directions with a VOI diameter not 
exceeding the total volume of selected 
tissue to avoid interfering signals from 
other tissues35. Average outcome from 
two independent skilled analysts were 
used. The percentage of injected dose 
per gram tissue (%ID/g) was calcu-
lated as VOI activity (MBq/ml) / total 
injected dose (MBq) * 100%. To de-
crease interference of background we 
allowed this uptake to wash out and 
quantified mean total uptake at steady 
state from the last 10 min of scanning 
in %ID/g. The median and interquartile 
range (IQR) in %ID/g were determined 
for the timepoints 0.5-30.0 min post-
injection (pi). Statistical analysis was 
performed using the Mann-Whitney U 
test. A probability of less than 0.05 was 
considered significant.
biodistribution studies
After PET scanning, VCaP tumour-
bearing mice were sacrificed for biodis-
tribution at ideal time points for each 
tracer. Biodistribution of 68Ga-AMBA 
was performed 1 hour (h) pi and for 
18F-CH this was 30 min pi following 
the previously mentioned schedule 
(Table 1). 
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Tumour, liver, heart, blood, muscle, tail 
and kidneys as well as the GRPR-ex-
pressing organs pancreas and colon36, 
were collected for counting of radioac-
tivity in the LKB-1282-compugamma 
system (Perkin Elmer, Oosterhout, the 
Netherlands). Radioactive uptake was 
calculated as %ID/g after correction 
for remaining activity in the tail. Mean 
uptakes of each group of mice (n = 4) 
were then calculated.
Statistical analysis was performed us-
ing the unpaired t-test. A probability of 
less than 0.05 was considered signifi-
cant.
resulTs
PeT scanning
Using 68Ga-AMBA, all VCaP and PC-3 
tumours were clearly visualised by 
PET. High uptake was seen in tumour 
tissue as well as in GRPR-positive pan-
creas tissue and in organs responsible 
for clearance (kidneys and bladder) 
while uptake in background organs was 
low (Figure 2 row A). When perform-
ing PET scans using 18F-CH it was 
more difficult to distinguish VCaP and 
PC-3 tumours from the relatively high 
uptake present in surrounding back-
ground organs (Figure 2 row B). In 
20% of all 18F-CH scans it was not pos-
sible to distinguish the tumour-related 
contrast from background.
Dynamic tracer uptake in VCaP tu-
mour, bladder and kidney over time is 
Day
68Ga–DOTA-AMBA
PET
18F-CH
PET
68Ga–DOTA-AMBA
biodistribution
18F-CH
biodistribution
1 Mouse I – IV
2 Mouse I - VIII Mouse I – IV
3 Mouse V - VIII Mouse V - VIII
Table 1
Time chart of the set up for PET and biodistribution studies.
figure 2
PET scans from four out of eight corresponding 
VCap bearing mice. Row A shows scans after 
tail vein injection of 68Ga-AMBA (300 pmol, 
1.5-0.5 MBq). Row B shows scans after tail vein 
injection of 18F-Choline (100 µl, 8.1-1.2 MBq). 
Using the OSEM3D/MAP algorithm the last 10 
frames of each scan were summed up for image 
reconstruction. Arrows indicate tumour location.
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shown in Figure 3. Tumour uptake for 
both tracers was fast, reaching peak 
values within 3-5 min.  68Ga-AMBA 
uptake reached a plateau phase ap-
proximately 20 min, with 18F-CH this 
took less then 10 min (Figure 3A). This 
plateau phase - occurring at the end of 
scanning - made us decide to calcu-
late total tumour uptakes derived from 
PET as the mean of data from the last 
10 min of scanning. Renal clearance of 
68Ga-AMBA was gradually progressing 
resulting in accumulation of bladder ra-
dioactivity after 10 min pi (Figure 3B). 
Renal clearance of 18F-CH started ear-
lier resulting in an increase in bladder 
radioactivity immediately after injec-
tion (figure 3C).
The average tumour uptake as calcu-
lated from the PET data over the last 10 
min of scanning in VCaP-bearing mice 
was 6.7±1.4 %ID/g (n = 8) using 68Ga-
AMBA, while for 18F-CH this was only 
1.6±0.5 %ID/g (n = 8). This difference 
was highly significant (p < 0.001). For 
PC-3 bearing mice average outcomes 
were 9.2±1.1%ID/g (n = 3) for 68Ga-
AMBA and 1.2±0.3%ID/g (n = 3) for 
18F-CH.
biodistribution studies
Biodistribution results are summarized 
in Figure 4. Average VCaP tumour up-
take for 68Ga-AMBA (n = 4) 60 min p.i 
was 9.5±4.8 %ID/g. For 18F-CH tumour 
uptake was 2.1±0.4 %ID/g at 30 min pi 
(n = 4). These differences in tumour up-
take were highly significant (p < 0.03).
As was expected using GRPR-based 
tracers, 68Ga-AMBA uptake was high in 
the GRPR positive pancreas (57.5±7.1 
%ID/g). This was much higher than the 
pancreas uptake of 18F-CH (3.6±1.0 
%ID/g). Also uptake of 68Ga-AMBA 
in colon (8.5±2.9 %ID/g) was signifi-
cantly higher as compared to that of 
18F-CH.
On the other hand, uptake of 18F-CH 
was much higher in kidneys (35.7±4.1 
%ID/g) as compared to 68Ga-AMBA 
(2.2±0.2 %ID/g). Like the kidneys, 
most other (background) organs had 
significantly higher uptakes for 18F-
CH as compared to 68Ga-AMBA: blood 
(0.8±0.1 vs 0.5±0.1 %ID/g tissue), 
heart (4.7±0.5 vs 0.2±0.0 %ID/g tissue) 
and liver (13.0±1.7 vs 0.9±0.5 %ID/g 
tissue). Only the uptake of choline in 
muscle was not significantly different 
from that observed with 68Ga-AMBA 
(0.9±0.2 vs 0.7±0.2 %ID/g tissue). 
Both radiolabelled tracers showed low 
activity levels in blood.
discussion
Accurate imaging of PC in patients 
is crucial for decision making as it 
strongly determines management of 
the disease. Accuracy of conventional 
imaging techniques is not sufficient5-7. 
Nuclear scintigraphy provides promis-
ing applications for sensitive imaging 
of PC. In this study we have compared 
a peptide-receptor-based tracer, the 
BN-analogue AMBA, with a metabo-
lism-based tracer, the choline deriva-
tive 18F-CH, for targeting of PC.
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figure 3
Uptakes in different tissues over time: A. VCaP tumour (Y axis in two segments), B. kid-
ney, C. bladder. Black solid lines show median uptake and black dashed lines IQR after 
tail vein injection of 68Ga-AMBA (300 pmol, 1.5-0.5 MBq, n = 8). Gray lines show me-
dian uptake and IQR after tail vein injection of 18F-CH (100 µl, 8.1-1.2 MBq, n = 8).
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Since only few imaging studies have 
been performed with radiolabelled cho-
line in PC-bearing mice, no consensus 
has been made about the optimal scan-
ning protocol for it in PET. Zeng et al. 
performed a PET study using 11C-cho-
line in PC-3 bearing mice starting a 60 
min scan immediately after injection27. 
In another group of PC-3 bearing mice 
Zheng et al. performed biodistribution 
at 30 min after i.v. injection. Belloli et 
al. decided to start a 30 min 11C-cho-
line PET acquisition in TRAMP mice 
immediately after tail vein injection37. 
Ebenhan et al. decided to start 18F-CH 
acquisition in xenograft-bearing mice, 
including DU145 prostate xenografts, 
only at 15 min pi38. Although sparse, 
dynamic data and reconstructions in all 
three reports implied that tumour up-
take of choline is rapid and that choline 
uptake and ratios to background do not 
improve when scanning is prolonged. 
Based on these data and our own pilot 
experiments (data not shown), we per-
formed PET scans for 20 min starting 
immediately after injection of 18F-CH. 
For biodistribution purposes, mice 
were sacrificed at 30 min pi, in accor-
dance with the time point used for bio-
distribution by Zheng et al.16.
Indeed there has been a change of par-
adigm in the field of bombesin radio-
pharmaceuticals from agonists towards 
antagonists as possibly preferable for 
tumour targeting. In fact in a previous 
study from our group - comparing pros-
tate cancer targeting efficacy of five ra-
diolabelled bombesin analogues – the 
BN antagonist Demobesin-1 was the 
best performing analogue. Nonetheless 
figure 4
Uptake in preselected organs after tail vein injection of both 68Ga-AMBA (300 pmol, 1.5-0.5 
MBq) and 18F-CH (100 µl, 8.1-1.2 MBq) in VCaP bearing mice. Ex vivo biodistribution was 
performed 60 min after injection of 68Ga-AMBA and 30 min after injection of 18F-CH. Re-
sults are indicated as mean±standard deviation of 4 mice per tracer per time point.
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in this study also AMBA showed to be 
an analogue with good, roughly compa-
rable, performance. 
PET imaging requires analogues la-
beled with positron-emitting radionu-
clides. AMBA is coupled to a DOTA 
chelator which enables labelling with 
the positron-emitting radionuclide 
68Ga. Demobesin-1 has a N
4
 chelator 
which does not allow labelling with ra-
dionuclides suitable for PET. 68Ga-AM-
BA was therefore selected in our study.
Despite a recent change of paradigm in 
the field of bombesin radiopharmaceu-
ticals from agonists towards antago-
nists as possibly preferable for tumour 
targeting, we made use of the agonistic 
BN analogue AMBA in this study2. In-
deed in a previous study from our group 
- comparing prostate cancer target-
ing efficacy of four agonistic and one 
antagonistic radiolabelled bombesin 
analogues – antagonist Demobesin-1 
performed best11. With its N4 chelator 
it does not allow for labeling with pos-
itron-emitting radionuclides required 
for PET. The DOTA chelator of AMBA 
does enable labelling with PET radio-
nuclides like 68Ga. It has shown to be 
a BN analogue with high potential for 
imaging of Pc, a roughly comparable 
performance to Demobesin-1 and good 
targeting performance in one of the few 
clinical BN studies10-11. For future PET 
studies it would be interesting to use a 
BN antagonist with a chelator suitable 
for a positron-emitting radionuclide. 
They have shown to washout from the 
pancreas more rapidly than agonists 
and seem to have a higher uptake and 
retention in PC2. Another advantage of 
antagonist is their lower expected tox-
icity as compared to the pharmacologi-
cally active agonists. 
For 68Ga-AMBA a slightly different 
protocol than for 18F-CH was followed. 
The biological processes targeted by 
the two tracers are quite different and 
therefore require different protocol de-
tails. Although AMBA can be labelled 
with positron emitting radionuclides 
it has not been published in (animal) 
PET studies nor has it been published 
labelled with 68Ga yet. Therefore, apart 
from our own experience with 68Ga-
AMBA, the only available informa-
tion to base an optimal PET protocol 
on came from studies using AMBA 
labelled with Lutetium-177 (177Lu) or 
Indium-111 (111In). In a biodistribution 
study using 177Lu-DOTA-AMBA in PC-
3-bearing mice, animals were sacrifi-
ced at time points 1h and 24h pi10. Ab-
solute uptake was almost twice as high 
at the 1h time point and overall tumour 
to background ratio was also favour-
able. Another study performing bio-
distribution in PC bearing mice using 
111In-DOTA-AMBA chose to sacrifice 
mice at 1h pi only, showing sufficient 
tumour uptake39. In our standardised 
comparative study between different 
BN-analogues 111In-AMBA also sho-
wed high tumour uptake and promising 
tumour-to-background ratios at 1h pi11. 
Based on these data, and to be able to 
compare our data with those from lit-
erature, we decided to perform biodis-
tribution 1h pi of 68Ga-AMBA. To get 
insight in the process of biodistribution 
with 68Ga-AMBA we decided to start 
imaging immediately after injection. 
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Comparison of tumour uptake in VCaP 
and PC-3-bearing xenografts revealed 
that peptide-receptor targeting was su-
perior to metabolic targeting for both 
tumour types. This may be explained by 
the fact that GRP receptor expression in 
early PC is generally high8, while meta-
bolic activity is predominantly low14-15. 
Although choline uptake has been re-
ported to increase with PC aggressive-
ness and rising PSA levels5, targeted tu-
mour imaging using AMBA performed 
better in both model systems. 
Besides the favourably higher tumour 
uptake of AMBA another important as-
pect that selected AMBA against cho-
line was its lower uptake in most non-
targeted (GRPR-negative) organs. This 
is particularly visible when comparing 
PET images of the two types of trac-
ers (Figure 2). The high background 
signal found with choline relates to the 
relative high metabolic activity in these 
organs which originates from general 
cellular processes not specifically re-
lated to cancer. Clearly, although is 
does show high background activity in 
GRPR-expressing tissues peptide-re-
ceptor targeting is more tissue-specific 
than metabolism based targeting. 
In order to make use of choline feasible 
for a large number of clinical centres 
that do not have a cyclotron, deriva-
tives with a longer-lived radionuclide 
than 11C, like 18F-CH, were introduced 
by DeGrado et al.28. Experiments with 
this derivative have shown to approach 
natural choline in the rate of phos-
phorylation by yeast choline kinase, 
as well as the rate of uptake by cancer 
cells (PC-3). 18F-CH can therefore be 
considered as a prototypical choline 
tracer. The renal uptake and excretion 
of this derivative is, however, known 
to be higher compared to natural cho-
line. High activity in the bladder en-
suing from this excretion could cause 
diagnostic limitations for the prostatic 
region40, 25. Zheng et al. describe kid-
ney uptake of 5.1 ± 1.8 %ID/g in PC-3 
bearing athymic mice 30 min after in-
jecting 11C-choline27 while in our study 
using 18F-CH this uptake was 35.7 ± 
4.11 %ID/g with comparable protocols. 
More importantly in our PET scans ac-
tivity in the bladder was also very high. 
The use of 11C-choline instead of 18F-
CH may probably reduce the undesir-
able high uptake in kidneys and blad-
der to a great extent while maintaining 
a tumour uptake comparable with that 
of 18F-CH.
Dedicated PET for imaging of small 
animals is a very useful application 
in the preclinical research of nuclear 
medicine. Besides its use to establish 
and validate novel tools for detection 
and visualization of tumours, PET data 
are also being used for in vivo quan-
tification. Quantification with PET al-
lows biodistribution processes to be 
followed dynamically without using 
separate groups of laboratory animals 
for each time point. Quantification of 
our own in vivo PET data was reliable 
and could be supported by ex vivo bio-
distribution results. The graphs show-
ing tumour, kidneys and bladder uptake 
over time are good examples showing 
the benefits of PET. Since spatial reso-
lution of PET remains inferior to that of 
other imaging techniques like CT, MRI 
and ultrasound, dual-modality scanners 
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like PET/CT have been developed to 
maximise imaging accuracy42, 13. 
Time activity curves derived from PET 
data showed that both imaging proto-
cols used for scanning of AMBA and 
choline were well chosen. Especially 
for 18F-CH immediate imaging after in-
jection was required, since tumour up-
take was fast. Tumour uptake reached 
a plateau at the endpoint of both scan-
ning protocols - which was 20 min pi 
for 18F-CH and 30 min pi for 68Ga-AM-
BA - indicating that the dynamic pro-
cess of tumour uptake did not require 
extended imaging. 
In conclusion: targeted nuclear imaging 
of tumours based on receptor-specific 
radiolabelled analogues offers good 
applications for clinical diagnosis of 
(early) PC. PET scanning and biodis-
tribution studies indicated that tumour 
uptake of 68Ga–AMBA was higher 
while overall background activity was 
lower than observed for 18F-CH in the 
same PC-bearing mice. These results 
suggest that peptide-receptor mediated 
PET using BN analogues is superior to 
metabolism-based PET using choline 
for scintigraphy of PC. The present 
study warrants further clinical evalua-
tion of GRPR-targeted nuclear imaging 
of PC using BN-analogues.
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Prostate cancer (PC) is the third lead-
ing cause of cancer-related deaths and 
the most frequently diagnosed cancer 
in men in Western countries 1, 2. Nowa-
days, suspicion on the presence of rel-
evant disease mostly ensues from el-
evated blood levels of prostate specific 
antigen (PSA) 3-5. Ultimately, PC is di-
agnosed by histopathology of transrec-
tal ultrasound-guided prostate biopsies. 
An important challenge in PC manage-
ment is to differentiate patients that 
need curative treatment from those 
that do not need intervention. Clini-
cal T-stage, that is determination of 
the extent of PC prior to treatment, is 
a crucial determinant for risk stratifi-
cation and management of the disease. 
Unfortunately, conventional imaging 
techniques are not accurate for visu-
alisation of locally advanced PC at 
time of diagnosis 6-9 and new imaging 
approaches are urgently needed to im-
prove staging. Sensitive imaging op-
tions would also be welcomed for lo-
calisation of PC recurrence after initial 
therapy with curative intent.
Nuclear medicine provides a new PC-
targeted imaging application by em-
ploying radiolabelled bombesin (BN) 
or Gastrin-Releasing Peptide (GRP) 
analogues to target the Gastrin-Re-
leasing Peptide Receptor (GRPR), a 
membrane-receptor overexpressed on 
PC cells 10, 11. BN-based radiopeptide 
analogues have shown high affinity to 
the GRPR, leading to excellent tumour-
specific binding 12, and they can be vi-
sualised by imaging modalities such 
as single photon emission tomography 
(SPECT) and positron emission tomog-
raphy (PET). Moreover BN analogues 
may also be applied for peptide recep-
tor radionuclide therapy (PRRT) with 
the intention of treating focal PC or 
(occult) PC metastases.
In this thesis we describe preclinical 
investigations to explore and optimise 
the potential of BN-GRPR-mediated 
targeting of human PC. We analysed 
GRPR expression in various stages 
of clinical PC, and studied hormonal 
regulation of GRPR using experimen-
tal xenograft and cell line models of 
human PC. Also, we compared various 
BN analogues for their efficacy to visu-
alise PC in mice. Furthermore, in order 
to optimise BN-targeting conditions, 
we carefully analysed the influence of 
experimental conditions on biodistribu-
tion of BN peptides. Metabolism-based 
imaging has been extensively studied 
for imaging of PC, while the poten-
tial of peptide-receptor-based imag-
ing using BN is not well-studied yet. 
We evaluated a BN analogue against a 
metabolism-based imaging tracer using 
PC xenograft-bearing nude mice.
chapter 1 of this thesis provides an 
introduction into the field of PC, its 
disease progression, management and 
the clinical issues that are related to 
that. It enunciates the need for more ac-
curate PC imaging and introduces the 
promising and GRPR-specific BN pep-
tide. The review article in chapter 2 
provides more extensive insight on the 
GRPR as a target for imaging and ra-
dionuclide therapy of PC using radiola-
belled BN analogues. Besides a general 
introduction on BN and BN analogues, 
it summarises the preclinical and clini-
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cal literature on BN analogues for PC 
targeting and imaging by SPECT and 
PET.
From a survey of the literature, it seems 
that consistency in study protocols that 
would allow for a valid comparison 
between radiolabelled BN analogues 
is lacking as different research groups 
have used different animal models, la-
belling techniques, radionuclides and 
evaluation protocols. In order to select 
the best analogue for clinical validation, 
we initiated a preclinical study to com-
pare five radiolabelled analogues under 
identical experimental conditions using 
one standardised protocol. This study is 
described in chapter 3 and shows that 
the receptor antagonist Demobesin-1 
was the best performing BN analogue 
with superior in vivo stability, highest 
tumour-uptake and retention of radio-
activity in the tumour, while pancreatic 
and renal clearance were fast. With suf-
ficient in vivo stabilities as well as high 
uptake and retention in tumour, the Pe-
sin and AMBA peptides were shown to 
be good performing GRPR-agonists. 
Receptor agonists have been reported 
to activate the receptor upon internali-
sation, stimulate cell growth 10, 13, 14 and 
induce side effects in other GRPR ex-
pressing organs such as pancreas and 
colon. Therefore the use of non-bio-
active receptor antagonists is strongly 
preferable 15-19. Moreover, in contrast 
to Pesin and AMBA 20, 21, the receptor 
antagonist Demobesin-1 is highly se-
lective for GRPR and has no affinity to 
other BN receptor subtypes 22.
Since the majority of patients with dis-
seminated PC will be offered hormonal 
therapy as first line therapy, it is essen-
tial to identify the impact of hormonal 
ablation treatment on GRPR expression 
in order to establish the appropriate po-
sition of GRPR-targeted imaging and 
therapy in the management of PC and 
the potential requirement for selection 
of patients eligible for GRPR-targeted 
modalities. chapter 4 and 5 both 
concentrate on this issue. Growth of 
prostate epithelial (tumour) cells de-
pends on a functional androgen axis 
with physiological levels of androgens 
that stimulate the androgen receptor 
(AR) and drives (tumour) cell growth 
23. In the case of disseminated disease, 
the first and so far most effective choice 
of treatment is endocrine deprivation 
therapy aiming at reducing circulating 
testosterone levels and/or blocking the 
AR 24, 25. Eventually, however, disease 
relapse occurs due to tumour progres-
sion towards so-called castration re-
sistant PC (CRPC) in the majority of 
patients leaving limited palliative treat-
ment options only 26, 27. 
Previous studies from our group 
showed down-regulation of GRPR ex-
pression after androgen withdrawal in 
experimental xenograft models bearing 
PC tumours that represent early stage 
disease 28. Low GRPR expression in 
CRPC was also reported in literature 
11. In chapter 4 we explored androgen 
regulation of GRPR expression in three 
in vivo early stage human PC xenograft 
models (PC82, PC295 and PC310) in 
more detail. This study revealed ex-
pression of GRPR in these androgen-
responsive xenografts to be significant-
ly reduced by androgen ablation and to 
be reversed after restoring the hormon-
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al status of the animals. These data sug-
gested that hormonally ablated patients 
might not be eligible for BN-GRPR 
based imaging and therapy. 
The vast majority of studies on GRPR-
targeting of PC are based on the GRPR 
overexpressing, but androgen-unre-
sponsive, AR-negative PC3 cell line. 
In order to unravel in more detail the 
effect of hormonal manipulation and 
AR status on GRPR expression in PC, 
we performed in vitro and in vivo stud-
ies as described in chapter 5 using the 
GRPR-overexpressing, androgen-re-
sponsive and AR-positive human VCaP 
cell line derived from a human PC me-
tastasis. Our data showed that GRPR-
specific uptake was similar between the 
VCaP and PC-3 cell line. In contrast to 
our earlier observations in other experi-
mental models described in chapter 4, 
however, GRPR mRNA expression as 
well as BN-specific binding of VCaP 
cells was not affected significantly by 
androgen manipulations in vitro and in 
vivo suggesting that GRPR expression 
was not androgen regulated in VCaP 
cells. One explanation for these con-
tradictory results may be that, in con-
trast to the human PC xenograft models 
representing early androgen respon-
sive disease with ‘normal’ upregulat-
ed GRPR expression, VCaP and PC3, 
representing a more advanced stage 
of PC, have a constitutively activated 
GRPR expression. This expression has 
escaped ‘normal’ androgen regulation 
control mechanisms, while in the case 
of VCaP, growth control is still (par-
tially) retained by androgens.
In chapter 5 we also assessed relative 
mRNA expression levels of the GRPR 
and GRPR-specific binding in human 
tissue samples derived from patient 
material. The Erasmus MC tissue bank 
contains PC from patients from vari-
ous clinical stages. Human PC mRNA 
samples were predominantly GRPR 
positive, but the expression was vari-
able. Only CRPC samples showed a 
tendency towards lower GRPR mRNA 
expression levels. Although the sample 
numbers in this group were low, this 
observation suggests that GRPR seems 
(at least initially) androgen regulated. 
Overall, higher median GRPR-specific 
uptake was observed in PC compared 
to benign tissue, but with a consider-
able overlap between the lower GRPR 
mRNA expression levels of PC and be-
nign tissue samples. This outcome was 
supported by the original data from the 
influential study by Markwalder et al. 11. 
A modified scatter plot based on these 
data showed a similar overlap in GRPR 
expression between PC and benign tis-
sue samples. In conclusion, these data 
suggest that BN-based imaging of PC 
is especially indicated for imaging of 
early PC; in men that have not received 
hormonal therapy. Furthermore, our 
data indicate that selection of GRPR 
expressing patients may be required 
when opting for GRPR-targeted BN-
based response monitoring and therapy 
of PC.
In chapter 6, the impact of various 
experimental conditions on the phar-
macokinetics of BN-specific binding 
in nude mice bearing human PC xe-
nografts is described with the aim to 
improve receptor-mediated targeting. 
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From this study it became clear that not 
only receptor affinity of BN analogues 
determines binding to GRPR in vivo, 
but that also experimental variations, 
including HPLC peptide purification of 
the BN analogue, variations in specific 
activity and saturation of the GRPR (by 
predosing with cold BN prior to admin-
istration of radiolabelled BN), signifi-
cantly affect peptide-receptor binding 
in vivo. These findings underscore the 
need for standardised protocols for op-
timal targeting.
As metabolic activity in cancer cells 
is often increased, the use of metabo-
lism-based targeting is being studied 
as a strategy for visualisation of can-
cer cells, including PC. In chapter 7 
we describe a comparative experimen-
tal animal PET-study between GRPR-
mediated targeting using 68Ga-AMBA 
and metabolism-based targeting by 
Flourine-18 labelled choline (18F-CH) 
in VCaP tumour-bearing nude mice. 
VCaP tumour uptake of 68Ga-AMBA 
was shown to be significantly higher 
than uptake of 18F-CH while overall 
background activity was lower. In this 
study, peptide-receptor imaging was 
clearly superior to metabolism-based 
imaging of PC using PET.
whaT has been 
accoMPlished by The 
sTudies in This Thesis?
This thesis describes preclinical work 
to determine the potential options of 
BN-GRPR-based targeted imaging and 
therapy in the management of PC. The 
critical examination of various proto-
cols that are being used in preclinical 
evaluation of peptide-receptor targeted 
imaging emphasises the importance of 
protocol standardisation to allow for 
valid selection of the most-promising 
peptides to be tested in a clinical set-
ting. To our knowledge we were the 
first to perform such a standardised 
experiment allowing for a valid com-
parison of five BN analogues designed 
by and obtained from different research 
groups. In accordance with literature 
29-31 we found the GRPR antagonist to 
be superior over the agonists tested; 
for our future clinical studies we will 
therefore focus on the use of GRPR 
antagonists. Also, original work was 
performed to elucidate the role of an-
drogens in expression of the GRPR. It 
provided more insight in GRPR expres-
sion in human (PC) tissues at different 
stages of disease. Finally, as there is 
no gold standard for imaging of PC, 
we used metabolism based imaging 
to set against GRPR-based imaging in 
a preclinical mouse study in order to 
determine the potential value of this 
new imaging approach. The potential 
of GRPR based imaging was under-
scored by a more than 4-times higher 
PC uptake and a generally lower uptake 
in background organs in comparison to 
metabolism-based imaging.
The data presented in this thesis raised 
the interest in and were the basis for 
further clinical evaluation of a GRPR 
antagonist in PC detection. Since the 
developments in BN analogues are fast, 
the best performing peptide Demobe-
sin-1 will not be the analogue of choice 
in the future clinical studies. It will 
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be replaced by a ‘second generation’ 
GRPR antagonist that is also useful for 
PET scanning and that was developed 
in a parallel research project. 
fuTure direcTions
development of new bn 
analogues
The field of radiolabelled analogues 
for receptor-based targeting is rapidly 
evolving. New peptide analogues are 
constantly being designed in order to 
improve targeting characteristics such 
as specificity, sensitivity and in vivo 
stability. BN analogues ideally have a 
high affinity for the GRPR and have an 
in vivo stability that is high enough to 
allow for proper accumulation in the 
target (tumour) tissue. Besides this, 
the radiolabelled analogue should be 
cleared fast enough to prevent radio-
toxicity when considering radionuclide 
therapy. The development of radiola-
belled analogues is focused not only 
on amino acid sequence for ligand 
binding, it also studies development 
of appropriate chelators, the chemi-
cal structure attached to a biotracer 
that facilitates specific radiolabelling. 
The choice of the chelator determines 
to which radionuclide(s) the BN ana-
logue can be complexed and herewith 
defines the potential application of the 
radiolabelled analogue. Moreover, the 
molecular charge of the BN analogue 
is an important characteristic as it has 
been reported to affect biodistribution. 
Introduction of a single negative charge 
to BN analogues has been shown to 
improve biodistribution by increasing 
tumour uptake and reducing uptake in 
background tissues 32. In contrast to 
this Marsouvanidis et al. showed that 
an additional positive charge, by add-
ing a single N-terminal lysine-residue 
to the peptide chain of a GRPR agonist, 
significantly improved GRPR-specific 
uptake in PC xenografts 33.
For long it has been assumed that re-
ceptor agonists are superior to receptor 
antagonist for peptide receptor based 
targeting 34, because of their efficient 
endocytosis-regulated 35 internalisation 
and subsequent higher in vivo accumu-
lation and retention in target tissues. 
Recent findings including ours, howev-
er, indicate that peptide receptor antag-
onists with comparable affinities to the 
respective receptor as their agonistic 
counterparts, exhibit higher tumour up-
take and at the same time lower reten-
tion of radioactivity in normal tissues, 
leading to superior target-to-back-
ground ratios 29-31. It has been suggested 
that the numbers of binding sites for re-
ceptor agonists and antagonists differ, 
which may be caused by the putative 
existence of different types of receptors 
they can bind to 36. Although the under-
lying mechanism for this differential 
effect is not yet fully understood, this 
finding paved the way for intensified 
development of new GRPR antago-
nists. From a pharmacological point of 
view the use of non-bioactive receptor 
antagonists is strongly preferable as it 
is expected to cause less side effects 
and to prevent non-desirable stimula-
tion of tumour growth 15-19 known from 
GRPR agonists 10, 13, 14. This will be 
particularly beneficial when using high 
therapeutic doses of peptide.
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standardised comparison of bn 
analogues
From current literature it is difficult 
to compare the potency of different 
BN analogues as study protocols vary 
considerably. We have shown that mi-
nor differences in study protocols may 
already have considerable effect on 
radiopeptide pharmacokinetics and 
strongly impair a proper and reliable 
comparison between studies. Examples 
of factors that often vary between stud-
ies and which may affect study out-
come include mouse strain (species, 
sex, weight), tumour cell type (cell 
line, culture conditions, passage num-
ber) and xenograft tumour character-
istics such as tumour size, inoculation 
site and tumour vascularisation. 
nuclear imaging modalities 
(sPecT and PeT)
The current developments in scanning 
modalities resulting in increased spatial 
resolution, sensitivity and accuracy, are 
crucial. In order to improve the ability 
to discriminate target from background 
and to improve localisation and dosim-
etry issues, the field of nuclear scin-
tigraphy for functional or metabolic 
imaging is dominated by multimodal 
SPECT and PET in combination with 
CT. Currently, new PET/MRI systems 
are entering the clinic, opening a whole 
new field of high resolution, high sen-
sititvity imaging options. 
specificity of GrPr 
overexpression
When considering a receptor as candi-
date for tumour targeting it should ide-
ally be highly expressed in the diseased 
tissue only. High expression in non-
targeted tissue will cause non-specific 
radiopeptide binding resulting in high 
background signal during scanning and 
in toxicity to healthy tissue when radio-
nuclide therapy is concerned. Both in 
the literature and in this thesis (chapter 
5), PC has been shown to overexpress 
the GRPR while expression in benign 
prostatic tissue is low 11. As expected, 
high uptake of BN analogues in the 
GRPR-expressing pancreas has been 
described in two patient studies 37, 38. 
In case of PC staging, high pancreatic 
uptake might cause interference with 
uptake in the often affected para-aortic 
lymph nodes 39, 40. For allowance of 
GRPR-targeted BN-based therapy of 
(local) PC, careful dosimetry studies 
are required in order to prevent toxic-
ity due to pancreatic uptake of high 
amounts of BN-peptide. Clinical stud-
ies are required to optimise tumour-to-
background ratios for the different ra-
diolabelled BN analogues and explore 
whether these are acceptable for imple-
mentation for PC imaging and therapy.
androgen regulation of GrPr
Hormonal deprivation therapy is stan-
dard treatment for disseminated PC. 
Understanding the role of androgens 
in the regulation of GRPR expression 
is essential for defining the potential 
use of BN-based imaging and therapy 
at different stages of disease. PC xe-
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nograft models representing early, 
androgen-responsive disease showed 
androgen-regulated GRPR expression. 
On the other hand GRPR of VCaP and 
PC3 cell lines, reflecting a more pro-
gressed disease stage, lacked androgen 
regulation (chapters 4 and 5). We hy-
pothesise that more advanced stage of 
PC, such as represented by the PC3 and 
VCaP cell lines, have a constitutively 
activated GRPR expression that has 
escaped ‘normal’ androgen regulation 
control mechanisms. In human samples 
the majority of (hormonally untreated) 
PC was GRPR-positive (see chapter 
5). Relatively low GRPR mRNA ex-
pression levels were only observed in 
CRPC suggesting that hormonal thera-
py generally results in down-regulation 
of GRPR expression. The above de-
scribed escape phenomenon suggested 
for VCaP cells, may thus be a rather un-
common clinical event. GRPR expres-
sion in human PC samples as deduced 
from BN binding data showed consid-
erable overlap with those of benign tis-
sue samples negatively affecting BN 
specificity. Overall, data suggest that 
BN-based GRPR-targeted imaging and 
therapy may be offered to hormone na-
ive PC patients and may be applicable 
also in (a subset of) hormonally treated 
CRPC patients with constitutively high 
GRPR.
PC is a heterogeneous and multi-stage 
disease 41. Also GRPR expression is 
variable between PC patients. In order 
to identify patients who will likely ben-
efit from GRPR-targeted disease moni-
toring and/or therapeutic intervention, 
assessment of the individual GRPR 
status is essential to select patients for 
GRPR-targeted imaging and/or ther-
apy of PC. Determination of GRPR 
expression at an individual basis may 
be performed on PC biopsies taken for 
diagnosis, on the premises that a good 
performing GRPR antibody is avail-
able or that frozen sections are avail-
able for autoradiogaphy. Alternatively, 
assessment of individual GRPR levels 
may be obtained by pre-scanning with 
a BN radio-analogue. The opportunity 
to have a tumour-targeted analogue for 
imaging with the option to use it as a 
therapeutic entity when labelled to a ra-
diotoxic radionuclide (the theranostics 
approach 42) offers personalised medi-
cine tailored to individual patients im-
proving disease management. 
in conclusion
Novel biotracers for imaging and ther-
apy of PC are required as currently PC 
staging is inaccurate and no curative 
treatment for disseminated PC exists. 
Molecular imaging using radiolabelled 
analogues for PET and SPECT enables 
non-invasive in vivo detection of tar-
gets at low nanomolar to picomolar 
concentrations 43. Radiolabelled BN 
analogues have shown to be promising 
tools for imaging of PC since GRPR 
expression is predominantly high in 
PC. Furthermore, receptor antagonists 
appeared to be superior to agonists in 
our preclinical studies. This thesis pro-
vides the required knowledge to start 
a clinical study in early PC patients to 
determine the potential of GRPR based 
imaging (and therapy) of PC.
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Stadiëren van prostaatkanker (PC) en 
lokaliseren van tumor-recidief blijft een 
onopgelost klinisch probleem vanwege 
het gemis aan accurate beeldvorming. 
Uitgezaaide PC kent geen gerichte the-
rapie en is tot op heden niet curatief te 
behandelen. De nucleaire geneeskunde 
biedt veelbelovende mogelijkheden om 
dit gemis aan accurate beeldvorming 
en tumor-selectieve therapie van PC 
te ondervangen door gebruik te maken 
van doelgerichte radioactief gemaakt 
peptiden. Een van deze peptiden is 
bombesine (BN). Het bindt met hoge af-
finiteit aan de Gastrin-Releasing Pep-
tide Receptor (GRPR), een membraan-
receptor, welke tot overexpressie komt 
op PC cellen.
saMenvaTTinG
Gezien de hoge incidentie en het aan-
zienlijk aantal sterftegevallen ten ge-
volge van PC vormt de aandoening er 
een groot probleem voor de volksge-
zondheid 1, 2. Verdenking op de ziekte 
volgt tegenwoordig meestal het na het 
vinden van een verhoogde waarde van 
het prostaat specifiek antigen (PSA) in 
het bloed 3-5. De diagnose PC kan alleen 
worden gesteld op basis van histopa-
thologisch onderzoek, meestal verkre-
gen door middel van echogeleide trans-
rectale biopsieën van de prostaat. Het 
ziektebeloop van PC is vaak indolent 
6,7 en kan prognostisch zo gunstig zijn, 
dat behandeling achterwege kan blij-
ven onder voorwaarde van een nauw-
gezette controle ('active surveillance') 8, 
9. Indien echter de kans op uitbreiding 
groot is, kan gelokaliseerde PC curatief 
worden behandeld door chirurgisch of 
radiotherapeutisch ingrijpen 10-18. Pa-
tiënten met uitgezaaide PC zijn tot op 
heden niet te genezen en kunnen enkel 
palliatief behandeld worden. 
Voor het opstellen van een behandel-
plan is het van cruciaal belang om zo-
wel agressiviteit als het stadium van PC 
te kunnen bepalen. Agressiviteit van 
PC wordt bepaald door de histopatho-
logische Gleason score. Een gradering 
tussen 0-5 wordt toegekend aan de twee 
meest voorkomende groeipatronen in 
prostaatbiopsieën. De optelsom van 
beide geeft de Gleason Score, waarbij 
lagere scores beter gedifferentieerde 
tumoren representeren 19. Stadiëren van 
PC ofwel onderscheid maken tussen lo-
kaal, lokaal uitgebreid en uitgezaaide 
ziekte is tot op heden een onopgelost 
probleem gebleken. Huidige conventi-
onele beeldvormende technieken, zoals 
echo, Computerised Tomography (CT), 
Magnetic Resonance Imaging (MRI) 
en bot-scintigrafie, hebben beperkte 
waarde vanwege hun matige accura-
tesse 20-23.
Het gelokaliseerd geacht prostaatcar-
cinoom wordt ingedeeld in drie risico-
groepen (laag, matig en hoog) aan de 
hand van de EAU/ESTRO indeling 24. 
Deze indeling maakt gebruik van de 3 
tumorparameters om de kans op uit-
breiding van ziekte buiten de prostaat 
te voorspellen, te weten, initieel PSA 
(iPSA), de Gleason score en het T-sta-
dium. Het iPSA is de PSA bloedwaarde 
bepaald vóór enige vorm van behande-
ling 3-5. Het T-stadium is een benade-
ring van uitgebreidheid van PC voor 
radicale chirurgie. Deze zogenaamde 
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klinische stadiëring wordt bepaald op 
basis van het rectaal toucher van de 
prostaat (digital rectal eximanation; 
DRE), PSA laboratoriumwaarden, be-
vindingen bij transrectale echografie 
(transrectal ultrasound: TRUS) en re-
sultaten van PC gezien in gereseceerd 
prostaatweefsel (na transuretrale re-
sectie; TUR). De Nederlandse richtlijn 
prostaatcarcinoom raadt aan om nomo-
grammen, welke gebruik maken van 
dezelfde parameters, toe te passen na 
in opzet curatief ingrijpen om een indi-
viduele uitspraak te kunnen doen over 
de kans op tumor-metastasering 25. Met 
het Kattan of Partin nomogram wordt 
een accuratesse tot 79% bereikt 26, 27.
Nucleaire geneeskunde maakt gebruik 
van radioactieve biomarkers welke zich 
bij voorkeur in een bepaald orgaan of 
afwijking ophopen. Na injecteren van 
een radiofarmacon vindt dit zijn spe-
cifieke doel. Met een detector kan ver-
volgens in beeld gebracht worden waar 
de toegediende radioactiviteit zich con-
centreert. Naast planaire scintigrafie 
wordt meer en meer gebruik gemaakt 
van 3-dimensionale tomografie met 
behulp van “single photon emissie”-
computertomografie (SPECT) en po-
sitron emissie tomografie (PET) 28, 29. 
Een varieteit aan radiofarmaca gericht 
op PC wordt ontwikkeld en onderzocht. 
Het radioactief gemaakte BN ofwel 
Gastrin-Releasing Peptide (GRP) is 
een veelbelovend nieuw peptide van-
wege de hoge affiniteit voor de mem-
braanreceptor GRPR, welke tot over-
expressie komt op PC cellen 30, 31. In 
de literatuur zijn met BN uitstekende 
PC-specifieke opnames beschreven 32. 
BN-GRPR gerichte radiofarmaca zou-
den van toegevoegde waarde kunnen 
zijn voor het stadiëren van PC. Ook 
kunnen ze mogelijk ingezet worden om 
PC recidieven te lokaliseren. Wellicht 
zou het zelfs mogelijk zijn om radio-
actieve BN analogen te gebruiken voor 
therapie (peptide receptor radionuclide 
therapy; PRRT) in de behandeling van 
locaal uitgebreid en (occult) gemetasta-
seerd PC.
In dit proefschrift worden pre-klinische 
onderzoeken beschreven, die gericht 
zijn op onderzoeken naar het potenti-
eel en de optimalisatie van BN-GRPR 
gemedieerde beeldvorming en thera-
pie van PC. Het expressie niveau van 
de GRPR in verschillende stadia van 
PC en onder hormonale manipula-
tie werd onderzocht in PC-dragende 
muizen, PC-cellijnen en patiënten-
specimen. Ook vergeleken we, onder 
gestandaardiseerde omstandigheden, 
verschillende BN analoga naar hun ef-
fectiviteit inzake beeldvorming van PC 
in muizen. Ten einde specifieke opna-
me te optimaliseren onderzochten we 
verder de invloed van experimentele 
omstandigheden op BN-GRPR gerela-
teerde biodistributie. Metabolisme ge-
relateerde radiofarmaca zijn uitgebreid 
bestudeerd en veelbelovend gebleken 
als nucleaire toepassing voor de beeld-
vorming van PC 32. PC scans met BN 
analoga, welke gebaseerd zijn op pepti-
de-receptor binding, is een minder uit-
gekristaliseerde en bekende nucleaire 
toepassing voor beeldvorming van PC. 
In PC-dragende muizen vergeleken we 
het metabolisme gerelateerde radiofar-
macon choline met het GRPR gerichte 
BN analoog AMBA.
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De introductie van dit proefschrift, 
hoofdstuk 1, richt zich vooral op PC 
en de klinische vraagstukken, die met 
deze ziekte samenhangen. Het bena-
drukt het gemis van accurate beeld-
vorming voor PC en introduceert de 
GRPR-specifieke BN peptiden. Het 
review artikel in hoofdstuk 2 gaat uit-
gebreid in op de toepassing van GRPR-
gerichte beeldvorming en therapie van 
PC met behulp van radioactief BN. 
Naast een algemene beschrijving wordt 
een literatuuroverzicht gegeven van het 
preklinisch en klinisch onderzoek naar 
de potentie van BN in de beeldvorming 
van PC met SPECT en PET.
In onderzoeken naar radioactieve BN-
analoga ontbreekt het in de literatuur 
aan gestandaardiseerde studie-proto-
collen. Studiegroepen maken gebruik 
van verschillende diermodellen, label-
ling technieken, radionucliden en expe-
rimenten. Het is derhalve onmogelijk 
om analoga uit verschillende studies 
op betrouwbare wijze met elkaar te 
vergelijken. Ten einde een selectie te 
maken van BN-analoga voor gebruik 
in klinische validatie-studies, heb-
ben we 5 radioactief gelabelde BN-
analoga met elkaar vergeleken onder 
identieke experimentele condities met 
een gestandaardiseerd protocol. Deze 
vergelijkende studie staat beschreven 
in hoofdstuk 3 en toonde aan, dat de 
receptor antagonist Demobesin-1 het 
best presterende BN-analoog is van-
wege een superieure tumor-opname en 
in vivo stabiliteit in PC. Ook bleek de 
retentie van radioactiviteit in PC bij ge-
bruik van Demobesin-1 hoger dan bij 
de overige peptiden, terwijl de klaring 
uit de achtergrond-organen (met name 
pancreas en nier) het snelst verliep. 
Met een behoorlijke in vivo stabiliteit 
alsmede een goede opname en retentie 
in PC, toonden de analogen Pesin en 
AMBA zich de beste GRPR-agonisten. 
Receptor agonisten staan bekend om 
het stimuleren van groei van PC 30, 33, 
34. Vanwege binding en daaraan gerela-
teerde activering van GRPR positieve 
organen (pancreas en colon), kunnen 
receptor antagonisten voor bijwerkin-
gen zorgen. Om dit te voorkomen is 
het gebruik van niet biologisch actieve 
receptor antagonisten sterk te prefere-
ren 35-39. Bovendien is de receptor an-
tagonist Demobesin-1, in tegenstelling 
tot Pesin en AMBA 40, 41, hoog selectief 
voor de GRPR en heeft het dus geen 
affiniteit met andere BN receptor sub-
typen 42.
Groei van PC is afhankelijk van an-
drogenen 43. Fysiologische testosteron 
niveaus stimuleren de androgeenre-
ceptor (AR) en zetten tumorcellen aan 
tot groei. De eerste therapie bij uitge-
zaaide PC is hormonale behandeling, 
welke als doel heeft om circulerende 
testosteronspiegels te reduceren of de 
androgeenreceptor (AR) te blokkeren. 
Na verloop van tijd gaat PC echter 
onafhankelijk van hormonen groeien. 
Op dit moment van progressie, wordt 
gesproken van een hormoon resistent 
of hormoon refractair prostaat carci-
noom (ofwel castration resistant PC; 
CRPC) 44, 45. Voor patiënten met CRPC 
resten enkel nog beperkte palliatieve 
behandelopties 44, 45. Vanwege het feit, 
dat de meerderheid van patiënten met 
uitgezaaide PC hormonale therapie zal 
worden aangeboden, is het essentieel 
om het effect van hormoontherapie op 
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expressie van de GRPR te onderzoe-
ken. Dit is met name nodig om de juiste 
plaats van GRPR-gerichte beeldvor-
ming en therapie in het behandeltraject 
van PC te bepalen. Verder kan het van 
belang zijn voor de selectie van patiën-
ten, die mogelijk baat zouden kunnen 
hebben bij BN-GRPR-gemedieerde 
modaliteiten. hoofdstuk 4 en 5 rich-
ten zich beiden op dit vraagstuk.
Eerdere studies van onze studiegroep 
toonden aan dat GRPR expressie in PC 
tumoren in een vroeg stadium, lager 
wordt na het onttrekken van androge-
nen aan PC-dragende muismodellen 46. 
In de literatuur is tevens beschreven 
dat GRPR expressie laag is in CRPC 31. 
In hoofdstuk 4 onderzochten we, in 
meer detail, het effect van androgenen 
op GRPR expressie in drie humane PC 
dragende muismodellen in vivo (PC82, 
PC295 and PC310). De studie toonde 
aan, dat expressie van de GRPR in de 
geselecteerde androgeen gevoelige 
xenotransplantaties significant gere-
duceerd werd door het onttrekken an-
drogenen. Tevens liet de studie zien dat 
reïntroductie van androgenen resulteert 
in hernieuwde toename van GRPR 
expressie tot aan het oorspronkelijke 
niveau. Resultaten suggereren dat pa-
tiënten onder hormoontherapie niet 
geschikt zijn voor BN-GRPR gemedi-
eerde beeldvomring of therapie.
In de meeste PC studies naar BN-
GRPR gerichte modaliteiten wordt 
gebruik gemaakt van de, androgeen-
onafhankelijke en AR negatieve, PC3 
cellijn. Een cellijn, die duidelijk niet 
geschikt is voor onderzoek naar de in-
vloed van androgenen op de regulering 
van GRPR expressie. Om het effect van 
hormonale manipulatie en de AR status 
op de expressie van GRPR in PC verder 
te exploreren, maakte wij in hoofdstuk 
5 gebruik van de androgeen-afhanke-
lijke humane cellijn VCaP. Een cellijn, 
verkregen uit een humane PC meta-
stase, met hoge expressie van GRPR, 
welke bruikbaar is in zowel in vivo 
als in vitro studies. Resultaten lieten 
zien dat GRPR-specifieke opname van 
VCaP en PC-3 overeen kwamen. In te-
genstelling tot onze eerdere observa-
ties beschreven in hoofdstuk 4, bleek 
GRPR expressie in de VCaP cellijn niet 
te worden beïnvloed door hormonale 
manipulatie zowel in vivo als in vitro. 
Androgeen regulatie van de GRPR kon 
derhalve niet worden vastgesteld over 
de gehele linie van androgeen-afhan-
kelijke PC cellijnen. Een verklaring 
voor de tegenstrijdige bevindingen uit 
hoofdstuk 4 en 5 kan zijn dat, in tegen-
stelling tot de xenotransplantaties, die 
representatief zijn voor vroege stadia 
van androgeen-gevoelige PC, de meer 
geavanceerde VCaP en PC3 cellijnen 
een constitutieve expressie van GRPR 
hebben. Ondanks een (deels) behouden 
androgeen-gereguleerde groei, lijkt 
GRPR expressie in VCaP ontsnapt te 
zijn aan de “normale” mechanismen 
van androgeen regulering.
In hoofdstuk 5 hebben we ons tevens 
bezig gehouden met de relatieve mRNA 
expressie niveaus van de GRPR alsme-
de GRPR-specifieke binding in humane 
weefsels verkregen uit de weefselbank 
van het Erasmus MC. Deze weefsel-
bank bevat PC materiaal van patiën-
ten uit verschillende klinische stadia. 
Humane PC mRNA was veelal GRPR 
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positief, maar expressie was variabel. 
Alleen CRPC weefsels neigden naar 
lagere expressie van GRPR mRNA. 
Ondanks het feit, dat het aantal speci-
mina in deze groep laag was, geeft deze 
observatie een indicatie, dat GRPR (in 
ieder geval initieel) androgeen geregu-
leerd is. PC toonde al met al een hogere 
mediane GRPR-specifieke opname dan 
benigne weefsels. Daarentegen was er 
wel een aanzienlijke overlap tussen de 
lagere opnames in PC en de opname in 
benigne weefsels. Deze bevindingen 
komen overeen met originele data uit 
een invloedrijk artikel van Markwalder 
et al. 31. Een aangepaste puntgrafiek met 
data uit deze studie, vergelijkbaar met 
de grafiek vervaardigd met onze data, 
toonde een overeenkomstige overlap in 
GRPR expressie tussen PC en benigne 
tissue samples. Concluderend implice-
ren de data dat BN-GRPR gemedieerde 
beeldvorming van PC uitvoerbaar lijkt 
bij patiënten met een vroeg staduim PC 
vóór het ondergaan van hormonale the-
rapie. Bovendien suggereren de resul-
taten aan, dat voorselectie van PC pa-
tiënten op GRPR expressie nodig lijkt 
bij de overweging om GRPR-BN ge-
medieerde technieken in te zetten voor 
post-operatieve monitoring of therapie.
In hoofdstuk 6 wordt het effect van 
verscheidene experimentele condities 
op de farmacokinetiek van BN-speci-
fieke binding in PC-dragende naakte 
muizen beschreven. Met deze kennis 
hoopten we de BN-GRPR-gemedieerde 
binding te kunnen verbeteren. Deze 
studie maakte duidelijk, dat receptor-
binding niet alleen afhankelijk is van 
de affiniteit van BN-analoga voor de 
GRPR, maar dat variaties in experi-
mentele protocollen, zoals zuivering 
van analoga met behulp van high-
performance liquid chromatography 
(HPLC), het toedienen van injectie-
vloeistof met verschillende specifieke 
activiteiten en saturatie van de GRPR 
(door het toedienen van niet radioactief 
gebonden BN vόόr radioactief gebon-
den BN) van significante invloed kan 
zijn op peptide-receptor binding in 
vivo. Deze bevindingen onderstrepen 
de noodzaak om experimentele condi-
ties nauwkeurig te bepalen ten einde 
een volmaakt gestandaardiseerd proto-
col op te stellen voor BN-GRPR geme-
dieerde toepassingen.
Aangezien het metabolisme van kan-
kercellen dikwijls hoog is, wordt er 
veel onderzoek gedaan naar beeldvor-
ming van PC met behulp van metabole 
radiofarmaca. In hoofdstuk 7 staat 
een PET-onderzoek met VCaP dra-
gende muizen beschreven, waarin een 
BN-GRPR gemedieerd radiofarma-
con, 68Gallium-AMBA (68Ga-AMBA), 
wordt vergeleken met een metabole 
radiotracer, 18Flourine- methylcholine 
(18F-CH). Opname in de VCaP tumor 
was flink hoger bij gebruik van 68Ga-
AMBA in vergelijking met 18F-CH, 
terwijl opname in achtergrondorganen 
grotendeels lager was. De studie be-
schrijft derhalve superioriteit van pep-
tide-receptor gemedieerde ten opzichte 
van metabolisme-gemedieerde beeld-
vorming met PET bij PC.
In dit proefschrift wordt preklinisch 
onderzoek beschreven naar de potentie 
van BN-GRPR gemedieerde specifieke 
beeldvorming en therapie van PC. Het 
belang van standaardisatie voor het 
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mogelijk maken van betrouwbare ver-
gelijking werd duidelijk uit een kriti-
sche evaluatie van veelgebruikte expe-
rimentele condities in BN-gerelateerde 
literatuur. Voor zover ons bekend wa-
ren wij de eerste studiegroep, die BN 
analoga testte onder gestandaardiseer-
de experimentele condities. In overeen-
stemming met de literatuur 47-49, vonden 
we dat GRPR antagonisten superieur 
waren ten opzichte van gelijkwaardige 
agonisten. Onze studiegroep zal zich 
voor toekomstige klinische PC studies 
zodoende richten op het gebruik van 
GRPR antagonist. We hebben in dit 
proefschrift ook origineel onderzoek 
beschreven naar de rol van hormonen 
voor de expressie van de GRPR. Dit 
heeft meer inzicht opgeleverd in de ex-
pressie van de GRPR tijdens verschil-
lende stadia van humane PC. Tenslotte, 
aangezien er geen gouden standaard 
is voor beeldvorming van PC, hebben 
we metabole radiofarmaca vergeleken 
met peptide-receptor radiofarmaca 
ten einde hun relatieve potentieel als 
beeldvormende tracer van PC te eva-
lueren. Het veelbelovende karakter 
van BN-GRPR gemedieerde beeldvor-
ming werd bevestigd door deze studie 
aangezien de tumorspecifieke binding 
ruim vier maal hoger was ten opzichte 
van de tumoropname van het metabole 
radiofarmacon. Bovendien was de op-
name in achtergrondorganen met BN 
radiofarmaca over het algemeen lager.
De gepresenteerde uitkomsten uit dit 
proefschrift vormen de basis voor toe-
komstige evaluatie van GRPR antago-
nisten inzake beeldvorming van PC in 
patiënten. Omdat ontwikkelingen van 
BN analoga snel verloopt, zal het door 
ons best bevonden analoog Demobe-
sin-1 niet het radiofarmacon van eerste 
keus zijn in klinische studies. Het zal 
vervangen worden door een verbeterde 
nieuwe GRPR antagonist, ontwikkeld 
in een binnen onze studiegroep paral-
lel lopend onderzoeksproject, die naast 
voor SPECT ook ingezet kan worden 
voor PET.
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Na het behalen van mijn geneeskunde 
bul aan de Universiteit van Utrecht, 
besloot ik vol overtuiging te gaan voor 
het specialisme urologie. Het doorlo-
pen van een promotietraject leek me de 
ideale eerste stap in mijn toekomstige 
carrière. 
Erg benieuwd was ik naar mijn nieuwe 
levensfase binnen de wetenschap. In-
middels heb ik ervaren dat het een in-
tensieve en leerzame periode is gewe-
est die moeilijk op papier is te omschri-
jven. Een promotie biedt veel meer dan 
alleen onderzoeksresultaten; het is een 
proces met hoge pieken en diepe dalen. 
Het is voor mij een periode geworden 
van vorming en verdieping, zowel op 
professioneel als persoonlijk vlak, 
waar ik de rest van mijn leven profijt 
van zal hebben.
Een proefschrift schrijf je niet alleen; 
de mogelijkheden die mij geboden zijn 
door medewerkers van de afdelingen 
nucleaire en urologie in het Erasmus 
MC hebben er toe geleid dat dit boek 
nu voor u ligt. 
Ik wil een aantal mensen, die voor mij 
van grote waarde bij het onderzoek en 
daarbuiten zijn geweest, nadrukkelijk 
bedanken. Helaas is het onmogelijk ie-
dereen die zich voor mij heeft ingezet, 
hier met name te noemen.
Professor dr. ir. M. de Jong, beste Mar-
ion, ongeveer 5 jaar geleden maakte ik 
kennis met je tijdens mijn sollicitatieg-
esprek. Ik had daar meteen een goed 
gevoel bij. Dit kwam waarschijnlijk 
door het enthousiasme dat je voor je 
vak uitstraalt en je sociale, open houd-
ing. Je was toen nog doctor ingenieur, 
maar door je gedrevenheid, kunde en 
hart voor het nucleaire onderzoek heb 
je inmiddels de titel Professor verwor-
ven. Daarbij ben je ook nog eens de spil 
van je gezin. Het is bijzonder dat je dit 
allemaal kan combineren. Dank voor je 
hulp en voor de mogelijkheden die je 
me geboden hebt. 
Dr. ir. W.M. van Weerden, beste 
Wytske, vanwege mijn affiniteit met de 
urologie kreeg ik, voor dit grotendeels 
nucleair-georiënteerde promotietra-
ject, een werkplek op de afdeling ex-
perimentele urologie in het Josephine 
Nefkes Instituut. Ik kwam zodoende 
onder jouw hoede. Dit bleek een geluk-
streffer te zijn! Je was altijd laagdrem-
pelig benaderbaar en steeds welwillend 
om me intensief te helpen. Je hebt een 
sturende rol gehad tijdens de gehele 
promotieperiode. Het lag voor mij dan 
ook voor de hand dat jij mijn co-pro-
motor zou worden. Je bent een kei in 
het scheiden van hoofd-en bijzaken en 
hebt hiermee mijn publicaties vaak op 
een hoger plan gebracht. Bedankt voor 
je geduld en continue begeleiding.
Beste Professor dr. C.H. Bangma, uw 
afdeling urologie van het Erasmus MC 
staat sinds jaar en dag aan de top van de 
urologische research in Nederland. Op 
afstand bleef u altijd op de hoogte van 
mijn onderzoek en de ontwikkelingen 
daarin. Als lid van de kleine commissie 
bleek u streng doch rechtvaardig. Dank 
voor uw doortastende handelen in de 
eindfase van mijn proefschrift 
Professor dr. ir. T.J. Visser en Professor 
dr. O.C. Boerman, leden van de kleine 
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commissie, ik wil u beiden bedanken 
voor de tijd die u heeft willen nemen 
om mijn manuscript te beoordelen
Mijn dank gaat ook uit naar de overige 
leden van de commissie: T. Maina-
Nock, PhD, en Dr. Th. M. de Reijke.
Dear Thea, it is a great pleasure and 
privilege that you travelled all the way 
to be present at the uphold of my the-
sis. We got to know each other during 
my stay in Greece because of the Short 
Term Scientific Mission at your insti-
tute sponsored by COST. At your labo-
ratory at NCSR ‘Demokritos’ I learned 
a lot about molecular radiopharmacy. 
Furthermore I had an enjoyable stay in 
a snow-white Athens. What a fantastic 
host you (and Berthold) are! I wonder 
if you still eat hutspot with Unox worst 
now and then?
Beste dr. de Reijke, als opleider zult 
u mij de komende 2 jaar in het AMC 
begeleiden tijdens mijn opleiding tot 
uroloog. Onverwacht speelde u (in-
direct) nog een aanzienlijke rol in de 
totstandkoming van dit proefschrift. 
Dank voor uw interventie en uw aan-
wezigheid als opponent tijdens mijn 
dissertatie. Ik weet zeker dat ik, in onze 
aanstaande meester-gezel verhouding, 
veel van u zal leren. 
Beste medewerkers van de (experi-
mentele) urologie. Iedereen in het lab 
wil ik graag bedanken (en niet alleen 
voor de champagne, Wilma...). Jul-
lie hebben me geïntroduceerd in een 
verscheidenheid aan basale laborato-
riumonderzoeken. Ik had het niet ver-
wacht, maar uiteindelijk heb ook ik de 
witte lab-jas aangetrokken en de pipet 
ter hand genomen. Van western blot 
tot TaqMan analyse passeerden de re-
vue. Jullie stonden mij hier steeds bij! 
Suus wil ik graag extra bedanken. Als 
mijn “persoonlijke assistente” heb je 
me enorm geholpen door het verzorgen 
van mijn proefdieren en het met mij 
uitvoeren van arbeidsintensieve dier-
proeven. Bovenal was het gezellig met 
je te werken. Jammer voor de afdeling 
urologie dat ze je hebben moeten laten 
gaan, maar goed dat je de stap hebt dur-
ven nemen.
Mijn klinische stage op de afdeling 
urologie van het Erasmus MC is een 
leerzame en leuke plezierige tijd gewe-
est. Zowel door de staf, verpleegkun-
digen als assistenten werd ik met open 
armen ontvangen. De jeu de boules 
ballen die ik, overigens met enig ges-
joemel, won tijdens het urologie-uitje 
kunnen na afronden van dit proefschrift 
weer uit het vet worden gehaald!
Beste medewerkers van de afdeling 
nucleaire geneeskunde, jullie zijn een 
gemoedelijk en hecht team gebleken 
waarmee ik met veel plezier heb sa-
mengewerkt. Ondanks dat ik maar 
af en toe mijn gezicht liet zien op de 
afdeling, voelde ik me altijd welkom 
binnen jullie gelederen. Veelal kwam 
ik de door Wout en Erik gelabelde pro-
ducten in het Dijkzigt ophalen, maar 
ook voor “Twiggy” wilde ik nog wel 
eens de lange wandeling ondergaan. 
Het was een cadeautje dat ik met vel-
en van jullie aanwezig mocht zijn bij 
het EANM congres 2009 te Barcelona. 
Vooral de mensen van de prekliniek 
ben ik veel dank verschuldigd. Als net 
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afgestudeerd arts had ik niet bepaald 
kaas gegeten van autoradiografie, bio-
distributie en internalisatie studies. Jul-
lie hebben me aan de hand genomen in 
het CIL en hielpen vaak mee om mijn 
proeven tot een succes te maken. Mijn 
voorgangster dr. M. de Visser (hey Mo-
nique) is inmiddels met hele andere 
dingen bezig dan met basaal onderzoek 
naar bombesine, maar ik hoop dat dit 
woord van dank, haar toch zal bereiken.
En dan de niet werk-gerelateerde 
mensen die ik wil bedanken. Vanzelf-
sprekend te beginnen met mijn ouders! 
Lieve mama, jouw wens tot een groot 
gezin is mijn levenszegen geweest 
(papa vond drie kinderen wel genoeg). 
Zoals al veelvuldig aangehaald, ben jij 
degene die de eenheid binnen ons gezin 
heeft gecreëerd en altijd waarborgt. Je 
hebt een belangrijk deel van je leven 
gewijd aan “moederen”. Helaas ben ik 
er de laatste tijd niet helemaal (voor je) 
geweest vanwege de drukte rondom dit 
boekwerk. Fijn dat je me atijd steunt. 
Ik kijk er naar uit om me weer eens te 
laten fêteren op een ouderwets avondje 
Tilburg.
Lieve papa, zonder de vierde, geen 
urologisch opvolger binnen de fami-
lie Schroeder, noch een Dr. binnen de 
geledingen... Wie had gedacht dat ik 
zoveel op jou zou lijken en dat ik zelfs in 
jouw voetsporen zou treden. De liefde 
die je had voor je vak is aanstekelijk 
gebleken. Bewonderenswaardig vind 
ik het dat je je altijd op de vlakte heb 
weten te houden wat betreft mijn car-
rièrekeuzes. Dank je voor de last die 
je me hebt ontnomen in de laatste fase 
van mijn proefschrift. Je stond me bij 
in raad en daad en hebt bewezen zowel 
als volwaardig secretaresse als onder-
zoeker te kunnen fungeren.
Mijn beide paranimfen, dr. Joost Boor-
mans en (aanstaand dr.) Pim van Leeu-
wen. 
Joost, jou ken ik al (van)uit Tilburg. 
En dat schept toch een band... We heb-
ben beiden een zelfde balans tussen de 
zin en de onzin in het leven. Jij bent 
degene door wie ik in Rotterdam ben 
beland. Onder het motto “A’k jou waar 
vatte ik mèn” leek het me logisch je tot 
mijn paranimf te maken. Als collega en 
vriend zullen we elkaar niet uit het oog 
verliezen. 
Pim, we zitten in hetzelfde schuitje; 
opleiding tot uroloog en afronden van 
een promotie. We hebben een mooie 
tijd gehad in Californië met onze, 
“toch wel erg relaxte”, Ford Mustang 
convertible. Jammer dat je niet naar 
“ons” in Amsterdam bent gekomen. We 
houden contact en komen elkaar vast 
later in het vak (of maatschap?!) tegen.
Beste vrienden, ook tot jullie wil ik mij 
graag richten in dit dankwoord, vooral 
om jullie te laten weten, dat ik weer van 
de partij ben. Normaliter zet ik sociaal 
gezien graag mijn beste beentje voor, 
maar de afgelopen tijd schitterde ik 
veelal door afwezigheid; Bheeren, sen-
atus, Tilbo’s, Romanisti, Ethanollekes, 
Cahunezen, Willem-II-ers en overige 
maatjes: I’m back!
Lieve broers en zus, pas geleden heb ik 
nog een avondje vrij gemaakt voor een 
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onderonsje in Amsterdam. Een avond 
in goed gezelschap is pas àf als hij ein-
digt in “la Bastille”! Ons nageslacht 
is via jullie inmiddels wel verzekerd 
en naast de gezinsdrukte zijn jullie op 
professioneel vlak ook flink aan de weg 
aan het timmeren. 
Marc, oudste broer, je volgt me vanuit 
Moskou op de voet. Afstand telt voor 
jou niet! Ik kom graag snel weer bij je 
langs om de stad onveilig(er) te maken.
Sabine, mijn favoriete zus, je bent dol 
op gezelligheid en sociale contacten. 
Toch houdt de combinatie gezin en car-
rière jou letterlijk regelmatig van de 
straat. Ook al voel je je soms mijlenver 
van Amsterdam verwijderd, de afstand 
met Den Haag bedraagt slechts een dik 
half uur. Als je wil doorzakken in het 
mooie Mokum, staat het aerobed altijd 
voor je klaar.
Pieter, Daan Rocky II is pas net gebo-
ren of jij kiest ervoor je eigen bedrijf in 
private equity op te zetten. Je zult hier-
mee een uitdagende en drukke periode 
tegemoet gaan, maar ik heb er het volste 
vertrouwen in dat Nobel Equity Part-
ners een groot succes zal worden. We 
wonen op een steenworp afstand, dus 
ik zal regelmatig blijven aanwaaien. Ik 
bied je hierbij een “bon voor een avond 
oppassen op mijn kleine neefje”aan.
Lieve Kelly, als diëtiste in het OLVG 
had ik je al snel in de smiezen. Door 
mijn doortastend handelen zijn we in-
middels de belichaming van het me-
disch cliché, ”de doktersroman”, ge-
worden. Ons officieuze samenwonen 
is sinds augustus officieel. In de peri-
ode waarin we nu samen zijn, heb ik 
je eigenlijk niet genoeg kunnen geven. 
De opleiding chirurgie, het gedoe ron-
dom mijn huis én de promotie hebben 
hiervoor gezorgd. In plaats van “qual-
ity time” met jou zat ik veelal achter 
de laptop. Door jezelf enigzins weg te 
cijferen voor mijn werk, heb je me fan-
tastisch geholpen. Op veel vlakken heb 
je me onvoorwaardelijk gesteund en 
bijgestaan. Vakantie zat er tijdens het 
eerste jaar van onze relatie nog niet in. 
Gelukkig hebben we in de alledaagse 
beslommeringen al veel plezier samen. 
Met de bestemming Zanzibar en Tanza-
nia hebben we onze eerste en welver-
diende droomreis nu wel voor de boeg. 
Dat er vele reizen mogen volgen, babe!
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Rogier Schroeder
Swammerdamstraat 19-II
1091RP Amsterdam
E-mail: r.schroeder@erasmusmc.nl
Mobile phone: 06-54274964
Date of birth:  20-02-1980
education
1998-2006  Medical school University of Utrecht
1991-1998  VWO/Atheneum (high school degree)
experience
2010-now Surgical residency “Onze Lieve Vrouwe Gasthuis” (OLVG), 
 Amsterdam
2006-2009 PhD Urology / Nuclear Medicine Erasmus MC Rotterdam
2003-2005  Vaccination of travellers at the Utrecht Public Health Service, or 
 GGD (Gemeentelijke gezondheidsdienst)
2003-2004 Internship gynaecology, hospital Umberto I, University ‘La 
 Sapienza’, Rome, Italy 
2001-2002  President of the students union, “het Utrechts Studenten Corps”, 
 with over 1000 members 
2000-2004  Student teacher Utrecht Medical Centre
Publications
- 'Improving radiopeptide pharmacokinetics by adjusting experimental 
conditions for bombesin receptor-targeted imaging of prostate cancer.' 
Rogier P.J. Schroeder1, 2, Erik De Blois1, Corine M.A. de Ridder2, 
Wytske M. van Weerden2, Wout A.P. Breeman1, Marion de Jong1
Departments of 1Nuclear Medicine and 2Experimental Urology, 
Erasmus MC, Rotterdam, the Netherlands
Manuscript submitted in June 2011 to the Quarterly Journal of Nuclear
Medicine and Molecular Imaging
- 'Gastrin-releasing peptide receptor-based targeting using bombesin analogues 
is superior to metabolism-based targeting using choline for in vivo imaging of 
human prostate cancer xenografts.'
R.P.J. Schroeder1, 2, W.M. van Weerden2, E.P. Krenning 1, C.H. Bangma2, 
S. Berndsen1, C.H. Grievink-de Ligt1, H.C. Groen1, S. Reneman2, E. de Blois1, 
W.A. Breeman1, M. de Jong1
Departments of 1Nuclear Medicine and 2Experimental Urology, 
Erasmus MC, Rotterdam, the Netherlands
Manuscript published in July 2011 in the European Journal of Nuclear 
Medicine and Molecular Imaging
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- 'A standardised study to compare prostate cancer targeting efficacy of five 
radiolabelled bombesin analogues.'
R.P.J. Schroeder1, 2, C.M. Müller1, S. Reneman2, M.L. Melis1, W. Breeman1, 
C. Bangma2, E. De Blois1, E.P. Krenning1, W.M. van Weerden2 and M. de Jong1
Departments of 1Nuclear Medicine and 2Experimental Urology, 
Erasmus MC, Rotterdam, the Netherlands
Manuscript published in July 2010 in the European Journal of Nuclear 
Medicine and Molecular Imaging
- 'Androgen-Regulated Gastrin-Releasing Peptide Receptor Expression in 
Androgen-Dependent Human Prostate Tumour Xenografts' 
 Rogier P.J. Schroeder1,2, M. de Visser1, Wytske M. van Weerden2, 
 Corrina M.A. de Ridder2, Suzanne Reneman2, Marleen Melis1, 
 Wout A.P. Breeman1, Eric P. Krenning1, Marion de Jong1.
 Departments of 1Nuclear Medicine and 2Experimental Urology, 
 Erasmus MC, Rotterdam, the Netherlands
 Manuscript published in June 2010 in the International Journal of Cancer
- 'Peptide receptor imaging of prostate cancer with radiolabelled bombesin 
analogues'
 R.P.J. Schroeder1,2, W.M. van Weerden2, C. Bangma2, E.P. Krenning1 and 
 M. de Jong1
 Departments of 1Nuclear Medicine and 2Experimental Urology, 
 Erasmus MC, Rotterdam, the Netherlands
 Manuscript published in June 2009 in Methods
Presentations
08-10-2010 'Visualisation and treatment of prostate cancer using radiolabelled 
bombesin' oral presentation, Dutch Association of Urology (NVU), 
Nieuwegein, The Netherlands.
13-10-2009 'Selection best bombesin-analogue for use in phase I trial 
imaging prostate cancer with SPECT' oral presentation, EANM 
congres 2009, Barcelona, Spain.
17-10-2008 'Radiolabelled Bombesin Analogues: a Promising Tool for Imaging 
and Radionuclide Therapy for Prostate cancer' poster presentation, 
European Society for Urological Research, Dublin, Ireland.
06-02-2008 'Characterisation of GRP-receptor expression in prostate cancer; a 
potential target for PET/SPECT imaging.' poster presentation, '12th 
Molecular Medicine Day' Erasmus Postgraduate School Molecular 
Medicine, Rotterdam, The Netherlands.
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28-09-2007 'Androgen regulation of Gastrin-Releasing Peptide Receptor 
(GRPR), a target for imaging and therapy of human prostate cancer' 
poster presentation, European Society for Urological Research (8th 
meeting), Barcelona, Spain
15-11-2004 'Life birth rate after vasovasostomy' oral presentation, Association 
for Fertility study (Vereniging voor Fertiliteitstudie), Rotterdam, 
The Netherlands
Grants
11-02-2008 until 23-02-2008
'Testing new bombesin analogues which are suitable for peptide receptor 
radiotherapy'
Short-term scientific mission in the framework of the European Cooperation in 
Science and Technology (COST)
Institute of Radioisotopes – Radiodiagnostic Products (I/R-RP), National Center 
for Scientific Research 'Demokritos' (NCSRD), Athens, Greece
Memberships
04-2008-now Member European Association of Urology
certificates
2011 Fundamental Critical Care Support
2010 Advanced Trauma Life Support
2006  'Animal handling' art 9
2006  'Safe Handling of Radioactive Materials and Sources' art 5B
2005  Teaching qualification, Centre of expertise for education of the Utrecht 
 Medical Centre
2001  Media training, 'Headline media trainers'
languages
Dutch, English and Italian
hobbies
Boxing, field hockey, tennis, golf, sailing and cooking
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Phd PorTfolio
summary of Phd training and teaching
Name PhD student: R.P.J. Schroeder
Erasmus MC Department: 
Urology / Nuclear medicine
PhD period: 10-2006 untill now
Promotor: Prof. dr. ir. M. de Jong
Co-promotor: Dr. ir. W.M. van Weerden
1. Phd TraininG
Year Workload
(Hours/ECTS)
General courses 
 - Biomedical English Writing
  and Communication 
 - Laboratory animal science
2009
2006
4 ECTS
3 ECTS
specific courses (e.g. research 
school, Medical Training)
 -  'Safe Handling of Radioactive 
  Materials and Sources' art 5B 2 ECTS
seminars and workshops
 -  Department journal club
 -  Department seminars Urology /  
  nuclear medicine (in and outside  
   Erasmus MC)
 -  General seminars
2006-2009
2006-2009
2006-2009
2 ECTS (28 hours)
3 ETCS (50 hours)
3 ETCS (50 hours)
Presentations
 -  JNI-meeting
 -  lab meeting
 -  seminars
2006-2009
2006-2009
2006-2009
5 ECTS (100 hours)
2 ECTS (30 hours)
2 ECTS (25 hours)
(inter)national conferences
 -  European Congress (poster presentations)
 -   European Congress (oral presentation)
 -  National Urological association  
  (oral presentation)
2006-2009
2006-2009
2006-2009
6 ECTS (100 hours)
2 ECTS (50 hours)
2 ECTS (30 hours)
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 -  Short-term scientific mission 
  in framework of Cost (Athens) 2008 7 ECTS (300 hours)
2. TeachinG
supervising practicals and 
excursions, Tutoring
 -  Translational research practical ‘07-‘08-‘09 2 ECTS (50 hours)
ToTal 45 ecTs 
(813 hours)
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lisT of abbreviaTions
PC prostate cancer
GRP Gastrin-Releasing Peptide
BN bombesin
TURP transurethral resection of prostate
TRUS transrectal ultrasound
TUR transurethal resection
LHRH luteinizing hormone-releasing hormone
CT computed tomography
MRI magnetic resonance imaging
FDG  fluoro-2-deoxy-D-glucose
PRRT peptide receptor radionuclide therapy
(i)PSA (initial) prostate specific antigen
DRE digital rectal examination
ERSPC European Randomised Study of screening for Prostate Cancer
PSMA prostate-specific membrane antigen
FDA American Food and Drug Administration
PIN prostatic intraepithelial neoplasias
BPH benign prostate hyperplasia
NMB / BB
1
 neuromedin B receptor
GRPR / BB
2
 Gastrin-Releasing Peptide Receptor
BRS-3 / BB
3
 bombesin receptor subtype 3
BB
4 
bombesin receptor subtype 4
pmol picomole
MBq megabecquerel
SPECT single positron emission tomography
PET positron emission tomography
SST somatostatin
DTPA diethylenetriaminepenteacetic acid
DOTA 1,4,7,10-tetraazacyclododecane-N,N’,N’’, N’’’-tetraacetic acid
N
4 
1,4,8,11-tetraazaundecane
HE haematoxylin-eosin
RCP radiochemical purity
ITLC(-SG) instant thin-layer chromatography (Silica gel)
HPLC high-performance liquid chromatography
TFA trifluoroacetic acid
FCS fetal calf serum
DEC Animal Experimental Committee / dierexperimentencommissie
EDTA ethylenediaminetetraacetic acid
pi post injection
%ID/g percentage of the injected dose per gram of tissue
SD standard deviation
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RT-PCR quantitative reverse transcriptase polymerase chain reaction
mRNA  messenger ribonucleic acid
HKG housekeeping gene
GAPDH glyceraldehydes-3-phosphate dehydrogenase
PBGD porphobilinogendeaminase
DLU/mm2 Digital Light Units per per millimeter square
dpm/mg disintegrations per minute per mg
cas castrated
T testosterone
R1881 synthetic androgen
AR androgen receptor
PAP prostatic acid phosphatise
DCC steroid deprived serum
CRPC castration resistant prostate cancer
RPMI Roswell Park Memorial Institute
Rad PC radical prostatectomy
LN(+) lymph node (metastasis)
PIN prostatic intraepithelial neoplasia
PMID PubMed identifier
MW molecular weight
n number
t timepoint
min  minutes
h  hours
RT retention time
(18F-)CH (18Flour-)methylcholine
NMR Nuclear magnetic resonance
aq  aqueous
FBP filtered backprojection
OSEM ordered subsets expectation maximization
MAP maximum a posteriori
VOI volume of interest
IQR interquartile range
